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PROLOGUE 
“Life is a journey, not a destination.” 
Anonymous 
A sequence of exceptional clinical, teaching and research appointments between 1967 
and the present have provided me with the unique opportunity of developing a body of 
work over these past 40 years that has, I believe, made a seminal contribution to two 
areas of women’s health, namely, infertility and the menopause. The latter contribution 
will be the subject for this submission. Fortunately, my academic career has afforded 
me the opportunity to introduce my observations into clinical practice and thereby to 
influence menopause management worldwide. It is this body of my work and the 
activities around it that I humbly submit for consideration for the degree of Doctor of 
Science in Medicine at the University of Cape Town. 
In the following sections of this submission, I will detail the nature of the work, its role in 
defining the menopause, its medical management, and the recognition of menopause 
as a lifecycle milestone that can serve as a catalyst for preventive health care. Given 
the impact of this body of work on the enhancement of overall and health-related quality 
of life for women worldwide, I hope the work will be regarded as seminal and justify the 
award of the degree. 
Two unusual assignments during my training years determined the path of my life’s 
work. In 1965, as a registrar in Obstetrics and Gynaecology at the Queen Victoria 
Maternity Hospital in Johannesburg, I was assigned a review article to summarize and 
present at the departmental journal club. The paper, entitled “The fate of the nontreated 
postmenopausal woman: A plea for maintenance of adequate estrogen from the puberty 
to the grave” (Wilson RA, Wilson TA, Am Geriatr Soc 11:347, 1963), triggered my 
interest. Menopause, in textbooks at that time, never merited more than one line, 
usually stating that “menopause is physiological amenorrhea”. Certainly the subject was 
6 
not further addressed in textbooks, nor was it part of the medical school curriculum or of 
registrar training in any specialty. The second assignment was given to me after I 
transferred to the University of Cape Town and Groote Schuur Hospital in 1966 to 
complete my registrarship in obstetrics and gynaecology. That assignment was to 
produce a poster on the demographics of the population explosion and the need for 
family planning. I was forcefully struck, not by the postwar population of baby boomers, 
but rather by the wave that would move inevitably forward in the next 20 to 30 years 
through the menopause transition and beyond. 
The consistent purpose of the studies conducted throughout this period of time has 
been to establish a scientific foundation for menopause, and to provide the factual 
substantiation for evidence-based guidelines for an extremely emotive subject. Initial 
data were gathered between 1967 and 1976 at a Menopause Clinic especially 
established for research purpose at the Groote Schuur Hospital and University of Cape 
Town. This was to become recognized as the first such unit of its type worldwide. 
Subsequent studies have been performed through the University Hospitals of Cleveland 
and Case Western Reserve University, and my clinical research center in Cleveland, 
Rapid Medical Research. Where collaborations have been undertaken with other 
researchers at other institutions, this is recognized in the citations and the body of the 
text. When referring to work undertaken with collaborators, I will utilize the collective 
term “we” in the text. 
This career-long body of work is described in several sections in which I have described 
the detailed nature of the publications and the reasons why it might be considered 
sufficiently seminal for the award of this degree. Because work in process was often 
simultaneous, or one question answered would often raise another, this presentation is 
given in a scientifically logical sequence that is not necessarily chronological with the 
publication dates of the papers. The list of publications presented in Section 4, and set 
of copies of these publications reproduced in Volume 2, has been re-ordered for a 
logical flow that is not chronological. State of the art reviews and clinical 
recommendations are listed separately, but considered of no less value than the bench-
type or clinical research, and will be referred to in the body of the text below. My 
complete list of publications by date of publication is listed in the full curriculum vitae 
presented in Section 8, which also includes my non-menopause-related contributions to 
medical science. 
 Studies were initially directed toward determining the specific clinical and metabolic 
effects of spontaneous menopause and of bilateral oophorectomy in the human female. 
Further studies have investigated clinical and metabolic responses to a wide range of 
exogenous hormones and pharmaceutical products after menopause and 
oophorectomy. The ultimate purpose of this research has been to determine the nature 
of menopause and its optimal clinical management in order to enhance the overall and 
health-related quality of life for women through and beyond menopause. The outcome is 
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“Those who cannot learn from history are doomed to repeat it.” 
    George Santayana 
 
An historical survey of all issues relating to the menopause was considered integral to 
understanding attitudes and the existing state of knowledge at the time of my planning 
and designing my initial investigations. While the research literature up to late 1966 was 
essentially narrative in nature, there were many indirect areas of research that could 
help define both the level of existing knowledge as well as attitudes and perceptions at 
that time. Above all, by understanding and documenting a comprehensive historical 
survey, it became possible to define the pertinent questions that needed answers. Key 
papers in which I documented the history and summarized the state of the art at that 
time are references 1-5, 107, 109, and my monograph, “Menopause in Modern 
Perspective (Appleton, Century, Crofts, New York, 1979).  
 
I can best summarize the background to my future studies by quoting from my first 
published analysis of the literature in 1968.107 The  critical review opened with the 
observation that “most of what is published is based on emotional and philosophical 
premises; the ‘change of life’ is an emotional subject not only to women, but to men and 
doctors.” The purpose of the review was then listed as: 
“1. To analyse the current thoughts regarding the menopause. 
 2.  To draw attention to the paucity of authoritative research and published data. 
 3. To serve as an indication for the urgent need for research, particularly into the nature 
of the menopause and the methods for the relief of menopausal symptoms and 
disorders; the process of ‘ageing’ and, in particular, the occurrence of osteoporosis and 
atherosclerosis in postmenopausal women; and the metabolic and vascular changes 
following acute hormone withdrawal, e.g. after bilateral oophorectomy in the pre- and 
postmenopausal female.”  
 
The conclusions of that 1968 critical review determined my future career path: 
“Several questions urgently require answers: 
1. Is the climacteric a normal physiologic stage in the life of the human female, or is 
it a simple result of ovarian failure and oestrogen deficiency? 
2. Are the manifestations of ageing directly related to diminution of circulating sex 
hormones? 
3. Can the administration of exogenous oestrogen or other sex hormones prevent 
the manifestations of ageing? 
4. Are the oestrogens at present available for administration equivalent in effect to 
circulating endogenous oestrogens? 
5. Does long-term oestrogen administration result in an increased incidence of 
breast or uterine carcinoma? 
6. Do oestrogens have a direct effect on the psychological state and sense of well-
being in the postmenopausal patient? 
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To these ends the development of more precise diagnostic techniques and methods of 
evaluation is vital.” 107
As my initial investigations progressed, I became quite vocal in my conclusions and 
recommendations. Given the major controversy that has been raging world wide, 
particularly since the initial publication of the Women’s Health Initiative findings by the 
National Institutes of Health in the United States in 2002, it is quite remarkable that I 
summarized the state of the art of postmenopausal hormone therapy as follows in 
another critical review of 1969: 131 
“The possible major disadvantages of long- term therapy on the one hand are a fear of 
carcinogenesis and thrombogenesis. These risks if valid are extremely rare. On the 
other hand, the possible advantages of long-term therapy are also as yet unproven. 
Exogenous oestrogens are of undoubted value in the relief of symptoms such as hot 
flushes, the associated bouts of perspiration, and atrophic vaginitis. 
Their use in the prevention of coronary arterial disease and the problems of 
osteoporosis hold definite promise but the results of long-term prospective studies must 
be awaited before their routine use for the prevention of these disorders can be 
advocated. Certainly, an important contribution of the gynaecologist would be a more 
conservative approach to the removal of normal ovaries from the pre-menopausal 
female. Endogenous oestrogen appears to have a definitive protective effect on the 
human female. Where bilateral oophorectomy in the young woman is considered 
necessary, the long-term use of oestrogens is probably justified in view of the risks of 
coronary arterial disease and osteoporosis. 
The prophylactic use of long-term exogenous oestrogen therapy in the prevention of 
aging has not been established…….It is therefore suggested that only specific 
problems be treated and that the routine use of oestrogens in all women after the 
menopause cannot be recommended at this time.” 131
In summary then, the key questions defined and for which I believe I was able to 
develop some answers in subsequent years were: 
1. What is the human female menopause and climacteric? Specifically, does it
represent a potential endocrinopathy and a possible health-related issue?
2. What impact do the climacteric and its treatment have on individual health, aging,
quality of life, and society in general?
3. What are the appropriate solutions – medical and general?
4. What is the role of hormone replacement therapy with regard to safety and
efficacy?
5. How do we disseminate knowledge and appropriate quality care at all levels?
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6.1.1 DEVELOPMENT OF MENOPAUSE-RELATED SCIENTIFIC  ORGANIZATIONS 
The following personal history is presented as biographical background to some of my 
seminal contributions that will be described in later sections. 
Menopause-related research in the late 1960’s and early 1970’s was a relatively lonely 
endeavor. There were few investigators worldwide with any interest in the subject. 
Those that did were more concentrated on a specific aspect such as osteoporosis or 
cardiovascular disease.  It was therefore serendipitous that I received a letter in April 
1973 from one Pieter van Keep, MD, PhD, Director-General of The International Health 
Foundation (IHF) based in Geneva, Switzerland, expressing interest in my early medical 
publications, telling me of his early social studies on menopause, and inviting my 
research collaboration. At that time my research in Cape Town was focused solely on 
the clinical and metabolic effects of menopause and hormone replacement therapy 
(HRT). I had heard neither of him or the IHF, but was delighted to discover another 
“menopausologist”, and intrigued by his early social studies. By coincidence, I was 
about to travel to Europe the next month, and responded suggesting we meet in 
Geneva.   
Pieter met me at the Geneva airport, explained that he had a light day at the office, 
would show me Geneva, and then we would meet Guus, his wife, for dinner. The day 
turned out uniquely. It was, when the full history of menopausology gets written, a true 
milestone. The germinal ideas for much of organized menopause-related medicine had 
its origin on that day in May 1973.  It was also the beginning of an instant and 
remarkable friendship that lasted until Pieter’s premature death in 1991. 
We wandered from pub to pub through old Geneva, getting more animated and excited 
in our conversation as the day wore on and also, perhaps, less than fully sober.  During 
the course of that brainstorming day we conceptualized the idea of a menopause club, a 
friendly organization that would draw together the few people worldwide interested in 
the subject to a series of meetings we planned to be held in Geneva under the auspices 
of the IHF.  This club was later to become the International Menopause Society (IMS).  
We also felt there was a need for some sort of newsletter or journal to act as a vehicle 
for news and new findings; this was the original concept later to become Maturitas, the 
first medical journal devoted to menopause, and of which we were destined to become 
the first medical editors.  We spoke of holding gatherings in exotic places such as the 
Bahamas, Sri Lanka, or Hawaii; the meetings ultimately were to be the IMS congresses. 
Above all, my basic and clinical science research approach melded well with Pieter’s 
psychosocial interests.  We spoke of a new concept of healthy women care, an idea for 
enhanced quality years for women by primary preventive health care, utilizing 
menopause as a positive entry point. By the evening we had run out of ideas, of 
soberness, and in great convivial mood joined Guus for dinner.  She was not impressed, 
but eventually she too was caught up in our excitement, “even though I was from South 
Africa”.   
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Over the next 3 years we conducted three closed workshops in Geneva, Switzerland – 
many ideas were discussed, and as interest increased, expanded  the concept of an 
International Menopause Congress, and the establishment of an “International Society 
for the Study of the Climacteric and Postmenopause.” Those 3 years were difficult ones 
for me and my personal career. An adversarial event with the apartheid South African 
government had made several people advise me that my continuing academic career in 
South Africa was jeopardized and in 1976, just before the Soweto riots, despite 
attempts by Pieter van Keep, who had now moved to Holland, to attract me there, I 
relocated to the United States. 
In considering the first organizing committee for the meeting to be held in Montpellier, 
France, as well as later in selecting the first IMS founding signers, we agreed that given 
the political reputation of South Africa at that time, it would not be politically correct for 
my name and country to appear. The Chairs for the 1st International Menopause 
Congress were therefore Pieter, Professor Robert Greenblatt from the USA, providing 
co-sponsorship of the American Geriatric Society, and Professor M. Albeaux-Fernet of 
France, providing co-sponsorship of the University of Montpellier.  
In June 1976, 165 professionals of varying disciplines and backgrounds, but all with the 
common interest of menopause, gathered in the resort town of LaGrande Motte in 
France, to attend the First International Congress on the Menopause. The year 1976 
also coincided with the development of a major controversy regarding hormone 
treatment after menopause. The “estrogen forever” attitude of the late 1960s and early 
1970s had been transformed to a fear of uterine cancer after publications in late 1975. 
The research world was also confused, and this was evidenced at the conference. It 
was clear to all attendees that better information and forums for presenting data were 
necessary, and that an International Menopause Society was essential. We therefore 
worked aggressively over the subsequent 2 years, and the IMS was formally launched 
in November 1978 after the Second International Menopause Congress in Jerusalem in 
June 1978. 
In retrospect, it seems remarkable to me that in the short space of time between 1973 
and 1978 so much could have happened – notably, the founding of IMS, the launch of 
Maturitas, the impetus for national menopause societies, and the recognition and 
development of meaningful menopause-related research; all being progress that Pieter 
and I could barely have hoped for at that fateful meeting back in 1973. 
During the following years, interest in national menopause societies escalated, and I 
was privileged to be involved in the planning or launch of almost 30 national societies, 
worldwide. 
The North American Menopause Society (NAMS) was established as a result of my own 
personal embarrassment. By the time of the Fifth International Congress in 1987 in 
Sorrento, Italy, I was repeatedly asked by non-North American friends about the large 
organization we presumably had in the United States. In fact, we had none. On my 
return to Cleveland, I contacted an attorney, Kenneth Kleinman Esq., and based on the 
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charter of the IMS, a preliminary charter was developed. NAMS was incorporated as a 
nonprofit scientific organization on November 29, 1988, with myself, Fredi Kronenberg 
PhD, of Columbia University in New York City, and Isaac Schiff MD, of Harvard 
University in Boston, as the founding Trustees. The organization was designed as North 
American to include Canada and Mexico. It was officially launched at a co-sponsored 
meeting held under the auspices of the New York Academy of Sciences on September 
21-23, 1989, in New York City. The proceedings are historically recorded in a full edition
of the Annals of the New York Academy of Sciences (Annals N.Y. Acad. Sci. vol. 592,
1990).
Today NAMS is an extremely large organization, based in Cleveland, Ohio, with over 
2500 members in 50 countries, and responsible for major scientific meetings, peer-
reviewed medical journals (e.g. Menopause, The Journal of The North American 
Menopause Society), a Web site with over 5 million hits per month, a national 
competency certification exam in menopause medicine, and multiple professional and 
consumer teaching activities. Further information will be provided in Section 2.15. 
SUMMARY - SEMINAL CONTRIBUTION #1 
1. My first significant contribution to medical science was the recognition of the
female menopause as being a health-related issue beyond simple loss of
menstruation. In drawing attention to this issue, I was also one of the pioneers in
identifying the key questions for future research.
2. Another major pioneering contribution to medical science and women’s
healthcare was to recognize the need to establish national and international
scientific organizations, peer-reviewed medical journals, and mechanisms both
for researchers to share and interact in the search for scientific progress, and for
clinicians to be apprised of current standards and recommendations for
evidence-based medical practice.
6.2 TERMINOLOGY AND DEFINITIONS 
Right from the beginning of my research it became apparent that there was confusion in 
terminology relating to the time of transition from the reproductive to the post-
reproductive years in a woman’s life cycle. Even the word menopause was defined in 
different ways. There was an obvious need for consistency in terminology so that 
research data from published studies would be comparable. But achieving agreement 
on appropriately defined terminology turned out to be more difficult than anticipated. 
The concept of defining the terminology and stages of the menopause transition has 
been addressed specifically on only a few occasions.  I was responsible for convening 
the first of the meetings and, bar one, significantly involved in all the others. The first 
effort to develop internationally acceptable definitions was co chaired by myself and the 
late Professor David Serr, of the University of Tel Aviv in Israel, (coincidentally, one of 
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the external examiners for my PhD from the University of Cape Town in 1970), at a 
workshop convened during the First International Menopause (IMS) Congress at 
LaGrande Motte in France in 1976.6 The definitions attempted to provide an explanation 
for the protean clinical presentation during and after menopause. 
Development of the first IMS definitions also highlighted the fact that appropriate 
definitions needed to incorporate a staging system that needs to be multidimensional. 
The 1976 IMS definition, in attempting to explain the protean associations with 
menopause, represented an early attempt at multidimensional staging.  The first level is 
chronological – the entire process labeled “climacteric” and the final menstrual period 
(FMP=menopause) being time specific. The second dimension addresses physical 
changes or symptoms. The third dimension involves integration of functional changes.   
A World Health Organization (WHO) Scientific Group on Research in the Menopause 
met in 1980 and published recommendations in 1981 (Research on the Menopause. 
Report of a WHO Scientific Group, Geneva, World Health Organization, WHO Technical 
Report Series 670, Geneva, Switzerland, 1981).  These definitions were revisited in 
1994 and published in 1996 (WHO Scientific Group on Research on the Menopause in 
the 1990’s.  WHO Technical Report Series 866.  Geneva, Switzerland, 1994). These 
scientific definitions were largely uni-dimensional with specific definitions for the phases 
of the life cycle being presented. The 1994 WHO Scientific Group on Research in the 
Menopause, of which I was a member, expanded on the relationship between different 
time periods surrounding the menopause, retained most of the 1980 definitions, but 
failed to make recommendations about staging the reproductive transition. 
In 1992, I published the first attempt at developing the third dimension of integrating 
functional changes.7  A potential fourth dimension was also recognized, namely, the 
possibility of addressing therapy through staging and definitions.  Based on the premise 
that the existing definitions did not take any potential residual ovarian activity into 
account and were thus of reduced value in describing populations either being 
considered for clinical study or for clarifying indications for postmenopausal hormone 
therapies, I proposed an ovarian function, therapy-oriented definition of the 
postmenopause in 1992 and expanded on this concept in1994.7,8 
The definition proposed was based on whether the postmenopausal ovary 
demonstrated lack of activity (type A), or functional ability (type B), or whether there was 
congenital absence of both ovaries (type C) or iatrogenic loss of ovarian function (type 
D), and in part was presented as follows: 
“This functional background allows integration into the definition a possible indication for 
hormone therapy (“estrogen dependent”), or a compensated type of climacteric 
(residual ovarian function) without clear indication for hormone replacement (“estrogen 
independent”).  The suggested classification is thus as follows: 
Type A – Spontaneous estrogen-dependent climacteric (ovaries intact) (i.e., no ovarian 
compensation). 
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Type B – Spontaneous estrogen-independent climacteric (ovaries intact) (i.e., ovarian 
compensation). 
Type C – Ovarian agenesis estrogen-dependent climacteric (ovaries absent). 
Type D – Iatrogenic estrogen-dependent climacteric (ovaries removed) (i.e., surgical 
menopause, chemotherapy).” 
In 1998, I was invited by the IMS to convene a working group through its internationally 
representative organ, the Council of Affiliated Menopause Societies, to define the 
terminology. This group reported in 1999.9  While the previous definitions were refined, 
the group did not reach consensus on a staging system.  
The research community involved in the area of the human female menopause 
continued to recognize the need for both universality in utilization of menopause-related 
terminology, and some form of a logical division of the last 10 to 15 years of 
hypothalamic-pituitary-ovarian function into stages that could be primarily relevant to the 
research community, but that could have clinical relevance as well. I was thus fortunate 
to be integral in jointly developing a consensus conference with the National Institutes of 
Health (NIH), the North American Menopause Society (NAMS), and the American 
Society for Reproductive Medicine (ASRM). The meeting was held in Park City, Utah in 
late July 2001 titled the STRAW meeting, that is, the Staging System for Reproductive 
Aging in Women. 
The experts at the closed meeting recognized that the prime objective for developing a 
staging system for reproductive aging is to allow researchers worldwide to enroll 
comparative populations in research studies.  The first step in development of such a 
staging system for reproductive aging necessitates correct use of menopause-related 
terminology. The majority of published clinical studies did not clearly define their studied 
populations and conclusions drawn are therefore often of limited utility.  For example, 
“menopause” is variously utilized to correctly refer to the final menstrual period (FMP) or 
incorrectly to the entire menopause-related transition. Another example is 
“perimenopause” where late perimenopause is utilized by some investigators to refer to 
the final years of reproductive age, and others to the first 12 months after the FMP. 
The July 2001 joint working group (STRAW) convened by the NIH, NAMS, and ASRM 
to attempt to develop a workable staging system for reproductive aging carefully 
considered all the menopause-related terminology, and utilized it in the staging system 
that resulted from the meeting. This is a workable system that relies on investigators 
worldwide to utilize correct definitions.  In particular, perimenopause (unless dropped 
from our lexicon) was redefined so that it is synonymous with climacteric.10,11
This new staging system is but one phase in an ongoing process.  For the moment, it 
should provide a basis for researchers to be more uniform in population selection. 
Clinicians may find it of value in explaining the reproductive aging process to women. 
With utilization of the scale should inevitably come greater detail of each of the stages, 
and ultimately refinement and perhaps even development of an enhanced system. 
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Hopefully, as this process unfolds, we will eventually have a system that addresses all 
four dimensions:  chronology, symptoms/physical changes, variance of functional 
groups, and finally, therapy orientation. Above all, there is now no excuse for 
investigators not to use correct terminology in selecting and describing their patient 
populations. 
SUMMARY - SEMINAL CONTRIBUTION #2 
Over a period of 30 years I was the first to introduce a standard set of definitions on 
menopause-related terminology, and then to work with international working groups and 
medical organizations to further develop this process. By helping standardize the 
semantics and the staging of reproductive aging, this represents a significant 
achievement in comparative research and evaluating clinical standards of care. 
6.3 RESEARCH METHODOLOGY, TECHNIQUES, AND 
INSTRUMENTS 
Beyond the initial problems of inaccurate use of language, necessitating defining 
semantics and staging, another issue that I identified very early in my investigations was 
the lack of specific instruments for measuring subjective parameters like sense of well-
being or sexual dysfunction, or objective parameters like bone density or bone quality. 
There was also a need for the substantiation of the value of biomarkers like the vaginal 
maturation index as a biomeasure of estrogenicity. Thus, a considerable amount of my 
energy over these years has been to work on developing or confirming instruments and 
methodologies that provide reproducible and quantifiable measures for such 
parameters. Review of references 12 through 25 will attest to the diversity of problems 
addressed. A review of some of the technical related issues is included in references 12 
and 17. 
6.3.1  ROLE OF VAGINAL SMEAR IN ASSESSMENT OF ESTROGENIC STATUS OF 
THE POSTMENOPAUSAL WOMAN 
Studies were undertaken to determine the relationship between ovarian function and 
menopausal status, and, particularly, the impact of exogenous hormonal therapy on the 
various cells of the vaginal epithelium.12,13,14  It was determined that the parabasal cell 
index was an exquisite measure of estrogenicity, and further studies demonstrated a 
strong correlation between the incidence of vasomotor symptoms and the vaginal 
parabasal cell index.16 This finding had immediate clinical application, as an in-office 
saline swab test could be undertaken for the presence or absence of parabasal cells, 
and the patient’s estrogenic status and possible need for estrogen replacement could 
be immediately diagnosed without resource to expensive blood measures. 
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6.3.2  PLASMA CALCIUM LEVELS AS A PROPOSED TEST OF ESTROGENIC 
POTENCY 
In the 1970’s and 1980’s attempts at prevention of bone loss leading to osteoporosis 
and fractures were hampered by both a lack of diagnostic tools and of any bone 
markers that could be utilized to either evaluate the efficacy of new drugs under 
investigation, or of patient response to the use of then currently available medications. It 
was therefore useful as a clinical diagnostic tool that in a series of studies I identified the 
fact that estrogen therapy could be extremely effective in reducing plasma calcium 
levels.12,15  This finding was also a milestone in estrogen-related research as it also 
demonstrated that different estrogens could have different effects. Prevailing opinion at 
that time was that an estrogen was an estrogen, and any differences in effect were due 
to dose response rather than inherent variations between different estrogens. Thus, 
these studies, for example, demonstrated conjugated equine estrogens to have a 
significant effect in reducing plasma calcium levels whereas estradiol valerate, in a 
bioequivalent dose, was ineffective. Thus, an adequate screening test of the potential 
therapeutic value of an estrogen in the prevention of osteoporosis would be its effect on 
fasting plasma calcium and urinary calcium levels over a period of time. A calcium-
lowering effect would be significant. It is unlikely that even the currently available 
telepeptide markers are much more sensitive than this test. 
6.3.3  RADIOLOGICAL TESTS OF BONE DENSITY 
At the time of my initial studies there were three imprecise, time-consuming, expensive, 
and often unavailable, methods for measuring bone mass change. These were whole-
body neutron activation, radiodensitometry, and radio grametry. All also suffered from 
severe sensitivity and specificity problems. A new technique was developing, namely 
single photon absorptiometry, and I was fortunate in being able to obtain a prototype of 
a single photon absorptiometer. This allowed a simple and noninvasive measure of 
bone density at the wrist through use of a radioisotopic source (Americium241) and a 
scintillation detector measuring radio transmission across the area of interest. Later 
CAT scanning became a possible tool, and single photon techniques were enhanced by 
the introduction of dual photon absorptiometry, but all of these methods involved either 
excess doses of radiation or the need to deal with isotopes, or both. The next advance 
was the introduction of dual energy X-ray absorptiometry (DEXA). The pioneer in this 
technology was Richard Mazess PHD, from Milwaukee, and we utilized my clinical 
research center in Cleveland as one of the  ß-sites for the testing of the prototypes, and 
ultimately the commercial models . Working with several colleagues across the country 
we attempted to define the place of this technology.18,19  Indeed, DEXA is now 
considered the gold standard for measuring bone density. 
As an item of interest, through this collegial association, over 20 years later in Cape 
Town, when the Groote Schuur Hospital’s only DEXA machine became irreparable, I 
was able to obtain a new state-of-the-art  machine from GE-Lunar as a gift, and that is 
the system currently being utilized for all clinical departments at the hospital. 
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My early involvement as a gynecologist was a factor in this technology being widely 
adapted by that specialty for evaluation of women transiting through and beyond 
menopause. 
6.3.4  THE DEVELOPMENT OF THE UQOL, A VALIDATED INSTRUMENT TO 
MEASURE SENSE OF WELL-BEING (GLOBAL QUALITY OF LIFE) 
Up to 1967 there were suggestions that exogenous estrogens had mood-enhancing 
effects, but no direct research had been conducted to confirm or refute these theories. 
The problem was the lack of any precise methodology to actually measure sense of 
well-being or so called global quality of life. Indirect parameters were usually applied, 
and I certainly did utilize tests such as the Beck Depression Inventory and checklists of 
psychiatric symptoms, given the lack of any direct instruments.48  Unfortunately,  the 
study subjects were not usually depressed, nor did they have major psychiatric disease, 
and those early studies can now only be recognized as pioneering attempts.  
In order to try to more accurately measure sense of well-being, in 1967 I devised an 
instrument for both patient self-completion and for investigator assessment with 
questions that more accurately reflected what I was attempting to measure. 
Unfortunately, again, at that time mechanisms for validation of such instruments were 
poorly understood or not even developed, and my early studies have inevitably to be 
regarded as pilot studies.12, 46-49 Fortunately, in Cleveland, as academic Chairman, I 
created in my department a division of behavioral medicine, staffed by a psychiatrist 
and a psychologist. What we believed would be a simple process of validation of my 
early sense-of-well-being instrument, became almost 6 years of work, but the end result 
is a validated instrument capable of measuring global quality of life in women aged 45 to 
65 that is of research value and clinically aplicable.20,22,23 The Utian Quality of Life Scale 
(UQOL) has been widely accepted as a well-validated clinically useful tool that can 
complement a symptom inventory to provide a broad overview of menopausal status.  
The UQOL is a 23-item questionnaire with a stable factor structure, demonstrating four 
separate, intercorrelated domains: Occupational QOL (e.g. “I feel challenged by my 
work”); Health QOL (e.g. “My diet is not nutritionally sound”); Sexual QOL (e.g. “I am 
content with my romantic life”); and Emotional QOL (e.g. “My mood is generally 
depressed”). It has been demonstrated to be a practical and psychometrically sound 
instrument for measuring quality of life. 
6.3.5 MODEL FOR STUDY OF SEX STEROID REGULATION OF NORMAL 
ECTOCERVICAL EPITHELIAL CELLS 
Despite clinical studies yielding considerable information regarding pathological 
processes in the cervix, little has been known about the underlying mechanisms 
responsible for these changes. Part of the difficulty was the absence of an adequate 
human ectocervical epithelial cell culture system. We established conditions for growing 
human ectocervical epithelial cells (ECE), proved that they were indeed ECE cells 
phenotypically different from epidermal keratinocytes and endocervical cells, and that 
they retained a high degree of differentiated function. Thus, they can be regulated by 
physiological levels of the appropriate sex steroid hormones. We considered this 
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system, therefore, to be useful for future studies on the effects of a variety of agents, 
including the sex steroids, on the female ectocervix.32    
 
6.3.6  OTHER INSTRUMENTS 
Hot flashes are the most frequent menopause-related symptoms, and the likelihood of 
impairing activities is related to the number, frequency, and intensity over any specific 
time period. This was not initially recognized, and only received adequate attention as 
studies were undertaken to determine the impact of therapies on these parameters. 
This was another area I have been involved in quantifying, indirectly with meetings with 
the Food and Drug Administration (FDA) in the United States as they developed their 
Guidance for the pharmaceutical industry for pharmaceutical studies, and also as I was 
involved in randomized placebo-controlled drug studies.12, 21,24 The preceding 
references are examples of this work, which will be dealt with in greater detail later.  
 
Sexual dysfunction is also impacted by the menopause transition. It too has been an 
area of poor mechanisms of clinical evaluation and quantification until recent years. In 
this instance, while directly involved in clinical study for measuring impact of natural and 
surgical menopause on sexual function, I have only superficially been involved in the 
development of structured diagnostic methods that can be used to diagnose female 
sexual dysfunction and its subtypes in postmenopausal women.25  We did develop a 
structured diagnostic method (SDM) to enable diagnosis of female sexual dysfunction 
(FSD) in postmenopausal women by healthcare professionals who are not FSD experts. 
We were able to demonstrate that the method had good convergent validity and 
excellent intrarater reliability and so to conclude that our SDM can reliably diagnose 
FSD status and FSD subtypes in postmenopausal women. 
 
 
SUMMARY - SEMINAL CONTRIBUTION #3 
 
Faced with a lack of methods to quantify the potential physical and clinical impact   of 
the menopause transition, I was forced to develop techniques for accurate quantification 
of change. The areas I have made a contribution to, in this respect, include: 
1. Documenting the role of  the parabasal cells of the vaginal smear as being 
adequately reflective of the level of estrogenicity of the postmenopausal woman. 
Thus, a simple vaginal smear was recognized as a good clinical instrument in 
determining therapeutic indications for estrogen therapy. 
2. Identifying the relationship between plasma calcium levels and estrogenicity 
presented an early potential marker of change in bone metabolism. 
3. Involvement in the evaluation and determination of the role of successive 
technologies for measurement of bone density. 
4. The development and validation of a precise instrument for measuring and 
following global quality of life. The UQOL is established in contemporary 
research as a good instrument for following four inter-related domains of quality 
of life. 
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5. Development of a laboratory cell line of ectocervical epithelial cells that can serve
as a system for studying the effects of a variety of agents, including the sex
steroids, on the female ectocervix.
6. Helping develop and test instruments to measure vasomotor symptoms and
domains of sexual function.
6.4 PHYSIOLOGY AND MECHANISMS 
I have never been a bench researcher. However, in attempting to elucidate 
endocrinological effects of the menopause transition, and the clinical and metabolic 
effects of exogenous hormone treatment, I have worked closely with researchers in 
proposing and testing theories and mechanisms. Therefore, in this section, unless I 
have been solely responsible for a specific study, I use the collective term “we” in 
acknowledging the colleagues with whom I have had a close working relationship. 
Some of these were at other institutions, and some have been my research staff or 
Fellows in training in my own institution. The latter without exception have gone on to 
outstanding personal academic careers. In this section, I particularly recognize the 
collaboration of George Gorodeski MD PHD, now Professor of Reproductive Biology at 
Case Western Reserve University, who joined my department in 1984, completed his 
PHD with me, and remained on my staff as a member of my faculty. 
6.4.1 DIFFERENT ESTROGENS HAVE DIFFERENT EFFECTS 
Despite prevailing dogma that all estrogens were the same, and that any variation in 
affect was dose related, I designed a series of studies to test the hypothesis. In 
comparative randomized-controlled studies, different estrogens in bioequivalent dose, 
actually demonstrated a remarkable degree of variance in impact on metabolic 
effects.12, 26,27.   For example, conjugated equine estrogens (CEE), but not an equivalent 
dose of estradiol valerate, were extremely effective in reducing the plasma calcium 
levels of oophorectomized women (p <0.0025).26 This suggested that such therapy 
might be of value in preventing osteoporosis, at least if administered to premenopausal 
women undergoing oophorectomy. On the other hand, administration of estradiol 
valerate continuously for 6 months to 50 oophorectomized females resulted in a 
decrease of the total serum cholesterol value of possible significance (p <0.05), 
whereas CEE administration had no or little effect on the cholesterol values.27
Further confirmation of this variation in effect was demonstrated in a later randomized 
placebo-controlled study comparing a nonsteroidal estrogenic product P1496, against 
CEE. The P1496 was demonstrated to have a statistically significant advantage over 
the CEE in reducing plasma calcium and cholesterol, and in doing so might in fact also 
represent the first study of a SERM (selective estrogen-receptor modulator).55
6.4.2 PITUITARY GONADOTROPIN IMPACT OF ESTROGEN  ADMINISTRATION 
There was a prevailing dogma that exogenous estrogen administration after menopause 
should reduce gonadotropin levels back to premenopausal values. The idea was that 
postmenopausal estrogen dose requirements could be titrated to follicle stimulating 
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hormone (FSH) or even luteinizing hormone levels (LH). We tested this hypothesis in a 
series of clinical studies. An initial study demonstrated significant depression of LH 
levels in postmenopausal women on doses of 1.25 and 2.5 mg CEE.28 The higher dose 
had no advantage over the lower dose, but both are high therapeutic doses. A 
subsequent study was therefore undertaken to serially measure FSH, LH and estradiol 
(E2) levels in premenopausal patients before and after hysterectomy with 
oophorectomy, and then to determine the incremental impact of CEE administration 
starting with the low dose of 0.3 mg per day, increasing to 0.625, 1.25, and finally 2.5 
mg per day, on these plasma levels. In only one instance did CEE succeed in reducing 
FSH to premenopausal levels, and that was at a dosage of 2.5mg, in which instance the 
estradiol level was higher than the premenopausal level. Thus this study indicated that 
CEE alone in dosages up to 2.5 mg per day was unable to reproduce in 
postmenopausal women the gonadotropin and E2 levels shown to exist prior to 
oophorectomy. It was concluded that usual CEE treatment after menopause does not in 
itself represent physiologic “hormone replacement therapy” (HRT), if defined as the 
dosage required to maintain premenopausal circulating concentrations of reproductive 
hormones.29  This study presaged the advent of low dose hormone therapy, and the fact 
that there was no need to try and emulate in postmenopausal women, the hormone 
profiles of premenopausal women. 
 
6.4.3 CELLULAR PHYSIOLOGY 
It was not until the early 1900’s that the modern conception of ovarian physiology took 
shape. Estimation of the estrogenic effect on vaginal smears is based on an observation 
by Stockard and Papanicolaou that the vaginal epithelium of rodents becomes cornified 
at the onset of estrus (Stockard CR, Papanicolaou GN. The existence of a typical 
oestrus cycle in the guinea pig with a study of its histological and physiological changes. 
Am J Anat 1917;22:225). We set out in a series of experiments to explain the changes 
in human vaginal and cervical epithelium at a molecular biological level. The first step 
was to develop a useful model for the study of sex steroid regulation of normal 
ectocervical epithelial cell  (ECE) function, reporting the methodology in 1990.32 
 
Our first results investigating the function of ECE cells suggested that:33 
1. in vivo, ectocervical cell squame formation is regulated by the direct action of 
estrogens, progestins, glucocorticoids, and retinoids; and 
2. envelope formation is not regulated by changes in the cellular content of the 
envelope precursor, involucrin. 
 
We tested this hypothesis directly by making detailed dose-response curves and 
concluded:34 
1. Differentiation-enhancing actions of glucocorticoids and estrogens can be 
antagonized by either progestins or retinoids. 
2. Glucocorticoids and retinoids are likely to determine the ECE cell-differentiation 
set point in vivo, with the sex steroids directly modulating the phenotype of the 
ECE cells around this set point during the menstrual cycle. 
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3. These results appear to explain some of the clinical descriptions of changes in 
ectocervical cell morphology resulting from hyper- and hypoestrogenic 
stimulation.  
 
Finally, we looked at the interaction between growth factors and sex steroids in 
regulating human endometrial stromal cell growth and differentiation. None of the 
growth factors tested (epidermal growth factor, basic fibroblast growth factor, insulin, 
insulin-like growth factor-I, IGF-II, or platelet derived growth factor) stimulated the 
growth of human endometrial stromal cells grown in progestin-free medium. Growth of 
progestin-treated cultures was dramatically increased by some growth factors, and 
estrogen could not substitute for progesterone in this protocol. Thus, we concluded that 
human endometrial stromal cell growth is:35 
1. regulated by a discrete set of growth factors, only a subset of which regulates 
stromal cell differentiation; and 
2. regulation of stromal cell growth and stromal cell differentiation by growth factors 
is progestin dependent. 
 
These studies have continued over the subsequent years, but my interest had taken a 
different course, and my role as a coinvestigator in this area ended.  
 
6.4.4 MECHANISMS INTO THE DEVELOPMENT OF CARDIOVASCULAR 
 DISEASE 
Multiple reports prior to 1970 linked changes of plasma cholesterol levels with bilateral 
oophorectomy in humans and experimental animals. Exogenous estrogens were also 
demonstrated to have effects on cholesterol metabolism. But in no instance were 
identical population groups studied and compared before and after oophorectomy and 
after estrogen therapy. In 1972, I reported on a prospective investigation into the effects 
of bilateral oophorectomy and subsequent estrogen therapy on serum cholesterol 
values in identical and statistically comparable groups of women. Oophorectomy was 
not shown to be associated with any significant increase in serum cholesterol levels. 
Moreover, exogenous estrogen was shown to have only a minimal impact on 
depressing serum cholesterol values, and of interest this property was not present in all 
estrogens tested. The conclusion of the study was that “these findings are considered 
sufficient evidence for questioning the empirical use of estrogenic hormones for the 
prevention of ischemic heart disease in postmenopausal women”.27  
 
Little was known about the actual mechanism of cholesterol agglomeration, particularly 
the role of unesterified cholesterol in atherogenesis, and most information was derived 
from studies that focused on the esterified form of cholesterol. In fact, unesterified 
cholesterol constitutes the major part of the total cholesterol mass of degraded low 
density lipoprotein (LDL). As this was most likely to play a role in lipid accumulation in 
peripheral tissues, notably in extracellular tissues of arterial walls, we therefore 
investigated the unesterified cholesterol aggregates in human arteries. The objective 
was to localize and characterize unesterified deposits in human arteries and to correlate 
this with the severity of the atherosclerotic lesion. We reported an order of age-related 
progressive severity of the atherosclerotic lesion that allowed us to formulate a working 
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hypothesis with respect to a possible physical aspect of unesterified cholesterol 
deposition in the arterial wall. The two-stage hypothesis involved a first stage in which 
there is small particle aggregation, but which is reversible. In the second stage, there is 
more massive agglomeration of irregularly shaped particles containing unesterified 
cholesterol and calcium phosphate. In this stage the cholesterol has made a transition 
to a post crystallization solid state, and the process is irreversible.36 These findings are 
particularly important because of the current suggestion from clinical studies that 
exogenous estrogen therapy commenced early in the process of atherogenesis in 
postmenopausal women may be cardioprotective, whereas therapy started several 
years after menopause may in fact be deleterious and result in increased risk of heart 
attack. That is, our earlier studies on postmortem aortas provide plausibility to 
contemporary thinking regarding the chronology of risk for coronary vascular disease in 
postmenopausal women. 
 
Recognizing that the risk of coronary artery disease in women before menopause is 
much lower than men of the same age, but increases steeply after menopause, we 
hypothesized that this could probably be a disorder of microvascular reactivity. Support 
for this idea is added by findings that women have less occlusive vascular disease than 
men of the same age, but a higher incidence of angina pectoris with normal coronary 
angiograms (i.e. syndrome X). Our earlier experiments had demonstrated modulation 
effects by sex hormones on flow velocity in the parametrial artery of pregnant rats.37 
Accordingly, we designed a series of experiments in rabbits to test the hypothesis that 
estrogen diminishes coronary vascular resistance and thereby increases coronary blood 
flow. Estrogen or its vehicle was administered in different groups either intramuscularly 
or transdermally for varying periods of time. In all instances, coronary blood flow was 
increased by an order of about 50%. Moreover, in all groups of experiments, the 
increments in coronary blood flow evoked by estrogen were virtually abolished by NG-
nitro-L-arginine, an inhibitor of nitric oxide synthase, leading us to conclude that 
estrogen regulates coronary blood flow, in part by upregulating nitric oxide synthase in 
the coronary vasculature.39  
 
We were also puzzled by our observations in pregnant rats that estrogen and 
progesterone may have opposing effects on blood flow.37  Narrative descriptions in the 
literature had also suggested that migraine headache, a vascular-related problem, had 
a relationship to the menstrual cycle, and that various combinations of estrogens and 
progestogens  could induce symptoms of syndrome X. The question was whether the 
progesterone or progesterone-like substances (progestogens) were responsible for 
attenuating the blood flow enhancing effect of the estrogen. In our first experiment, 
utilizing a Langendorff isolated perfused heart model of ovariectomized normal adult 
rabbits, we demonstrated that in the female rabbit progesterone may significantly 
attenuate the estrogen-related decrease of coronary vascular resistance.38 We then, in 
a further series of experiments, tested the impact of progesterone and several 
progestogens (megestrol acetate, norethindrone, medroxyprogesterone acetate) on the 
regulation of coronary flow in female rabbits. We confirmed again that estradiol 
decreases coronary vascular resistance, and hence increases coronary flow. Treatment 
of the animals with progestogens alone had little effect on coronary flow. However, 
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when administered with estradiol, all progestogens and progesterone abrogated the 
estradiol-related increase in coronary flow.40  In later years, there were clinical studies 
suggesting that administration of combined estrogen and progestogen might be 
associated with an increased risk of heart attack in the first year of therapy. These 
earlier studies may be evidence of a potential mechanism. 
 
We were further intrigued by reports suggesting that estrogens might act directly on the 
cardiac myocytes and in this way affect the mechanical performance of the heart. To 
clarify these findings, we tested the hypothesis that the overall influence of estrogen on 
the coronary circulation and its influence on the contractile function of the heart would 
combine synergistically to exert a cardioprotective effect. Adult female rabbits were 
treated with either estradiol or with the vehicle (control) and the hearts subjected to the 
Langendorff perfusion technique. Cardiac stunning was achieved by halting of the 
perfusion of the coronary vasculature for four successive periods of 1, 3, 5, and 15 
minutes, followed by reperfusion between nonperfusion periods. In summary, short-term 
treatment of adult female rabbits with doses of estrogen that are physiologic for the 
rabbit exerted a protective effect on cardiac contractility and relaxation from repetitive 
flow deprivation and reperfusion. The results confirmed that estrogens are 
cardioprotective agents in females.43 The molecular mechanisms by which estrogens 
protect the heart from the detrimental consequences of ischemia and reperfusion are 
unclear. A possible protective mechanism is the nitric oxide (NO) system because NO 
may act as a scavenger of free radicals, and, as described above, estrogens tend to 
increase NO activity in the coronary vasculature. Another possible explanation could be 
modulation of endothelial permeability. 
 
 In view of the foregoing, we designed studies to determine the effects of estrogen on 
transendothelial paracellular permeability in women. Cultured human umbilical vein 
endothelial cells (HUVEC) form tight junctions. Estrogens were shown to increase the 
cation selectivity across HUVEC cultures. That is, we reported from these experiments 
that HUVEC’s form a confluent epithelium on filters and that the endothelial cells form 
intercellular connections which restrict free movement of anions, relative to cations, 
through the paracellular pathway. Our results also indicated that estrogens increase the 
cation selectivity of the paracellular pathway, and suggest that the effect of estrogen is 
mediated by an estrogen receptor. These effects may be important for vascular 
protection in cases of sudden changes of ion levels across the capillary wall, such as 
ischemia or reperfusion.41 We then designed a series of experiments to test the 
hypothesis that the effects of estrogen on HUVEC permeability are mediated by NO-
related mechanisms. In summary, we presented results in HUVEC that revealed a dual 
modification of endothelial paracellular permeability by estrogen: 
1.  An eNOS-, NO-, cGMP-dependent decrease in permeability  activated by nanomolar 
concentrations of estradiol resulting in enhanced Cl- influx and increased cell size, and 
2.  An iNOS- and NO-dependent increase in permeability activated by micromolar 
concentrations of estradiol resulting in enhanced Cl- efflux and decreased cell size.  
The net effect on transendothelial permeability will depend on the relative contributions 
of each of these two systems. Understanding the mechanisms by which estrogens 
modulate endothelial permeability may be important for development of drugs that can 
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target the specific mechanisms involved in the actions of estrogen and may provide the 
pharmacological means to selectively regulate the permeability.42   
 
SUMMARY - SEMINAL CONTRIBUTION #4 
 
Working alone or with coinvestigators I have been able to contribute some significant 
basic research findings toward explaining the fundamental physiology and mechanisms 
of disease, and the pharmacologic function of female hormones. These contributions 
include: 
1. I was the first investigator to suggest that different estrogens demonstrate 
different properties and effects. Studies with the nonsteroidal estrogenic product 
P1496 might also represent the first study with a SERM. 
2. The prevailing dogma that hormone replacement therapy dosage should be 
titrated to gonadotropin levels was shown to be incorrect. Moreover, low dosages 
of estrogen were shown to be potentially effective, presaging the advent of low-
dose hormone therapy. 
3. We were amongst the first investigators to explain changes in human vaginal and 
cervical epithelium at a molecular biological level. 
4. Through a series of studies and experiments, a window has been opened into 
explaining the role of estrogens and progestogens in potential protection from 
and pathogenesis of cardiovascular disease. 
1) The impact of bilateral oophorectomy and replacement estrogen was 
studied and “these findings considered sufficient evidence for questioning 
the empirical use of estrogenic hormones for the prevention of ischemic 
heart disease in postmenopausal women”.27 
2) Our studies of unesterified deposits in human arteries demonstrated 
correlation with the severity of the atherosclerotic lesion. This allowed a 
working two-stage hypothesis involving a reversible first stage in which 
there is small particle aggregation, and a  second irreversible stage with  
more massive agglomeration of irregularly shaped particles containing 
unesterified cholesterol and calcium phosphate. These findings are 
particularly important because of the current suggestion from clinical 
studies that exogenous estrogen therapy commenced early in the process 
of atherogenesis in postmenopausal women may be cardioprotective, 
whereas therapy started several years after menopause may in fact be 
deleterious and result in increased risk of heart attack. 
3) Our early experiments demonstrated modulation effects by sex hormones 
on flow velocity in the parametrial artery of pregnant rats.37  Following on 
this we showed coronary blood flow to increase by an order of about 50% 
and to be virtually abolished by NG-nitro-L-arginine, an inhibitor of nitric 
oxide synthase. We were able to conclude that estrogen regulates 
coronary blood flow, in part by upregulating nitric oxide synthase in the 
coronary vasculature. 
4) Puzzled by our observations in pregnant rats that estrogen and 
progesterone may have opposing effects on blood flow, we were the first 
to prove that when administered with estradiol, all progestogens and 
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progesterone abrogated the estradiol-related increase in coronary flow.40  
These studies may be evidence of a potential mechanism to explain later 
clinical studies suggesting that administration of combined estrogen and 
progestogen might be associated with an increased risk of heart attack in 
the first year of therapy. 
5) To investigate whether estrogens might act directly on the cardiac 
myocytes and in this way affect the mechanical performance of the heart, 
we demonstrated that the overall influence of estrogen on the coronary 
circulation and its influence on the contractile function of the heart 
combine synergistically to exert a cardioprotective effect. The results 
confirmed that estrogens are cardioprotective agents in females. 
6) Because that cardioprotective effect could result from modulation of 
endothelial permeability, we investigated and effectively demonstrated that 
the net effect on transendothelial permeability depends  on the relative 
contributions of each of two systems. This has current relevance because 
understanding the mechanisms by which estrogens modulate endothelial 
permeability may be important for development of drugs that can target 
the specific mechanisms involved in the actions of estrogen and may 
provide the pharmacological means to selectively regulate the 
permeability. 
 
In summary then, my seminal contribution in investigating the potential relationship 
between female hormones, ovarian function, and heart disease has been to identify 
areas in need of study, and to work closely with colleagues in attempting to clarify those 
relationships. The outcome has been to provide a further impetus to elucidating the 
basic biological mechanisms of this important component of women’s health. 
 
 
6.5 CHARACTERIZING MENOPAUSE, SPECIFIC SYMPTOMS, AND 
 CHRONIC CONDITIONS 
 
It is quite extraordinary how frequently in medicine a finding published three, four,  or 
more decades ago languishes in obscurity until the observation is rediscovered and that 
idea then becomes the newly accepted dogma.  An example of this phenomenon is  the 
summary statement from the March 21-23, 2005, National Institutes of Health (NIH) 
State-of-the-Science Conference, titled “Management of Menopause-Related 
Symptoms.”   (NIH State-of-the-Science Panel. National Institutes of Health State-of-the-
Science Conference Statement: Management of Menopause-Related Symptoms. 
Annals Int. Med. 2005;142:1003-1013). 
 
 In 1972, I published a paper based on several years of PhD thesis work at the 
University of Cape Town titled “The True Clinical Features of Postmenopause and 
Oophorectomy and Their Response to Oestrogen Therapy.”12,46  The summary read, in 
part, as follows: “The true clinical effects of endogenous oestrogen withdrawal  following 
bilateral oophorectomy and menopause were assessed….The subsequent response of 
these effects to exogenous oestrogen therapy was determined, and true hormonal 
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effects differentiated from simple placebo responses. It was found that the only 
symptoms directly associated with the menopause and occurring specifically after 
oophorectomy are those related to hot flushes and atrophic vaginitis. In turn, these 
symptoms are the only ones to be specifically relieved by exogenous oestrogen 
therapy….The symptoms of depression, irritability, angina pectoris, insomnia, and 
palpitations responded significantly to placebo therapy and are, therefore, most likely of 
psychological origin….the use of indiscriminate oestrogen therapy as a panacea against 
any ‘postmenopausal symptom’ other than hot flushes or atrophic vaginitis is 
condemned.” 
 
These findings formed the basis of a 1976 report from an international task force, 
chaired by the late David Serr and me, convened at the time of the First International 
Congress on Menopause in France, to classify the symptomatology associated with 
menopause. The key summary statement published read as follows: 
“Climacteric symptoms and complaints are derived from 3 main components: 
1.  Decreased ovarian activity with subsequent hormonal deficiency resulting in early 
symptoms (hot flushes, perspiration, and atrophic vaginitis) and late symptoms related 
to the metabolic change in the end organ affected. 
2.  Sociocultural factors determined by the woman’s environment. 
3.  Psychologic factors, dependent on the structure of the woman’s character.”6 
 
Twenty-eight years later, these findings were confirmed in Melbourne, Australia. 
Dennerstein et al concluded from a longitudinal, prospective, population-based study of 
menopausal symptoms in 438 women observed for 7 years, during which time 172 
advanced from premenopause to perimenopause or postmenopause, that:  “Although 
middle-aged women are highly symptomatic, the symptoms that appear to be 
specifically related to hormone changes of the menopausal transition are vasomotor 
symptoms, vaginal dryness, and breast tenderness. Insomnia reflected bothersome hot 
flushes and psycho-social factors.” (Dennerstein L, Dudley EC, et al. A prospective 
population-based study of menopausal symptoms. Obstet. Gynecol 2000;96:351-358). 
 
The NIH meeting, 33 years after my original report, confirmed in their summary 
statement that there is strong evidence that menopause causes vasomotor symptoms 
and vaginal dryness, moderate evidence that menopause is the cause of sleep 
disturbance in some women, and an absence of evidence showing that menopause 
might be a cause of depression, anxiety, and/or irritability. They also stated that there 
was insufficient information to conclude any causal relationship between the 
menopausal transition and difficulty thinking, forgetfulness, or other cognitive 
disturbances. Other than a definite relationship between painful intercourse from vaginal 
atrophy and dryness, a causal relationship between menopause and libido was 
considered to have not been established.  
 
Clearly then, despite the fact that these reports originate from four continents and vary 
vastly in date reported and methodology used to address the question, they all are in 
agreement in defining true menopause-related symptoms during the peri-  and early 
postmenopausal years, and confirm the validity of my original studies. Moreover, the 
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NIH State-of-the-Science Panel confirmed my other studies into the lack of confirmation 
of any impact of menopause or bilateral oophorectomy in premenopausal women  on 
minor or major psychiatric symptoms. 47-50  
 
As a result of my combined studies, the menopause transition was identified as a 
potential endocrinopathy. These studies really set the foundation for defining the 
symptoms and physical signs related to the changes in endocrine profiles. Specifically, I 
was able to demonstrate that the early direct symptoms of menopause are few, that the 
response by women to those symptoms are impacted by psycho-socio-cultural factors, 
and that long-term problems may result from metabolic changes, for example, bone loss 
leading to osteoporosis or cardiovascular changes increasing the risk of cardiovascular 
disease.44,45,51-54 
 
Of further significance was the demonstration that symptoms responsive to estrogen 
replacement therapy could be differentiated from symptoms responding to general 
supportive and placebo therapy. Indeed, so well recognized are these findings at the 
present time, they form the basis of evidence-based guidelines identifying the specific 
symptom-indications for hormone therapy after menopause that have been published by 
various national and international scientific organizations worldwide. 
 
These studies have also demonstrated that while the treatment of the postmenopausal 
women with estrogens may alleviate true menopause-related symptoms, they may also 
induce a pharmacologic effect such as enhancing the sense of well-being.47,49,50  In this 
respect, my 1972 paper on the “mental tonic effect of oestrogens administered to 
oophorectomized females” was a pioneering paper and the first in the medical literature 
to prove this relationship with appropriate clinical research.47  The papers of 1972 were 
also the first to reveal the placebo effect of hormones administered to postmenopausal 
women.46,47 
 
Finally, as part of these studies, it was possible to determine the clinical response to 
removal or conservation of ovaries at the time of hysterectomy in women of 
reproductive age. Retained ovaries were demonstrated to remain fully functional for at 
least 2 years after surgery.12,13,15,26,27,44-46  It was therefore possible to “make a plea for 
the conservation of functional ovaries at the time of hysterectomy”12  in women of 
reproductive age, something that was foreign to general clinical practice at that time. 
Previously the general consensus was that ovaries were of little value post surgery, and 
representing an unacceptable cancer threat, justified excision. 
 
 
SUMMARY - SEMINAL CONTRIBUTION #5 
 
1. The menopause transition was shown to represent a potential endocrinopathy. 
2. The definitive symptoms and physical signs directly related to the change in 
endocrine profiles were defined and classified. 
3. Those symptoms responsive to estrogen replacement therapy were differentiated 
from those responding to general supportive and placebo therapy. This finding 
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has formed the foundation for national and international evidence-based 
guidelines for symptomatic indications for estrogens after menopause. 
4. The mental tonic effect of estrogens, or ability to produce a feeling of well-being, 
was scientifically documented and established for the first time. 
5. The significant response of vasomotor symptoms to placebo in randomized 
placebo-controlled clinical research studies of estrogen therapy was recognized 
and reported for the first time.  
6. The continued function of ovaries conserved at the time of hysterectomy in 
premenopausal women was confirmed, and a plea made for their conservation at 
a time during which routine ablation of the ovaries concomitant with hysterectomy 
was standard practice. 
 
 
 6.6 NEW DRUGS AND DELIVERY SYSTEMS 
 
My early research, such as that referred to above, had convinced me that the available 
exogenous sex steroids generated different clinical and metabolic effects. Indeed, I had 
demonstrated a remarkable variance even between steroidal and nonsteroidal products, 
with a nonsteroidal analogue demonstrating estrogenic similarities to conjugated 
estrogens, but also clear variances. 55   I was also in the fortunate situation of being 
appointed Chairman of Obstetrics and Gynecology at the Mt. Sinai Medical Center of 
Cleveland at the end of 1979, an affiliate department of Case Western Reserve 
University School of Medicine. This allowed me to open my own clinical research 
center. 
 
Over the subsequent quarter century I have been intensely involved in clinical safety 
and efficacy studies of multiple substances, dosage forms, routes of administration, and 
drug combinations and regimens. My role has varied from Principle Investigator at a 
single site to collaborating in multicenter studies, often as National Principle 
Investigator. In more recent years, my clinical research center was established as a 
free-standing independent site, greatly enlarged in capacity, and a significant site in the 
United States for menopause-related Phase II and Phase III new drug studies.  
 
This section illustrates my progression and activities in the development of drugs for 
potential therapeutic use after menopause without giving the detailed differences 
between each of these drugs. While these findings are considered seminal to the 
development and investigation of products designed for enhanced safety and efficacy, it 
is the evolutionary process rather than the detail that I consider to be my personal 
contribution to this area of medical progress. 
 
My initial efforts were to compare different estrogens available on the market in head-to-
head studies.12,26,27 These are not usual in the area of testing of products designed for 
menopausal therapies, most undertaken as  placebo-controlled studies.56  But they do 
offer the advantage of comparing new substances to what is currently available in order 





Determination of lowest effective dose through dose-response studies is critical to 
reducing potential risk as well as lowering cost.  From the outset of testing hormonal 
therapies, I have been directly involved in planning and executing such studies. Indeed, 
I have been the Principle Investigator of the two largest pivotal studies into dose-
response comparisons with both oral conjugated equine estrogens and 
medroxyprogesterone acetate (the HOPE study),21    and the transdermal  estradiol 
patch.61 Perusal of my publications bears witness to my role in utilization of lower doses 
by, for example, my earliest studies recommending doses of conjugated equine 
estrogens of 1.25 to 2.5 mg per day, and my most recent studies promoting 0.3 to 0.625 
mg per day, or equivalent low doses. 
 
New product development is of extreme importance in the constant search for ways to 
enhance benefit and reduce risk. Examples of my contribution to new drug development 
include P1496 (an estrogen analogue)55  and a new synthetic, 10-component, modified 
release conjugated estrogen tablet.62,63  At this time, both the latter papers represent the 
only scientific clinical studies published on these products. Another new product 
investigated was a novel estrogen, estradiol acetate, which is an estradiol prodrug.67 In 
head-to-head comparative studies, we demonstrated this product to be well tolerated 
and effective in treating vasomotor and urogenital symptoms in postmenopausal 
women.    
 
In the early 1980’s evidence began to develop that a nonoral route of administration of 
estrogen might offer advantages over the traditional oral route. The key objective was to 
determine whether avoidance of the first liver passage that follows absorption of drugs 
taken orally, would reduce the liver-induced side effects of the orally induced drug 
bolus.  
 
Initially working with scientists at the Ciba-Geigy Pharmaceutical Company, and later 
with other companies, I was able to become involved ab initio in the development and 
testing of the transdermal patch technology. The background, overall safety profile, 
clinical efficacy, and utility, were documented in a series of communications.57-61  These 
studies included testing of the first and subsequent generation of patches, as well as  
evaluation of dose response between patches and comparison of efficacy to oral 
estrogen. In reporting on pooled data from 448 subjects, I confirmed this therapeutic 
approach to be safe and effective. “Severe adverse reactions were rare. The patch has 
been proven to be well tolerated, highly acceptable to patients and an important 
therapeutic alternative in the management of postmenopausal woman”.58 The 
transdermal patch was thus  demonstrated to be an effective mode of delivering 
estradiol while having no effect on certain liver proteins and no adverse biochemical 
changes. Moreover, vasomotor symptom relief was shown to be effective with low-dose 
transdermal patch therapy.61 
 
Another transdermal development was the evaluation of the testosterone skin patch for 
its effect on sexual function.64,66   Hypoactive sexual desire disorder (HSDD) is one of 
the most common sexual problems reported by women, yet largely ignored until 
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recently. As indicated in Section 2.3.5, the development and validation of instruments to 
measure human sexuality has been a very recent phenomenon. Utilizing validated 
instruments able to measure different domains of sexual function, we were able to 
demonstrate that in estrogen-replete surgically menopausal women with HSDD, the 
testosterone patch improved sexual function and decreased distress.66 
 
There continues to be a need to recognize other problems that may be experienced 
through and beyond the menopause transition, and my current studies are involving 
nonhormonal drugs for  symptoms such as insomnia or alternate bone active drugs to 
prevent or treat osteoporosis.65,68 
 
 
SUMMARY - SEMINAL CONTRIBUTION #6 
 
1. Different estrogens were shown to induce different clinical and metabolic effects. 
This seminal finding has influenced my search for safer and more effective 
hormonal products and routes of administration. 
2. I initiated, completed, and published the world’s first randomized, placebo-
controlled blinded study, including head-to-head comparison of bioequivalent 
doses of different estrogens. 
3. I have been the first, and sometimes only, investigator to evaluate and report on 
new products. 
4. I have been one of the initial investigators to promote scientific comparisons of 
lower doses of hormone products.  
5. I was one of the first investigators to evaluate nonoral routes of administration of 
hormones through technologies such as the   transdermal patches and gels. 
 
 
6.7 SEXUAL FUNCTION 
 
Knowledge about sexual function and sexual response after menopause is less than 
satisfactory and was virtually unaddressed at the time of my first investigations in this 
area. The perpetuation of a number of myths about sex in aging populations has 
resulted in unsatisfactory stereotyping and negative attitudes. In my first studies, 
menopause appeared to have little effect on sexual function. Painful intercourse as a 
complication of vaginal atrophy is a cause of dyspareunia, not true loss of libido. I 
reported that the operation of hysterectomy per se, irrespective of whether the ovaries 
are removed or not, is associated with a significant loss of libido. Estrogen replacement 
was shown to be of no benefit in the treatment of decreased or absent libido unless 
specifically associated with dyspareunia.46,69  Speculation as to the cause of the 
decreased libido was beyond the scope of these studies. 
 
As described in Section 2.3.5, the use of validated instruments for measuring sexual 
response and dysfunction has allowed for acquisition of meaningful data about sexuality 
and limited efficacy of current therapies.22,25,72,74   In turn, this has allowed us to develop  
recommendations and guidelines for the assessment and management  of women’s 
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sexual dysfunctions focusing on low desire, low interest, and lack of arousal, something 
I have contributed to as part of a collaborative group.75   
 
An issue relating to sexuality in the perimenopause is the need to consider reproductive 
potential and the role of contraception. My personal contributions to this literature 
focused initially on oral contraceptive (OC) formulations and their influence on user 
compliance and reliability of the method. My interest came from my experience in 
working with developing populations, and the observation that the best formulation in 
one culture, society, or economic subgroup, is not necessarily the best for another. 
Hence, I reported  recommendations to “keep it simple”.70  Another area I addressed 
related to age of onset and of use of oral contraceptives. While the danger of death from 
complications of childbirth in the woman over 40 probably outweighs that of death due 
to the use of OC’s, there remains inadequate data on ‘never-users’ over age 40 who 
start OC’s compared with matched “never-users” who go on not using it. Despite raising 
questions in the medical literature, I do not feel I have made any novel contribution in 
this area.71 
 
My initial observations on post hysterectomy ovarian function, referred to previously, 
and my subsequent involvement with the development and clinical trials of the 
testosterone transdermal patch studies in post oophorectomized estrogen-replete 
women, allowed for my further observations relating to problems with desire and arousal 
in surgically menopausal women. By 2005, I was able to conclude that “depletion of 
testosterone levels may be a contributor to loss of desire postoperatively. In turn 
testosterone patch therapy was shown to significantly increase sexual desire and 
activity scores in controlled clinical trials in surgically menopausal women with female 
sexual desire disorder (FSDD) receiving concomitant estrogen.” 74   Additional studies 
remain necessary to define the long-term safety profiles of individual testosterone 
formulations in this population. At this time, I am involved in conducting such studies, 
including determination of the effects of testosterone administration to the surgically 
menopausal woman without added estrogen therapy. 
 
 
SUMMARY - SEMINAL CONTRIBUTION #7 
 
1. My oophorectomy studies in women of reproductive age, and assessment of  the 
role of exogenous estrogen replacement, were the first of this type in this 
population, and brought attention to an area in need of research. 
2. I have worked as part of collaborative groups in developing and testing validated 
instruments for measuring female sexual response. 
3. Estrogen therapy after surgical menopause was shown to be of no value in 
restoring or enhancing libido. But in later studies of testosterone in estrogen-
replete surgically menopausal woman, the testosterone was shown to 





6.8 BODY WEIGHT  
 
Three questions have existed for many years regarding an association between body 
weight and female sex steroids: 
1. Is the menopause per se associated with weight gain? 
2. Does exogenous hormone therapy to the postmenopausal woman induce an 
increase in body weight? 
3. Does body mass influence the dose requirement for hormone therapy? 
 
My personal research was not designed to answer the first question, but did address the 
second question. In 1978, I was able to report that neither estradiol valerate nor 
conjugated equine estrogens were associated with any increase in body weight.76  This 
finding did not gain widespread recognition. Twenty five years later, as Principle 
Investigator of the largest randomized, placebo-controlled, dose-ranging study ever 
undertaken, we were able to confirm that indeed, lower and standard-dose regimens of 
CEE or CEE/MPA are not associated with greater weight gain than placebo.77,78  This is 
a seminal finding, and hopefully lays that particular myth to rest. 
 
In the latter study, we also addressed the third question, namely, whether there is an 
influence of body mass index (BMI) on the effect of different doses of hormones on 
vasomotor symptoms, vaginal atrophy, bone mineral density (BMD), endometrial safety, 
and side effects such as endometrial bleeding and breast pain. Fortunately, the results 
of this 2-year study conducted in 2,673 women enrolled at 57 sites in the United States, 
was able to provide a definitive answer to this vexing question. Results from the study 
demonstrated that in a large population of healthy, early postmenopausal women, 
baseline BMI had no influence on vasomotor, vaginal, and endometrial responses to 
various doses of CEE and CEE/MPA. Nor did BMI affect the occurrence of side effects 
such as endometrial bleeding or breast pain. These results were able to demonstrate for 
the first time that the therapeutic effectiveness of lower dose ET/HT is not influenced by 
a woman’s BMI. The conclusion was that, whereas the evaluation of BMI should be 
included in the overall health assessment of women entering menopause, BMI need not 
be considered when determining the clinical dose of ET/HT for menopause symptom 
relief.76,77 
 
SUMMARY - SEMINAL CONTRIBUTION #8 
 
1. I was the first to report that exogenous hormone therapy to the postmenopausal 
woman does not induce an increase in body weight. 
2. We were able to report from a large multicenter study, that BMI is not an 








6.9  QUALITY OF LIFE 
 
Quality of life (QOL) is increasingly being recognized as a key outcome measure of 
quality of healthcare. Moreover, it is now widely accepted that a clear distinction needs 
to be made between health-related QOL (HRQOL) and global or overall QOL. HRQOL 
can be conceptualized as a patient’s perception of their physical, cognitive, and mental 
health. Global QOL is a broader measure and may be defined as a reflection of a 
person’s beliefs about functioning and achievements in various aspects of life, that is, 
an overall sense of life satisfaction and well-being.  
 
As mentioned in Section 2.3, measuring global QOL was dependent on the 
development of validated instruments targeted at this specific population. My 
contributions to medical science in this area therefore fall under three headings: 
1. Development of a validated instrument, the UQOL. This was described in Section 
2.3. 
2. Research contributions into multiple therapies for reducing or alleviating specific 
menopause-related symptoms, with consequent enhancement of HRQOL. 
3. Application of the UQOL in clinical research to demonstrate the impact of specific 
treatments on global QOL. 
 
Strictly speaking, much of my entire body of work as summarized in this doctoral 
submission has been directed at addressing item #2 above. Thus, identifying the true 
symptoms and potential pathologies associated with the menopause transition, and 
undertaking blinded and controlled studies of various potential therapies, has resulted in 
the multiple publications demonstrating improvement with most of these therapies, and 
which are referenced in this submission. Examples that have been referred to in the 
foregoing pages include demonstration of therapeutic efficacy of hormone therapies in 
alleviating vasomotor symptoms, night sweats, enhancing sleep, improving sexual 
function, and reduction of the likelihood of fracture following osteoporosis. 
Consequently, my having demonstrated therapeutic efficacy, and publicizing these 
results in research journals, medical reviews, and other resources for modifying clinical 
health practice, must inevitably have resulted in improved HRQOL for multiple 
thousands of women. The many ways in which I have been involved beyond the actual 
research studies in disseminating information to both health providers and the 
community at large will be described in Sections 2.12, 2.13, 2.14, and 2.15. 
 
The development of the UQOL and related instruments is now allowing direct 
measurement of the effect of specific therapies on both HRQOL and global QOL. For 
example, treatment of postmenopausal women with a combination of conjugated 
estrogens and trimegestone was shown to result in significant improvement of 6 of 9 
domains of HRQOL compared to placebo.79   
 
Whereas the validation of the UQOL was horizontal or cross-sectional in nature, the 
UQOL has been demonstrated to be effective in vertical application, that is in 
randomized, blinded, prospective investigations. The first randomized, prospective 
study with the UQOL has now been completed, and multiple other studies are in 
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progress. Raloxifene, the first selective estrogen-receptor modulator (SERM) approved 
in the United States by the Food and Drug Administration (FDA), was demonstrated to 
improve the occupational and health domains in the overall score of the UQOL.80
Finally, I have also drawn attention to the fact that while the presence of a medical 
problem or symptom may negatively impact both HRQOL and global QOL, of equal 
importance is the fact that the level of QOL may impact the outcome of the medical 
problem. Utilizing osteoporosis as the example, it is clear that fracture and resultant 
pain and disability would negatively impact QOL. Less well defined has been the impact 
of global QOL on osteoporosis. But a decreased perception of well being will be 
associated with poor compliance/adherence with drug therapies, exercise programs or 
fracture outcomes. An understanding of both sides of the coin would assist healthcare 
providers to appreciate more fully the importance of prevention and treatment. 81
SUMMARY - SEMINAL CONTRIBUTION #9 
Perhaps my greatest contribution in this area has been to bring medical attention to the 
importance of defining, recognizing, accurately measuring, and enhancing quality of life 
in women through and beyond menopause. This has been accomplished through: 
1. Development of a validated instrument, the UQOL.
2. Contributions of specific research in therapy for reducing or alleviating specific
menopause-related symptoms and consequent enhancement of health related
QOL.
3. Application of the UQOL in clinical research to demonstrate the impact of specific
treatments on global QOL.
4. Multiple reviews and other educational activities.
6.10  POPULATION SURVEYS 
Contemporary healthcare necessitates clear knowledge and understanding of the 
attitudes and experience of a target population, without which adherence to preventive 
or therapeutic programs are likely to be unsuccessful. In 1993, in the absence of any 
recent published survey of women’s attitudes and experience  with menopause and 
various forms of hormone replacement therapy, we organized a Gallup Survey through 
my organization, The North American Menopause Society (NAMS), (the details on 
NAMS are presented in Section 2.15). The objectives of the study were to determine 
women’s knowledge about menopause, identify obstacles to efficient physician/patient 
communication, and to define issues of concern to women over age 45. The results 
helped in answering these questions, and are presented in the reference itself.82
However, it is not the results but the actions taken because of the results that I believe 
lead to the significant contribution of this effort. These actions lead to the recognition 
that a scientific organization, namely NAMS, had an obligation beyond its health and 
scientific constituency, and that was to the health consumer. Accordingly, NAMS 
changed its mission/vision statement, developed a consumer education division, and 
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developed multiple educational programs for the public. In addition, the lessons learned 
from the survey also influenced development of teaching materials for doctors and other 
healthcare providers.  
 
Public knowledge and attitudes are subject to constant change, and we continued to 
undertake population surveys. A repeat Gallup Survey in 1997 found women to be still 
divided in their views on menopause, some seeing it as a medical condition requiring 
treatment, whereas others see it as a natural transition to be managed by “natural” 
means. The single main source of women’s information on menopause was a health 
professional (49%). The majority of women who were already menopausal or 
experiencing menstrual changes expressed an attitude towards menopause that was 
either neutral (42%) or positive (36%).83  Again, the study confirmed that providing 
women with accurate and up-to-date information and enhancing communication 
between healthcare providers and menopausal women remained the challenge. 
 
In 1998, yet another survey was undertaken to assess perceptions held by 
postmenopausal women in the United States aged 50 to 65 years regarding their 
menopause transition and early postmenopausal years. The findings suggested an 
improving population trend. Although the postmenopausal women surveyed had 
differing views of menopause as well as their perceptions of postmenopause compared 
with premenopause, the majority viewed menopause and midlife as the beginning of 
many positive changes in their lives and health. Hysterectomy was a factor associated 
with improved sexual relationships, spouse/partner relationships, sense of fulfillment, 
and physical health.84 
 
 
In summary, population surveys are a necessary part of healthcare research. Properly 
designed with clear objectives and questions that are lucid and appropriate to the 
information being researched, these surveys provide invaluable information in 
understanding the attitudes, concerns, frustrations, and needs of the population for 
which healthcare regimens are being designed. For me, they provided important 
information on educational needs, and helped in our design, planning, and 
implementation of consumer-friendly educational programs that would clearly address 




SUMMARY - SEMINAL CONTRIBUTION #10 
 
The design and implementation of health surveys on population knowledge, attitudes, 
and experience regarding menopause and hormone therapies, was the tool which aided 
my key contribution under this section. That contribution was to recognize what the 
population was telling us about their health concerns and the health care system, and to 
translate that need into appropriately designed and distributed materials that were 
informative and understandable to that target population. 
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6.11 COST-EFFECTIVENESS ANALYSIS AND 
 PHARMACOECONOMICS 
Effective healthcare delivery is dependent on multiple factors. The health program or 
therapy must be effective, safe, and affordable. Three areas that have intrigued me for 
many years, and that have challenged me to explore in depth for mechanisms of 
analysis able to provide measurable outcomes, are: 
1. Mechanisms for quantifying risk and benefit of therapies in relation to quality of
life.
2. Considering the psychosocial and socioeconomic burden of true menopause-
related symptoms or conditions.
3. Incorporating healthcare costs into risk and benefit analysis.
In summary, then, it is essential to quantify the impact of a medical problem on the 
individual and on society, to have a clear measure of the potential risks and benefits of 
the available therapeutic approaches, and, finally, to be able to rank the costs of these 
issues in financial and quality of life terms. Only then, having these answers, can 
effective cost-efficient public health policy be developed. 
I first considered the issues of risk, cost and benefit ratios in menopause management 
in a brief 1977 review.85 In 1978, observing the swinging pendulum of medical and 
public opinion of postmenopausal hormone therapy usage, I stated “…a previously 
neglected area has become a subject of intensive research. Every new answer, 
perhaps inevitably, has posed yet more questions, so that debate and discussion have 
become even more acrimonious now than in the past. It is therefore time for us to put 
the subject in perspective; for a balanced evaluation of specific benefits and actual risks 
to be made. An attempt at evaluation of the risk benefit ratio of long-term effects of pure 
estrogens highlights the fact that, compared to the many carefully designed large scale 
epidemiologic studies on the health consequences of oral contraceptive use, no 
comparable body of data is available for pure estrogen. Despite this lack, it is possible 
to subject these risks and benefits, and their potential costs, to some form of 
mathematical evaluation and analysis, and to come out with some form of answer or 
direction.”86  
Exploring the various analytic methods and equations available in 1978 revealed two 
different analytic approaches to the assessment of health practices: 
1. Cost-benefit analysis. This values all outcomes in economic terms, requiring
human lives and quality of life to be valued in dollars.
2. Cost-effectiveness analysis. Healthcare costs are measured in dollars, but health
effectiveness can be measured as quality of life through “quality adjusted life
years.” This approach was reported in 1977 by Weinstein and Stason to evaluate
the outcomes for renal dialysis, and I immediately recognized the applicability of
this approach to menopausal therapies (Weinstein MC, Stason WB. Foundations




I modified and adapted the equation and mechanism of analysis, and reporting on the 
application of cost-effectiveness analysis to postmenopausal estrogen therapy in 1978, 
concluded that :”Application of cost-effectiveness analysis to long-term estrogen therapy 
should be of value in that it will force physicians and health planners to be explicit about 
the beliefs and values that underlie their decisions. Where points of view differ, the 
relative trade-offs can be compared more directly….At the present time the decision to 
prescribe long-term estrogen therapy must rest upon a choice between relying on a 
proper analysis despite the present imperfections, or on no analysis at all”. 86 
 
In 1982, I attempted to put actual numbers into the equations, but remarked on the 
difficulty of finding adequate accurate data.87  It was possible to conclude, despite the 
limitations, that a mechanism did exist for minimizing risks and maximizing benefits. 
Moreover “the harsh facts of limited budgets and possible rationing of health services 
are fast becoming a fact of life in medical practice. It is extremely important that 
physicians consider the implications of any health preventive program they introduce 
and that they take into account not only the potential benefit, but also the potential risks 
and the relative costs of both”. 88   
 
The modified equations for measuring cost-effectiveness analysis had thus been 
introduced into this area of health care as a mechanism for ranking the issues of 
importance. Application of this line of thought was taken further when we reported on 
the risk-benefit appraisal of transdermal estradiol therapy.90 
 
Later, I returned to my earlier interest on the psycho-socio-cultural aspects of 
menopause and menopause management. In an abstract to a paper in 1990, I stated:” 
The climacteric is a pathophysiologic event involving morphologic and clinical changes 
that can lead to clinical symptoms. This event has to be considered in the broader 
perspective of the woman’s psycho-socio-cultural milieu, which influences how she 
reacts to whatever symptoms she may experience. Studies have shown that women of 
lower socioeconomic status experience the most problems. Economic realities of the 
health care system call for cost-effectiveness analysis to determine the role of hormonal 
replacement therapy in relieving symptoms and preventing further disease, specifically 
osteoporosis and cardiovascular disease. To help make such an analysis and justify the 
cost, a series of formulas is presented, based on quality of life”. 89 
 
I returned to this subject in greater depth in 2005, stating in a detailed analysis that: 
“Menopause-associated vasomotor symptoms are associated with significant direct and 
indirect costs. Overall costs of traditional pharmacotherapy or complementary and 
alternative medicine modalities, including over-the-counter treatments and dietary 
supplements, for managing menopause-related vasomotor symptoms (VMS) are 
substantial and include initial and follow-up physician visits and telephone calls. 
Additional costs include laboratory testing, management of adverse events, loss of 
productivity at work, and personal and miscellaneous costs. Pharmacoeconomic 
analyses, including those that consider risks identified by the Women's Health Initiative, 
generally support the cost-effectiveness of hormonal therapy for menopause-associated 
vasomotor symptoms, which have been the mainstay for the management of these 
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symptoms for more than 50 years. However, because many women now want to avoid 
hormone therapy, there is a need for new targeted therapies, validated by results from 
controlled clinical trials that are safe, efficacious, cost-effective, and well tolerated by 
symptomatic menopausal women”.91 
 
The conclusion to that 2005 analysis was that the state of the art still remains less than 
satisfactory: “Menopause-related VMS are very common and can be associated with a 
high patient and societal burden… The physiology underlying VMS is complex and not 
fully understood, but it is clear that alterations in noradrenergic and serotonergic 
mechanisms during hypothalamic thermoregulation are involved in their development. A 
significant unmet need remains for menopause-related VMS treatment options. Among 
women who are eligible for the treatment of menopause-related VMS, 80% do not seek 
treatment, receive inadequate counseling, or do not have access to local medical aid. 
The development of therapies that specifically target VMS may provide high efficacy 
and reduced risk of serious and potentially costly adverse events, thus increasing the 
overall cost-effectiveness of therapy”. 91 
 
SUMMARY – SEMINAL CONTRIBUTION #11 
 
Pioneering the concept of balancing the risks and benefits of menopause-related 
hormone therapies, I was the first to introduce the application of cost-effectiveness 
analysis to this area of medicine. This emphasized the need for incorporating risk, 
benefit, the costs incurred or saved with each, as well as quality of life, into a 
measurable analysis. In turn, this will allow for impartial selection of such therapies in 
both individual and overall health planning.  Most importantly, such analyses allow for 
the ranking and comparison of the cost-effectiveness of other therapeutic modalities for 
other health problems, and placing postmenopausal hormone therapies in perspective 
within the big picture. 
 
 
6.12 HEALTHCARE DELIVERY AND MENOPAUSE CLINICS 
 
Health care for women with menopause-related symptoms was an area of medical 
neglect. A mere 25 years ago the subject of menopause was considered to be of so 
little importance that there was no real mechanism for women to get appropriate 
therapy. My contribution to describing strategy and tactics for such health care came 
through an indirect path. 
 
The concept and value of a menopause clinic for the centralization and coordination of 
menopause management was first described by me in 1977.133 The Groote Schuur 
Hospital Menopause Clinic, started in 1967 and the first menopause research clinic in 
the world, was highly successful in stimulating interdisciplinary long-term collaborative 
research, and served as a role model for later descriptions of the values of such 
clinics.53  This led to an informal discussion conducted on menopause clinics during the 
Second International Congress on the Menopause, held in Jerusalem in 1978, and a 
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formal session entitled “Menopause Clinics: purpose, function, and international 
comparisons,” during the next Congress in Ostende, Belgium, in 1981.92  
 
Volunteers to clinical research studies were reluctant to leave the Groote Schuur 
Menopause Research Clinic at the end of their research protocol, and by default 
became patients of the clinic. Lessons were learned. For example, listening to women 
discuss their problems animatedly in the waiting room led to my descriptions later of 
“menopause support groups.” 
 
The purpose and benefits of such clinics have been summarized in a number of 
papers.92-95 These will not be elaborated on here. In summary, beyond an educational 
function and screening center for many menopause and age-related health problems, 
the menopause clinic represents the most cost-effective care because it is centralized. 
All medical specialties can be involved and their services coordinated through this 
central point. They are also ideal for conducting medical research. Perhaps most 
important, the patient is able to interact with health professionals who are truly 
empathetic with the special concerns of the menopausal woman. 
 
Clearly, it is not always practical to “compartmentalize” health care. What is essential is 
that the health care be appropriate and cost effective. Menopause clinics have been 
good testing sites for evaluating protocols for optimal screening and evidence-based 
guidelines, and we have described the former as well.96,97,98.  Recommendations were 
also presented for developing a menopause component in existing medical practices.96  
 
In the 1980’s I conducted a series of teaching seminars in Cleveland for clinicians 
across North America entitled “The Menopause Clinic – A Practical Workshop,” the 
result being a proliferation of such centers of excellence.  
 
SUMMARY SEMINAL CONTRIBUTION # 12 
 
The original Groote Schuur Hospital menopause clinic was the first such facility in the 
world. Following publications on the role of such a facility, the clinic became a role 
model for similar clinics worldwide. Thus, I was the first person to start a menopause 
research clinic and then a comprehensive menopause clinic, and later to describe the 
role of such centers within the context of generalized healthcare distribution. 
 
I educated clinicians from across North America and internationally in the details of 
establishing these centers, or developing a menopause management component within 
their existing medical practices. I advised on the establishment of such clinics in South 
Africa, the United Kingdom, the United States, Europe, and Asia. 
 







6.13 CLINICAL PRACTICE GUIDELINES 
 
The concept of developing clinical guidelines or position statements is really quite 
recent, initiated in the 1970s by the U.S. National Institutes of Health with the 
development of consensus reports. The process changed radically through the 1990s 
with the “evidence-based medicine” movement that began to mandate a comprehensive 
and systematic review of the medical and scientific literature and for the requirement 
that recommendations needed to be directly linked to supporting evidence. 
 
In principle, developing position statements should be easy. Presumably, using identical 
data bases and published evidence, the process should be straightforward for any 
group developing consensus statements and clinical guidelines. So why then do 
different organizations, after scrutinizing the same evidence, come out with different 
interpretations and recommendations? 
 
The simple truth is that we will always lack a complete database. It is literally impossible 
to undertake and complete evidence-based clinical research in any area of medical 
science that incorporates all populations, subpopulations, conflicting and confounding 
factors, comorbidities and risk factors, and combinations and permutations of 
medications. The targets, such as risk factors, demographics, drug development and 
usage, and so on, keep moving and a complete contemporary database will therefore 
always be no more than wishful thinking. In short, therefore, the guideline-development 
concept would be flawed were it to rely entirely on the base of evidence existing at any 
one point in time. The process has to allow for clinical and scientific judgment to be 
taken into account by both the developer and those who ultimately put the 
recommendations into clinical practice. 
My first experience in the difficulties involved goes back to 1988, and an attempt at 
setting guidelines on progestogen use for postmenopausal women.102  It also raised my 
awareness of the need for basic rules and mechanisms for creating such documents. 
 
 As Executive Director of The North American Menopause Society (NAMS), I found 
myself in the advantageous position of being able to develop multispecialty expert 
panels, and having the organizational capacity to develop evidence-based guidelines. 
Through NAMS, we commenced development of consensus opinions in 1998, 
emphasizing that they do not represent “practice standards” that would be codified and 
held up as standards by regulatory bodies and insurance agencies.  Rather these are 
prevailing opinion pieces, attempting a best effort at incorporating current best evidence 
into practical clinical recommendations. (Boggs PB, Utian WH. The North American 
Menopause Society develops consensus opinions. Menopause, 2004;5:67-68). 
 
Since that time we have developed multiple consensus opinions and position 
statements. These have included the following: 
1. Utian WH, NAMS Consensus Group,   A decision tree for the use of  
estrogen replacement therapy or hormone replacement therapy in 
postmenopausal women: consensus opinion of the North American 
Menopause Society.  Menopause 7: 76-86, 2000.99 
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2. Utian WH, (Rapporteur) NAMS Consensus Group.  Effects of menopause 
and estrogen replacement therapy or hormone replacement therapy in 
women with diabetes mellitus: consensus opinion of the North American 
Menopause Society.  Menopause, 7:87-95, 2000.103 
3. Utian WH, (Panel Chair). Position Statement: Estrogen and progestogen use 
in peri- and postmenopausal women: September 2003 position statement of 
The North American Menopause Society. Menopause, 10:497-506, 2003.104 
4. Utian WH, (Panel Chair). Position Statement: Recommendations for 
estrogen and progestogen use in peri- and postmenopausal women: 
October 2004 position statement of The North American Menopause 
Society. Menopause, 11:589-600, 2004.105  
5. Utian WH, (Panel Chair). Estrogen and progestogen use in peri- and 
postmenopausal women: Position statement of The North American 
Menopause Society. Menopause,  14:--------,2007 (In Press) 
 
These recommendations have been translated into multiple languages and published in 
medical journals worldwide. They have exerted considerable influence in the appropriate 
usage of these medications after the menopause. But translating these positions into 
clinical practice must still necessitate taking into account the complete health profile of 
the individual woman as well as her personal preferences and beliefs. That is, the 
position statement is intended to enhance the quality of patient care and to modulate 
the clinician’s pattern of practice. Consumers of health care need to find them practical 
and acceptable. Fortunately, I have had the opportunity of explaining and further 
disseminating these positions through other vehicles, such as lectures, reviews, 
consumer education pieces, and other medical publications.100,101,106. 
 
SUMMARY – SEMINAL CONTRIBUTION #13 
 
I have initiated, coordinated, and disseminated evidence based position papers for best 
medical practice utilizing international panels of medical experts in multiple disciplines 
pertinent to the topic under consideration. These position statements have consequently 
had a major impact on medical management of the menopause. 
 
6.14 CONTRIBUTION TO INTERNATIONAL PRACTICE THROUGH 
 STATE OF THE ART REVIEWS, EDITORIALS, AND CLINICAL 
 RECOMMENDATIONS  
 
This section represents the evolution of my thinking about the subject of menopause 
over four decades. Based on my personal research, the current literature, and clinical 
experience, I produced a series of review articles and editorials that would express my 
recommendations for best clinical practice, or highlight areas of concern. This section is 
best divided into two subsections, the first with pertinent extracts from formal published 
reviews (2.14.1), and the second with selected abstracts on a chronological basis taken 
from editorials written for Menopause Management (2.14.2). 
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Since 1968, I have authored or coauthored nearly 40 major state-of-the-art reviews with 
clinical recommendations for best practice of menopause-related medicine. These are 
itemized as references 107 through 145 in Section 4. Additionally, I have written well in 
excess of 120 editorials in medical publications on virtually every facet of the subject. I 
have authored 3 books as an individual, and coauthored a further 4 books, most of which 
have also been translated into other languages. I have personally taught or lectured on 
every continent. All of these editorials and books are listed in my complete curriculum 
vitae  in Section 8, as are my major lectures and medical congress presentations.  
To attempt to summarize this massive body of work would virtually create another 
textbook, obscuring my key contributions or original ideas. Given the requirements for the 
Doctor of Science degree, I have therefore decided that instead of a narrative summary, I 
would select direct quotations from some of these publications that are representative of 
my forward thinking and seminal contributions to medical science at the time they were 
written. These unedited direct extracts or conclusions would also best represent the 
evolution of my personal thought processes over the last 40 years. Not every paper is 
abstracted, but all key publications are. Editorials from publications other than 
Menopause Management are not abstracted, but are listed in the curriculum vitae. 
6.14.1 REVIEWS: 
QUOTES FROM REVIEWS ARE PRESENTED BY YEAR  
AND REFERENCE NUMBER (SEE SECTION 4 FOR COMPLETE TITLE) 
1968/107 
The menopause, once regarded as a physiological norm, has in recent years been described as being a 
hormone-withdrawal syndrome, and this as yet unproven assumption has resulted in a spate of literature 
enthusiastically describing the prevention of various ageing processes in the older female. It is therefore 
apparent that the current concepts leading to this dramatic swing of the pendulum need to be critically 
reassessed. 
Investigators in the field of menopause therapy fall into 2 distinct schools: the ‘enthusiasts’ and the 
‘doubters’. As a result, most of what is published is based on emotional and philosophical premises; the 
’change of life’ is an emotional subject not only to women, but to men and doctors. 
Evidence for the current concept that the climacteric is a result of hormone deficiency is critically 
appraised. There is as yet no proof that long-term oestrogen therapy to the postmenopausal female is of 
any major benefit in the prevention of coronary occlusive disease or osteoporosis. Further controlled 
investigation into the use of natural oestrogens, particularly their effect on ageing, is an urgent necessity. 
1969/131 
The possible major disadvantages of long-term therapy on the one hand are a fear of carcinogenesis and 
thrombogenesis. These risks, if valid, are extremely rare. On the other hand, the possible advantages of 
long-term therapy are also as yet unproven… 
Exogenous oestrogens are of undoubted value in the relief of symptoms such as hot flushes, the 
associated bouts of perspiration, and atrophic vaginitis. 
Their use in the prevention of coronary arterial disease and the problems of osteoporosis hold definite 
promise but the results of long-term prospective studies must be awaited before their routine use for the 




The prophylactic use of long-term exogenous oestrogen therapy in the prevention of ageing has not been 
established and Wilson’s description of the probable fate of the non-treated elderly female as being one 
of hypertension, atherosclerosis, flabby breasts, dowager’s hump and a vapid, cow-like feeling called a 
‘negative state’, would appear to be an overstatement of the case. 
 
It is therefore suggested that only specific problems be treated and that the routine use of oestrogens in 
all women after the menopause cannot be recommended at this time. 
 
1970/120 
Recent research has shown a relationship to exist between ovarian endocrine function and the density of 
bone. Osteoporosis is a metabolic disease of bone characterized by a disturbance between bone 
formation and resorption. The main disturbance is an increased resorption of bone which is related to 
production of hormones. The osteoporosis commences or accelerates in women soon after the natural or 
induced menopause and it does seem that osteoporosis is related to endogenous oestrogen deficiency. 
Recent work has tended to show that osteoporosis is more likely to develop when both calcium and sex 
hormones are deficient. 
 
Osteoporosis is probably the commonest cause of chronic backache in the elderly patient. Although all 
parts of the skeleton are affected, the spine and pelvis are more extensively involved than other parts. 
Radiologically there is rarification and collapsed vertebrae are often seen. 
 
The pain is characteristically worse when the patient is up and about or tired and is accompanied by 
rounding of the back and loss of stature. 
 
At present it appears that removal of normal ovaries from a female of reproductive age will certainly result 
in osteoporosis. 
 
Administration of exogenous natural oestrogens may prevent the development or extension of this 
process. Unfortunately, there is no evidence as yet that such female hormones can cure or improve 
osteoporosis once it has developed. 
 
PREVENTION: A discussion such as this would be incomplete without some comment on prophylaxis. 
The following factors are important if backache is to be minimized in the female: 
• Retention of ovaries at gynaecologic surgery. 
 Premature removal of the female ovary has been shown to result in a negative calcium balance 
and the subsequent development of osteoporosis. It is therefore  incorrect for the gynaecologist to 
remove ovaries of normal appearance at the time of hysterectomy on women of reproductive age. 
 
1974/121 
The possible relationship between headache and the oral contraceptive is considered. In the present 
study, no association has been demonstrated between oestrogen withdrawal (as produced by 
oöphorectomy, or cessation of exogenous oestrogen replacement therapy in oöphorectomised females) 
or by exogenous oestrogen therapy, and the symptom of headache. This would support current theories 




THE SO-CALLED ‘MENTAL TONIC’ EFFECT: A profound psychological, euphoric and mental tonic effect 
of estrogen administration on ageing women has long been described. There were, however, until 
recently, no satisfactory single or double-blind trials and in the absence of such information it was difficult 
to assess the effect of sex hormones on the psychological state. Utian showed both estrogen and 




True estrogen deficiency symptoms have been differentiated from indirect ones and the management 
thereof discussed. The pros and cons of long-term therapy have been considered. Taking all factors into 
account it would appear that such therapy is justified in females undergoing premature menopause, either 
natural or artificial, but that further research is necessary before this therapy can be recommended for all 
females after normal menopause. 
 
The value of a Menopause Clinic to centralize such control and experience has been stressed and it is 
strongly recommended that such a facility be made available at all major gynaecological institutions.  
 
1977/133 
The true early symptoms of ovarian failure are shown to be remarkably few and must be differentiated 
from psycho-socio-cultural factors. Alternate pathology should always be sought for unexplained 
problems. Only complaints of hot flushes and those related to vaginal atrophy are estrogen related, and 
hence justify short-term estrogen therapy. Other early “climacteric” problems should be evaluated and 
treated according to acceptable medical criteria. 
 
There is an urgent need for clarification of the benefit/risk relationship of long-term estrogen therapy and, 
for example, factors such as development of uterine or breast cancer and thromboembolic disease. 
Present indications are that such risks exist but that the order of risk is relatively low…... Further research 
is necessary before this therapy can be recommended for all females after normal menopause. Until 
specific answers are forthcoming it is best to keep an open mind on the subject. 
 
1979/108 
An endocrinopathy can be defined as a metabolic disease following an abnormal increase or decrease in 
function of an endocrine gland. Decreased function with resultant deficiency of a specific hormone or 
hormones and concomitant pathologic target organ changes have been described for all endocrine 
glands. Diabetes Mellitus for example, is an endocrinopathy even though insulin replacement therapy 
may fail to prevent all the associated pathologic changes…..The Current debate regarding oestrogen 
replacement therapy after menopause fails to recognize this analogy. That is, if ovarian failure and 
menopause are a physiologic event and part of the concurrent ageing process, then there is no 
justification for hormone replacement. If the climacteric-related events are the result of an endocrinopathy 
(a true hormone deficiency disorder following ovarian failure), then the syndrome should be defined and 
recognized as such, and determined efforts be made to evaluate methods of physiological replacement or 
substitution. 
 
The purpose of this presentation will be to examine the arguments for and against the above concept, 
and for appropriate conclusions to be drawn regarding the current status of climacteric…..Sufficient 
evidence exists to justify the classification of ovarian failure and climacteric as an endocrinopathy with 
specific hormonal changes, notably decreased oestrogen production, change in ratio between different 
oestrogens, loss of oestrogen cyclicity, loss of ovarian cyclic progesterone production, and an increase in 
gonadotropin and androgen production. The direct effect of these alterations is on specific target tissues 
where there will develop significant genital and extra-genital responses. These in turn cause specific 
symptom formation. It follows that some form of hormone therapy appears justifiable and necessary. 
 
I would therefore submit that I have proven my case; that the female climacteric constitutes an 




The mounting evidence for a relationship between continuous long-term estrogen therapy and the 
development of uterine cancer should not, therefore, have come as any surprise. The hope for the future 
is that cyclic administration of estrogen in low dose, with added progestin, will not carry the same relative 
risk. There is a theoretical foundation for this hope, but no published proof as yet. 
 
Until further results are forthcoming, the following attitudes to practice could be adopted. 
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1. Short-term estrogen therapy for specific menopausal symptoms (hot flushes and atrophic 
vaginitis) is fully acceptable. 
2. Long-term hormone therapy is justified in young women undergoing premature menopause, 
provided the due precautions, previously mentioned, are observed. 
3. Long-term therapy cannot yet be recommended for all women after menopause. 
4. It is not, however, justifiable to withhold such treatment from a normal informed patient who 
requests it on an individual basis, provided there are no contraindications and the patient agrees 
to regular check-ups. 
5. Certain rules for estrogen usage and patient follow-up exist and have been discussed. In 




The climacteric can be considered a definitive endocrinopathy. Loss of ovarian function is associated with 
specific metabolic sequelae. Unfortunately at the present time exogenous estrogen replacement therapy 
offers neither a completely safe nor a fully effective physiological substitution. 
 
The indications for exogenous estrogen therapy are well defined: 
Specific Symptoms – Hot flushes and atrophic vaginitis only. The rule is minimal dosage, for a short-time 
period. 
Long-term replacement – Whilst not indicated for all females from menopause onwards, it should be 
offered to patients with premature menopause or castration. The risk/benefit/cost ratio must be 
considered for each individual and the patient must be well informed, particularly of the potential risk of 
breast and uterine cancer, and of venous thrombosis. 
 
The practicing clinician should keep an open mind to further developments in relation to long-term 
estrogen therapy. Much data is forthcoming and will change the risk/benefit ratio. It is to be hoped that the 
indiscriminate use of long-term estrogen therapy during the past decade becomes no more than another 
chapter in the history of medicine. 
 
1982/126 
An in-depth analysis of the scientific, medical and health-related epidemiologic literature was undertaken 
in order to determine whether women in the second half of their reproductive life were at increased 
medical risk specifically because of their reproductive age and sex. The outcome has been generally 
reassuring except for a steep increase in the incidence of breast cancer which occurs from age 35 
onwards. Hypertension also increases dramatically at this time of life, but does not appear to be directly 
sex-related. The greater rate at which women between 35—45 years visit their doctor’s office as 
compared to other women, or men of all ages, is probably accounted for by routine checkups and 
partially, perhaps, by psycho-socio-cultural factors, an area not considered in this report. 
 
1986/143 
Although historical references to non-endocrine treatment of the menopause may sound amusing, it is a 
sad reflection of the state-of-the-art, that even today we can offer little more in the way of non-hormonal 
medication to the women suffering severe hot flushes and having a reason not to take hormonal therapy. 
 
The general lack of information on non-hormonal medication of the menopause can best be exemplified 
by the following analysis. As editor of Maturitas, the International Journal for the Study of the Climacteric, 
I reviewed the subject of all papers published between 1978 and this meeting. Out of 227 papers 
published, 96 related directly to hormonal therapy, yet only 7 were on non-hormonal medication. 
 
Perhaps the problem really does not lie as much in the realm of therapeutics as it does in the actual 
definition of “menopausal symptoms”. 
 
CONCLUSION: The selection of pharmacologic agents, hormonal and non-hormonal, for use after 
menopause needs to be specific. Misuse or abuse of drugs can no longer be justified. This does not imply 
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that physicians and patients should shun their use, an opposite extreme that also cannot be supported. 
When a definitive indication exists, and the basic principles of drug therapy and follow-up are observed, 
then the use of such agents will often generate extremely gratifying results and should not be unduly 
withheld. There is an urgent need for further research in this area. 
1987/53 
Considerable research is still necessary to define all the specific sites where sex-steroid hormone 
receptors may be present and to clarify the response of these tissues to the altered endocrine state of 
climacteric. Nonetheless, more than enough evidence does exist to define the climacteric as an 
endocrinopathy in which changes in hormonal profile are associated with extensive pelvic and extrapelvic 
target tissue effects.  
The longer these effects are allowed to continue without corrective therapy, the more likely there is to be 
expression of pathologic process and clinical symptoms. The nature of these changes does, however, 
justify some form of hormone replacement therapy in appropriately selected women. The dilemma facing 
the clinician is that not all of the changes described occur in all women. Methods to predict the onset, rate 
of progress, and ultimate severity of climacteric-related events thus present a major challenge to modern 
medicine. 
1987/109 
Postmenopausal women comprise an ever-increasing percentage of the population. The alteration in 
ovarian function with loss of cyclic hormonal activity after menopause appears to be an actual 
endocrinopathy that produces definite metabolic effects. Clinicians must therefore become able to 
differentiate postmenopausal endocrine changes from those associated with the aging process. Four 
criteria are necessary for endocrinopathy to be present; morphologic changes, functional changes, 
hormonal changes, and target-tissue changes. The metabolic and pathologic changes after menopause 
appear to satisfy these criteria. If an actual endocrinopathy is determined to be present, long-term 
hormonal replacement therapy may be appropriate. 
1989/136 
USA NATIONAL MULTICENTER STUDY: The largest study of transdermal oestrogen to date was 
undertaken in 12 centers in the United States (Ciba-Geigy Study 01).57,58,59  The primary objectives of this 
double-blind investigation were to assess the safety and efficacy of the transdermal patch, as well as to 
determine equivalent therapeutic doses of transdermal oestradiol and oral conjugated oestrogens in 
patients whose severe hot flushes had been controlled with the latter therapy. Some had been receiving 
medroxyprogesterone acetate in addition to conjugated oestrogens.  
THE CURRENT STATUS OF TTS OESTRADIOL: There appears to be little doubt that the TTS oestradiol 
system has a significant role in the treatment of appropriately selected postmenopausal women (i.e. in 
these individuals there should be an indication for therapy and no contraindications such as breast cancer 
or recent uterine cancer). 
1989/137 
THE PLACE FOR ORAL CONTRACEPTIVES (OC’s): Common practice rules out OC’s for women over 
40, but this precaution is largely based on studies that involved high-estrogen pills and did not control for 
smoking. In short-term studies using the newer, low-dose OC’s, risks appear to be reduced. Benefits of 
OC’s for older women include relief of premenstrual syndrome and improvement of benign breast disease 
and menstrual cycle control. 
1989/138 
Women are increasingly spending more years of their lives beyond the menopause, which places them at 
risk for various health problems due to estrogen deficiency. Tissues and organs with estrogen receptors 
such as the ovaries, endometrium, vaginal epithelium, hypothalamus, urinary tract, and skin are directly 
affected by a lack of estrogen production. Other tissues in which estrogen receptors have not been 
consistently identified, such as bone, are also affected by waning levels of estrogen. The postmenopausal 
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woman frequently experiences neuroendocrine changes (hot flashes) that often dissipate over time and a 
steady rise in her risk of cardiovascular disease, which approaches that in men of comparable age. 
 
1989/144 
INTRODUCTION: Is quality of life impaired by ovarian failure and enhanced by hormone-replacement 
therapy? “Quality of life: (QOL) has no clear definition or simple description. It cannot be directly 
visualized, tangibly palpated or specifically quantified. Mood and feeling of well-being or satisfaction with 
self and surroundings are perceived remarkably differently by different individuals. There does exist, 
nonetheless, a large body of literature linking ovarian function and hormone-replacement therapy (HRT) 
with specific aspects of QOL. Trying to piece the puzzle together, to identify meaningful relationships 
between the variable parameters has offered a most intriguing challenge.  
CONCLUSION: Finally, the question again, does ovarian failure impair QOL and HRT enhance it? 
Undoubtedly, yes. Nonetheless, we face a peculiar paradox. We currently have much of the necessary 
knowledge and tools required to prevent major morbidity and mortality, to enhance not only the quality but 
also the quantity of life after menopause, but only a small fraction of the eligible population currently 
receives proper care. We face a major health-care crisis in the future and are always calling for more and 
more research, but we do not even utilize our current knowledge properly. Essentially, we practice crisis 
care when preventive care is called for. The challenge is to disseminate knowledge and appropriate care 
to the population at risk. Let us meet this challenge with immediate and effective action. 
 
1990/11 
Marking as it does the loss of the ability to have children, menopause is a critical stage in the life cycle of 
the human female. Rather than dwelling on negative aspects, the modern woman should regard 
menopause as a time to look ahead and take actions that can help ensure a healthy and fulfilled future. 
High on a list of such actions should be a full medical evaluation. Women identified as being in need of 
hormone replacement therapy would be well-advised to consider going ahead with this highly effective 
form of treatment. Those not needing is should still see menopause as a signal to reevaluate all their 
health habits. Women who may need some form of hormone treatment but are unable to undergo HRT 
should not despair. Other methods of treatment, though not generally as effective as HRT, are available, 




Recent research on the menopause and experience with available treatments has generated interesting 
philosophic issues. The concept of hormone ‘replacement’ therapy covers a multitude of therapeutic 
circumstances, not all of which are best described as replacement. Replacement is perhaps the correct 
concept for oestrogen therapy given to the woman who has undergone premature oophorectomy, but the 
woman with an intact ovary may receive something closer to additive therapy. Another distinction 
requiring further scrutiny is that between physiologic restitution and pharmacologic treatment. 
 
An ever-widening array of therapeutic alternatives is now available for administering oestrogens. More 
research is needed to define optimal combinations and duration of therapy, as well as the type, dose, 
potency and precise route of administration in each case. We must all be prepared to accept changing 
concepts and new treatment strategies. In the interim, the advantages and disadvantages of HRT should 
be carefully weighed in each individual patient. 
 
1992/113 
The modern therapeutic armamentarium is broad but in some respects superficial. Diet and nutrition, 
exercise, and hormonal medications receive the most attention and the latter the most debate. Hormone 
replacement therapy of varying types, formulations, doses, and routes of administration produce certain 
benefits and entails certain side effects and risks. The benefits include alleviation of hot flashes, 
urogenital atrophy, osteoporosis, and coronary hear disease, as well as improvement in sexual response, 
mood, sleep, and memory. In addition, it may promote longevity. Negative responses to hormone 
replacement therapy include nausea, mastalgia, menstrual bleeding, increased necessity for surgery, 





The significant differences in the steroid profile between the premenopausal and postmenopausal female 
are as follows: 
1. The blood production rates of estrogen decrease; 
2. The cyclicity  of estrogen production is lost; 
3. Cyclic production of progesterone ceases; 
4. There is an increase in the plasma levels of androgens relative to the reduction in estrogen 
values; 
5. The major free estrogen becomes estrone, of which about 40μg per day is excreted; and 
6. Androstenedione is of considerable importance as a precursor of estrone, although it is still 
uncertain what factors influence peripheral conversion. Peripheral aromatization of 
androstenedione to estrone increases over time but it is not clear whether this increase is related 
to the menopause of to age or both. Initially, the ovary and adrenal gland are the major sources of 
androstenedione, and estrone production remains fairly constant. Eventually, with ages, the 
ovarian stroma ceases production. The adrenal contribution, inadequate as a single source, is not 
able to maintain sufficient estrone production, and specific target-tissue deficiencies become 
apparent. 
 
One final important piece of information should be added. It may be that not all postmenopausal women 
are the same, in that differences between the ovaries may occur. Procope has clearly shown that two 
populations of postmenopausal females exist: one group demonstrates atrophic ovaries after menopause, 
and oophorectomy makes little difference to steroid production, whilst the second group shows ovarian 
cortical stromal hyperplasia, with removal of these ovaries making a considerable difference to the 
postoperative steroid profile. 
 
1993/139 
A COMPREHENSIVE APPROACH: It is often gratifying to note the extent to which a comprehensive 
approach to the perimenopausal woman can greatly enhance her quality of life beyond that which 
estrogen alone can accomplish. Health advice, including establishment of a sound diet and physical 
fitness program, is highly desirable. Counseling can also be extremely helpful, particularly in the area of 
marital problems or psychosexual adjustment. Finally, ongoing education is most helpful in having the 




Postmenopausal estrogen replacement therapy, however, emerges as the single most significant factor in 
the prevention of CAHD in women. While most of the available data are based on observational studies, 
which may have several types of flaws, it is unlikely that in the next decade well-designed, experimental 
studies will be completed, and patients and physicians alike will have to make some practical decisions 
based on the presently available data with regard to estrogen replacement. As in most such situations, 
the determination of risks and benefits of hormone replacement therapy will depend on the multiple 
factors described in this and the chapters to follow. 
 
1994/124 
Among the mechanisms by which estrogen might decrease coronary artery heart disease in 
postmenopausal women may be the reduction of platelet aggregation. This response might be a 
combination of a direct effect on platelet function or an indirect effect by increasing PGI2. The increase in 
PGI2 can be secondary to an increase in cyclooxygenase activity and/or enhancement of PSF, which was 
identified as apoprotein A-I. 
 
There are a limited number of studies looking at the effect of estrogen on platelet activity in post 
menopausal women. There is a need for large, randomized clinical trials addressing the question of 
whether postmenopausal hormone treatment reduces the risk of cardiovascular disease in women. There 
is also a need for more studies to determine the effect of estrogen and different therapeutic combinations 
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of estrogen and progesterone/progestogen on platelet function so that the pathogenesis of CHD can be 
more clearly explained. 
 
1995/127 
Office management of gynecologic problems in elderly female patients requires sensitivity to the special 
needs of this group. The gynecologist can expect to see more and more geriatric women as the U.S. 
population continues to age. In 1990, 12.6% of the U.S. population was over the age of 65. By the year 
2060, this figure will almost double to 22.9%, or over 100 million elderly. 
This chapter will address some of the issues that are uniquely important in caring for older women, 
including screening and disease prevention, hypoestrogenism, pelvic floor support problems, urinary 
incontinence, gynecologic neoplasia, and sexuality. The pathophysiology of aging as it relates to the 
reproductive and lower urinary tract will be covered. Lastly, the impact of other medical problems on 
surgical treatments for gynecologic conditions will be discussed. 
 
1999/128 
The overall management strategy for the peri- or post-menopausal woman at high risk for breast cancer 
should be to (1) reduce modifiable risk factors (2) promote a healthy lifestyle, and (3) use alternate 
therapies for management of vasomotor symptoms and reduction of osteoporotic and cardiovascular risk. 
Breast cancer risk in such women may be reduced by the use of tamoxifen. Physicians should provide 
education and counseling to menopausal women regarding management of menopause and the various 
options available and should follow up to ensure adherence to the patient’s chosen management plans. 
 
2000/129 
As the new millennium begins, menopause specialists will find themselves in a unique situation in the 
years to come. The aging baby boomer population will increase the number of older patients in clinicians’ 
practices, as evidenced by the estimate that nearly one of every four persons in the United States will be 
over age 65 by the year 2050. Since more of these elders will be women than men, it is imperative that 
gynecologists and other practitioners providing care for menopausal women (the elderly of the future) be 
comfortable in both the primary and specialty care of these sometimes complex patients. 
 
This article is intended to help clinicians become more familiar with the unique medical and social issues 
that affect the care of women over the age 65. To this end, we will provide an overview of the issues that 
clinicians should keep in mind when treating elderly postmenopausal women. 
 
2000/140 
CONCLUSION: Reports of administration of combinations and permutations of female sex steroids to 
women of older age are beginning to trickle in. With respect to osteoporosis it appears that some gain in 
bone mass in certainly possible, and that this is reflected in a decreased incidence of osteoporotic 
fractures or refractures. Unfortunately, studies of women in the perimenopausal age group are unlikely to 
be of much value in the near term in determining the impact of HRT on Alzheimer’s disease incidence or 
severity in older patients, given the lower incidence in the perimenopausal population. 
 
Given that one of the most frequent reasons women cite for not considering HRT is fear of breast cancer, 
and that the risk/benefit in older age is far more likely to be weighed in favor of preventing osteoporosis 
and cardiovascular disease than causing an increased incidence of breast cancer, it would appear 
mandatory to develop active research protocols in older women to clarify these issues. 
 
All in all, based on the current evidence, it certainly is my opinion that women of older age would be an 
ideal populations to experience the immediate benefits of reduction in cardiovascular events, 
maintenance of bone mass, and potential brain effects. However, many new questions demand urgent 
answers. In older populations would lower estrogen doses provide the same benefits? These are just a 





IF SHE IS ON HRT FOR QUALITY OF LIFE ISSUES: The Women’s Health Initiative did not address a 
variety of conditions that estrogen-progestin therapy may or may not improve, such as vaginal atrophy 
and problems with the skin, teeth and gums, cognitive function, mood, sleep, sexuality, and quality of life 
(appropriately measured by a validated instrument such as the Utian Quality of life Scale). 
 
Many women experience subjective negative feelings when they stop HRT and state they “feel better” on 
hormones. These responses are difficult to quantify, but women often weigh them heavily in favor of 
continuing HRT when they consider risk and benefit issues. 
 
HRT TO PREVENT CARDIOVASCULAR DISEASE: Postmenopausal women should clearly stop taking 
estrogen-progestin therapy if they have no symptoms and are taking it only for cardiovascular protection. 
It is essential, however, to define their cardiovascular risk factors and treat these accordingly, for example 
with anti-hypertensive or lipid-lowering drugs. 
 
2004/118 
The past 2 years have witnessed a flurry of scientific publications on menopause and related therapies, 
particularly use of the sex steroid hormones. In turn, attitudes about menopause and hormone therapy 
have changed. Perhaps the greatest consequence of all the attention is the confusion about what to do, 
on the part of both provider and patient. 
 
Many organizations responded with considered, evidence-based, practical guidelines. The most detailed 
and practice-oriented of these guidelines is the North American Menopause Society’s (NAMS’S) 
September 2003 Position Statement on use of estrogen and progestogen in peri- and postmenopausal 
women (www.menopause.org). Even as this Update on Menopause is being written, the report of the 
terminated estrogen-only arm of the Women’s Health Initiative (WHI) is in press and may further change 
clinical practice. NAMS will present an updated report on all these developments at the 2004 scientific 
meeting in Washington, DC, October 6 to 9, 2004. In the interim, the current recommendations hold. 
 
2005/130 
Are there issues specific to HIV-positive women and hormonal therapy for menopause? Do we have good 
data on these issues? Do the Women’s Health Initiative (WHI) results impact on the treatment of HIV-
positive women? 
 
There is no current consensus on the role of sex steroid usage for women through and beyond the 
menopause. There is virtually no information on the impact of HIV/AIDS on the menopause or vice versa, 
and nothing regarding the benefits or risks of postmenopausal hormone therapy. The purpose of this brief 
review is to cover the current issues as they apply to all women. 
 
Finally, the lack of data regarding the impact of HIV/AIDS on all the above issues is apparent and in need 
of urgent address. A call is therefore made immediately to set in place mechanisms for the following 




DISCUSSION: As an active ingredient that can provide potent estrogenic activity for the effective relief of 
vasomotor symptoms while having antagonistic activity or no effect on peripheral tissue sites, ∆8,9DHES 
holds great promise for the optimization of ET. Of particular interest are compounds that can achieve a 
reduction of troublesome vasomotor symptoms and help reduce bone loss while minimizing the affects on 
other peripheral tissues normally affected by nonselective estrogens. 
 
2006/145 
Domains of QOL are remarkably consistent through all cultures and socio-economic groups. The major 
objective of contemporary healthcare should be to assist our patients and populations to achieve these 
goals. Getting there requires the efforts of multiple public agencies and health care organizations, and the 





6.14.2 EDITORIALS IN MENOPAUSE MANAGEMENT  
 
EXCERPTS FROM MENOPAUSE MANAGEMENT EDITORIALS  
ARE IDENTIFIED BY DATE AND TITLE OF THE EDITORIAL 
 
The purpose of this section is to indicate one leadership role I have taken within 
organized medicine, namely, to speak out on behalf of the medical profession and in 
support of women’s health issues. 
 
The following are taken as direct quotes reflecting personal opinions in editorials that 
have I have written in Menopause Management. Since its inception in 1988, I have 
authored well over 100 editorials for that journal, a significant body of work in itself. The 
publication has a circulation in excess of 32,000 medical practitioners in the United States 
and Canada, and is also circulated internationally, thus providing a unique “bully pulpit”. 
The complete list of editorials can be found in my curriculum vitae (Section  8).  
 
Not all editorials have been abstracted. Also please note that these are short excerpts 
specifically selected to give an idea of the theme of the editorial. 
 
Fall/1988 
Menopause management: The changes…and the challenge 
There are many reasons why we should know how to manage the menopause, but three reasons 
tell us why we should learn about them now… 
 
First, the aging baby-boom generation, now entering its 40s, will enter the climacteric in just the 
next decade… 
 
Second because the current life expectancy for women is 78 years, many more numbers of 
women will live well beyond the menopause… 
 
A third and very important reason is that many of us are dropping the “Ob” from Ob/Gyn, probably 
because of today’s litigious climate… 
 
Why then another publication? Although the medical literature reports on scientific findings 
relating to the human climacteric, not enough practical advice for direct clinical care is available. We are 
providing this forum to meet that need. 
 
Winter/1989 
Renewing our commitment to the remaining 85% 
Only about 15% of all postmenopausal women receive estrogen replacement 
therapy….Recognizing that estrogen deficiency occurs in 100% of all postmenopausal women, and not 
suggesting that all women after menopause require replacement, the question nonetheless is—what 
happens to the remaining 85%?... 
 
Summer/1989 
The North American Menopause Society: Why another society? 
The News and Notices of our winter issue announced a conference on Multi-disciplinary 
Perspectives on Menopause, which is to take place in New York on September 21-23. This will also be 
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the inaugural meeting of The North American Menopause Society. You may ask: why then, another 
society?... 
There are two very important reasons. First, since the founding of The International Menopause 
Society in 1978, nearly all European and Latin American countries have developed national societies of 
their own; the U.S., however, has not. In this regard, the U.S. medical community has fallen behind its 
international contemporaries. 
Second, menopause management—as a discipline—cannot be limited to the practice of any 
single specialty. Rather, it comprises the expertise of a multitude of medical and basic sciences: 
cardiology, endocrinology, family medicine, geriatrics, gynecology, orthopedic surgery, psychiatry, 
psychology, anthropology, nutrition, sexology, and social sciences—to name a few. The purpose of The 
North American Menopause Society, therefore, is to provide a common meeting ground for those medical 
and paramedical specialties that are touched by some aspect of menopause. 
December/1989 
“Multidisciplinary Perspectives on Menopause”—Agreeing to Disagree 
I am most pleased to report that September’s conference, “Multidisciplinary Perspectives on 
Menopause,” which also officially marked the inauguration of The North American Menopause Society 
(NAMS), was a well attended rousing success! 
The 350 attendees, who gathered to discuss a multidisciplinary approach to this multifactorial 
condition, included basic and social scientists, Ob/Gyn clinicians and family practitioners, members of the 
press and media, and representatives of various special interest groups. 
August/1990 
Spreading the news 
The good news is that attempts to distribute appropriate healthcare to peri- and postmenopausal 
women are escalating. There are numerous vehicles for such care, ranging from full-service menopause 
clinics to individual private practices. However, the primary challenge remains to inform women about the 
real meaning of menopause, and to encourage re-entry into healthcare services. 
November/1990 
Our Responsibilities in HRT and Beyond 
Clearly, the responsibility of the physician in caring for the menopausal woman reaches beyond 
the realm of hormonal therapy. We must counsel our patients about lifestyle changes, and we must 
screen them for risk factors of diseases that occur for nonhormonal reasons around the time of the 
climacteric. One of the most important lifestyle changes we can advocate is for them to stop smoking. 
International/Volume IV, Number 1/1991 
Welcome 
With this issue, we begin publication of an international edition of Menopause Management. We 
are pleased to have the opportunity to address an international audience with information on the care of 
menopausal and postmenopausal women, and in so doing, to play a role in helping to establish an 
international consensus on appropriate methods of care for these women.  
International Volume V, Number 1/1992 
Spreading the Facts about Menopause 
It is a staggering fact: in most countries of the world, more women will pass through the 
menopause during the next decade than at any other time in history. For the majority of women, their 
understanding of the event will not be based upon medical fact; they are likely to receive a good deal of 
anecdotal misinformation from family, friends, and media. Who should assume the responsibility for 
educating the general public about the menopause? Clearly, the responsibility lies with the members of 




The challenges ahead 
Only a new focus on preventive health care will prevent a total collapse of our healthcare system.  
The menopause is an ideal time for women to reenter the healthcare system, to be evaluated, 
and to participate in appropriate preventive programs. Unfortunately, with the majority of third-party 
payors, the emphasis is not on preventive medicine. We urgently need for policy makers to recognize the 
scope of symptom formation and disease often associated with the climacteric, and the impact the aging 
female populations will have on the healthcare industry in the next several decades… 
 
We must make it an urgent priority to identify the population at risk, introduce cost-effective 
preventive treatment modalities, educate the population about preventive vs. crisis treatment, and 
maintain compliance. The goals are to enhance the quality of life while increasing its duration. 
 
January 1993 
Menopause research—the dilemma 
Addressing an NIH meeting in 1989 on the subject of menopause, I made the following comment: 
“We face a peculiar paradox. We currently have much of the necessary knowledge and tools required to 
prevent major morbidity and mortality, to enhance not only the quality but also the quantity of life after 
menopause, but only a small fraction of the eligible population currently receives proper care. We face a 
major health care crisis in the future and are always calling for more and more research, but we do not 
even utilize our current knowledge properly.” Dr. Bernadine Healy, Director at NIH, agreed when she said, 
“It is disgraceful that in our sophisticated world of medicine, with our phenomenal track record, we still 
can’t answer simple questions about menopause.” 
The dilemma is clear. We will always need additional research, but we fall short when it comes to 
applying our current knowledge. Our challenge is to address both issues with equal vigor. 
 
February 1993 
Menopause: What it is—and what it is not 
There is a lack of consensus regarding the important terminology that defines stages and events 
in a woman’s life…  
 
While it is essential to define carefully what menopause is, it also is necessary to consider what 
menopause is not. Menopause is not the end of meaningful life. It is not a dramatic event leading to 
sudden behavior alteration, nor is it a disease.  
The climacteric is not an endocrinopathy per se; clearly, however, it holds the potential for 
endocrinopathy… 
 
One of the challenges facing us is to determine more clearly the specific effects related to the 
menopause and to differentiate them from those that are age-related or influenced by psycho-social-




Listening to patients: What is said…and left unsaid 
The importance of listening to what our patients say cannot be overstated. Equally significant —
and more challenging—is the need to discover our patients’ questions that remain unasked…the 
concerns that are unexpressed… 
 
April 1993 
Appropriate postmenopausal health care: A dilemma 
The physician who is concerned about providing appropriate care to postmenopausal women 
faces a curious dilemma. One objective of this clinician must be to provide primary preventive care with 
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the goals of preventing illness, prolonging life, and enhancing the quality of life. While attempting to 
achieve this, the physician may be criticized for “medicalizing menopause.” 
I believe that this dilemma is due, in part, to the extreme positions that certain healthcare 
providers have taken. There are the “estrogen evangelists’ who recommend estrogen replacement 
therapy (ERT) for every woman, while students of the “estrogen never” school find every possible reason 
not to prescribe ERT. 
It would appear to me that members of the medical community have helped to create this 
dilemma. Too often, the medical and popular media—inappropriately—equate menopause with hormone 
replacement therapy (HRT)… 
 
While the responsibility for adopting an appropriate approach to postmenopausal healthcare 
should be borne by both the provider and the consumer, the first educational steps must be taken by the 
healthcare provider. 
So there you have it: Educate yourself and then educate your patients. The decisions regarding 
future care then can be reached by consensus. 
 
May 1993 
NIH and NAMS create joint research agenda 
The National Institutes of Health and The North American Menopause Society recently completed 
a landmark workshop in Washington, D.C.; the purpose was to summarize the status of current 
knowledge on the menopause, and to establish an ongoing research agenda. The significance of this 
meeting for NAMS cannot be overstated: An organization barely four years old has joined with the highest 
agencies in the land to set priorities and goals for menopause-related research. 
 
June/July 1993 
Managing Menopause in a changing healthcare environment 
As I travel around the United States teaching on the subject of menopause and its management, I 
sense a remarkable degree of gloom in the academic medical centers and private medical practices. I 
doubt that any factor promotes such feelings more than the pessimism and apprehension surrounding the 
anticipated changes in healthcare law. 
I, for one, am especially optimistic about what the future may hold. During the last 25 years, I 
have grown to regard the menopause as a significant marker in the female life cycle—an event that takes 
place as concurrent age-related illnesses begin to occur more frequently. My early approach was to 
manage menopause as a potential endocrinopathy by treating problems as they occurred. This attitude 
changed drastically when I began to view the menopause as an opportunity to actively introduce primary 
preventive care. Those of you who accept this philosophy should welcome the upcoming changes in the 
healthcare industry… 
 
Therefore, I encourage you to re-evaluate your medical practice and to make sure you are geared 
for the appropriate provision of primary preventive health care. 
 
August 1993 
International Congress engenders remarkable consensus 
I have just returned from the 7th International Congress on the Menopause in Stockholm. 
Sweden, where I had the privilege of being elected President of the International Menopause Society for 
1993-1996. The organization, founded in 1978, has been instrumental in the development of national 
menopause societies in many diverse countries throughout the world. Indeed, one of my prime objectives 








The 4th Annual Meeting of NAMS–Take-home lessons 
What was the single most memorable or striking aspect of the 4th Annual Meeting of The North 
American Menopause Society?... 
I think that most observers must have found the nature of the meeting participants, themselves, to 
be most impressive. The meeting was multi-disciplinary, as always, and the attendees represented 
leading American academic and clinical institutions, women’s groups, the nursing profession, and the 
National Institutes of Health, as well as experts from over 20 countries. All in all, this was the largest and 
most influential gathering in the interests of health care for women in their middle years yet to take place 
in the United States. 
October 1993 
Menopause education, instant experts, and the NAMS Gallup Poll 
A cause of singular concern to me in recent years has been the amount of misleading information 
provided on the subject of the menopause. In particular, I am troubled by the escalating volume of 
magazine articles and books written by “lay instant experts” who lack experience and background in basic 
science, health care, or well-documented research findings -- and who, more often than not, express 
opinion rather than fact… 
November/December 1993 
Clinical research in a climacteric medicine practice 
Have you ever considered incorporating clinical research into the menopause in your medical 
practice? While the study of basic biological mechanisms, outcomes of spontaneous or premature 
ovarian failure, or clinical and metabolic effects of ovariectomy might be out of your clinical purview, there 
is one area that is wide open to your interest… 
January 1994 
Examining the effect of ERT on breast cancer 
Studies suggest that postmenopausal ERT has no negative effect on recurrence of disease or 
survival in postmenopausal women who develop carcinoma of the breast. However, when a woman with 
pre-existing breast cancer requests ERT, management decisions must be made on an individual basis. It 
would appear that, other than previous breast cancer, there are no definitive breast conditions that 
contraindicate ERT. However, as in all instances where ERT or HRT is being prescribed, it is mandatory 
that the woman be well-counseled so that she can make an informed decision and her care can be 
individualized. In general, a conservative approach appears justified because definitive answers are 
unavailable at this time. Fortunately, studies are commencing that soon may provide solutions to this 
vexing dilemma. 
May/June 1994 
A simple message: Stop smoking! 
Prevention is a buzzword in discussions on proposed new healthcare legislation. Almost half of all 
deaths in the U.S. have an identifiable source of preventable morbidity, and cigarette smoking tops the 
list. Smoking cessation is known to result in significant financial savings for each successful outcome. 
Discuss the risks of smoking with every patient! 
July/August 1994 
Thyroid function and menopause 
Hypothyroidism can cause lethargy, poor memory, cold intolerance, and weight gain. The non-
specific nature of these symptoms can result in thyroid dysfunction being overlooked, the necessary 
treatment being delayed, or—equally unfortunate—the wrong treatment being prescribed. Therefore, it is 
prudent always to have a high index of suspicion for thyroid dysfunction when evaluating women for 
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“climacteric syndrome.” Moreover, while routine thyroid function screening is not generally recommended 
for a healthy adult population, postmenopausal women comprise a group who could be considered an 
exception to the rule. 
 
September/October 1994 
The mystery of the worried well 
I am increasingly impressed by a phenomenon observed in an escalating number of healthy 
perimenopausal women who visit my office. They present with furrowed brows and evident concern 
saying, “I feel perfectly well, but from what I have read or heard, something should be wrong; what hidden 
problems might I have?” These women are representative of an epidemic of the “worried well.”… 
 
Never in our history have so many women lived as long–or as well. Yet never has there been 
such a concern for diseases that they do not –and may never–have. 
As healthcare providers who should meet this issue head on, we face a potential “catch 22.” How 
do we inform the general population about preventive health care without creating a climate of fear and 
anxiety?... 
 
There is also a challenge for the development of well-informed, up-do-date, and unbiased 
educational materials for presentation in various forms to this constituency, and NAMS should be at the 
forefront of such activity. 
 
November/December 1994 
Predicting endometrial pathology by timing of withdrawal bleeding to sequential HRTA 
disturbing aspect of modern medicine is the speed at which limited information is incorporated into current 
practice dogma. Case in point: using the day of bleeding onset in response to sequential 
estrogen/progestin therapy as a predictor of endometrial hyperplasia… 
 
The lesson to be learned from this is that we should scrutinize all studies very carefully before 
allowing the results to affect the dogma of clinical practice. 
 
January/February 1995 
Engaging women in comprehensive preventive health care 
Therefore, I would submit that the best way of encouraging women to become involved in their 
own comprehensive care is to engage in education, counseling, and selective screening while addressing 
the primary reason for each office visit. For example, a woman presenting with a urinary tract infection 
should receive not only appropriate treatment, but also be counseled in behavioral risk factors such as 
the use of tobacco and alcohol, lack of exercise, and poor nutrition. Her record should also be reviewed to 
see when she last underwent a Pap smear, mammography, or other selective screening… 
 
We must encourage women to assume a greater responsibility for their own health as we, the 




Heart Disease in Women: Where Are We? 
Each year in the U.S., ten women die from heart disease for every death due to breast cancer. 
Yet the healthcare system has historically underestimated the severity of heart disease—and women 









Has “less then monthly progestin” come of age? 
It would therefore seem that the time has arrived to offer patients on sequential HRT a reduction 
from 12 withdrawal bleeding episodes a year to only six and possibly fewer by administering progestin at 
two- to three-month intervals. While current evidence would suggest this regimen to be appropriate and 
safe therapy, I would suggest we continue to monitor patients so that any increase in hyperplasia (and 
potentially uterine carcinoma) can be avoided. In the continuing challenge of minimizing risks and 
maximizing benefits for women on long-term HRT, longer withdrawal intervals for progestin may likely 
prove to be the best protocol. 
 
September/October 1995 
Postmenopausal HRT and breast cancer revisited 
I do believe we will have to address a point of real concern: the role of added progestin. 
Undoubtedly of value in obviating the estrogen-induced increase in uterine cancer, there is no protective 
effect—and possibly a compounding of risk—for breast cancer. Progestin’s blunt the beneficial effect of 
estrogens on lipids, and there is direct animal-based evidence that progestin/progesterone negates 
estrogen-induced increase in coronary blood flow. When evaluating risks versus benefits, I would 
speculate that, in the future, progestin may have a minimal therapeutic role, if any. 
 
November/December 1995 
NAMS: A success story of remarkable growth and development 
As the Sixth Annual Meeting of The North American Menopause Society in San Francisco 
proceeded, I was overcome by an escalating sense of amazement and satisfaction. Those few members 
who were present at the New York inaugural meeting in 1989 will well remember a meeting in which 
probably the only consensus was lack of consensus. There appeared to be conflict between physicians 
and nonphysicians, men and women, young and old, basic scientists and clinical scientists. Indeed, for a 
while I questioned my own mental stability in attempting to draw an interdisciplinary group into discussion 
of the menopause 
Yet, in six brief years, a new Society nurtured by a few loyal members, and a dedicated Board of 
Trustees, has grown into a large international organization… 
 
March/April 1996 
Incorporating new options for osteoporosis management into clinical practice 
Options for clinical management of osteoporosis have increased as rapidly as the recognition of 
the problem by the general public. Currently, it is more often the exception than the rule for a 
perimenopausal woman not to raise the topic during a medical evaluation… 
 
To provide optimal clinical management, the practitioner needs to constantly bear in mind the 
objective of this action, that is, the avoidance of fractures… 
 
Achievement of this goal necessitates incorporating into standard practice effective screening 
mechanisms. These include a comprehensive history and physical and selective use of screening tests. 
Densitometry of the spine and hip is the current gold standard for risk assessment… 
 
An understanding of the technology, physiology, and interpretation of these tests is a necessary 
requirement for proper clinical management… 
 
May/June 1996 
Testosterone therapy after menopause 
The word is out in the popular media—testosterone enhances sexuality, has a euphoric effect on 
mood, and healthcare providers are being uncooperative and are resistant to prescribing if for all women. 
Consequently, practitioners are receiving more and more requests for androgen prescriptions. But, how 




There is literally no data available for risk or benefit of long-term postmenopausal testosterone 
therapy. Does it increase or decrease the risk or coronary heart disease, or have no effect? We simply 
don’t know. Given the adverse effects of progestins, it would be surprising if there were no negative 
consequences to long-term testosterone. However, the data simply does not exist… 
 
What do we do? Basic principles mandate avoidance of harm. My personal approach is to advise 
against long-term testosterone therapy until adequate studies have been completed, to occasionally 
prescribe to women without ovaries on a short-term basis, and above all, to educate women about the 




National menopause awareness 
June 1996 may well be remembered as a turning point in consumer education on menopause. 
The NAMS Menopause Awareness Program was interfaced with the National Menopause Awareness 
Month Program resulting in over 1,000 health centers being provided with educational materials for their 
own subsequent consumer education programs. 
 
September/October 1996 
The Antioxidant Issue 
Approximately 50 years ago, at the height of the poliomyelitis epidemic, a popular belief existed 
that wearing garlic around the neck reduced the risk of developing the feared disease. Perhaps the odor 
of the garlic kept people at a distance, reducing the opportunity for transmission. In this decade, due to 
epidemiologic studies reporting lower rates of cancer and/or cardiovascular disease by eating a healthy 
diet preponderant in fruits, grains, and vegetables, the ”garlic” of the era has been hailed as beta 
carotene. Indeed, both the popular media and scientific literature has so popularized this issue that an 
entire industry has developed and millions of individuals consume beta carotene supplements. 
Unfortunately, like garlic did not prevent polio, definitive reports now prove that current formulated 
beta carotene supplements do not reduce the risks of heart disease or cancer. 
 
November/December 1996 
Long-Term Estrogen Therapy and Alzheimer’s Disease 
One of the biggest concerns facing healthcare planners, policy makers, and individuals alike, is 
the fact that an increase in life expectancy has not been paralleled by a reduction in the time of disability 
before death. Indeed, the enlarging elderly population spend a greater proportion of their lives with some 
disability. In this context, particularly the female population with a greater life expectancy than men, 
Alzheimer’s disease (AD) represents a major health problem… 
 
As the first investigator to report the ERT brain effect on mood elevation in 1972, I would certainly 
be more than thrilled to see confirmation of an even greater neurological action. Regrettably, until we 




Menopause and HRT—Science, Politics and Pseudoscience 
Many clinicians are currently being asked if they are “for or against” HRT, as if this were a political 
issue on which it was necessary to take sides. Regrettably, the written and visual media persist in 
focusing on this question in the same way, presenting a picture of us engaged in some form of modern 
medical warfare… 
 
The truth, need I repeat at the risk of “crying Wulf,” is that genuine medical science is a search for 
facts. In the absence of definitive data, the objective is to “do no harm,” that is, to carefully balance 
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potential risks and potential benefits on a case-by-case basis. Under these circumstances, there is no 
side to take—only the best care for each woman… 
 
I encourage you to respond proactively to inappropriate presentation of the “for and against” 
approach. But do it the scientific way, not the political way. Mixture of science and politics becomes 
pseudoscience, and that is unacceptable. 
 
July/August 1997 
Is “Natural” Natural? 
Over the past few years, we have witnessed increasing confusion over defining products as 
pharmaceuticals or foods… 
 
Clearly, there is an astounding degree of hypocrisy in all of this. Estrogens can’t be declared to 
be the cause or accelerator of breast cancer if “synthetic,” yet anti-cancerous if “natural.” Nor can there be 
calls for more research on pharmaceutical ERT/HRT products amidst proclamations of the safety and 
effectiveness of “natural” estrogen or progesterone in the absence of long-term studies… 
 
It is my hope that the FDA will soon identify this entire “natural”’ remedy arena as one in need of 




Has Gender Bias Affected Menopause Management? 
While listening to a presentation on gender bias in biomedical research, the question of whether 
gender bias might have affected menopause-related research and management crossed my mind. On the 
surface this might sound like a ridiculous concept—menopause is specific to women, making gender bias 
apparently irrelevant—but it struck me that much of what we say or do with regard to management of 
postmenopausal women might well have been influenced by gender bias. 
 
November/December 1997 
Hormone Replacement Therapy and the Older Woman 
The shift in thinking to which I want to draw your attention is the question of whether we are 
treating the wrong populations, or at least ignoring one significant part of the population, namely, the older 
woman… 
 
All in all, based on the current evidence, it certainly is my opinion that women of older age would 
be an ideal population to experience the immediate benefits of reduction in cardiovascular events, 
maintenance of bone mass, and potential brain effects. However, many new questions demand urgent 
answers. In older populations would lower estrogen doses provide the same benefits? Is added progestin 
still necessary? Would aspirin, exercise and healthy living give equal benefits? These are just a few 
examples. Here also is a whole new world of research for young investigators. 
 
March/April 1998 
The 1997 NAMS Gallup Survey—Evidence of Good Progress 
Most of the women surveyed had a positive or neutral perception of menopause. Thus, we seem 
to be experiencing a “generational shift” in attitudes toward menopause as a phase in the female life 
cycle. Half of the women reported getting their information about menopause and other healthcare 
concerns from their healthcare professionals, specifically physicians and the obstetrician/gynecologist. 








Determining Endometrial Pathology in Women on HRT 
From a practical perspective, therefore, it would not seem appropriate to endorse ultrasound 




The Menopause Clinic 
Today, the concept of a Menopause Center is well accepted, but the definition of such a facility 
has become quite variable. Indeed, there is no single accepted format… 
 
November/December 1998 
HRT and the HERS Findings—Has the Ground Shifted? 
There is a clear lesson to be learned. Observational studies are of value in indicating trends. 
Randomized studies are necessary to test these observations. But these studies need to be based and 
planned on what the observational studies suggest, not what we hope a different treatment or drug 
combination would produce. Progress is only made one step at a time… 
 
March/April 1999 
The FDA, Soy Protein and Coronary Heart Disease 
As your read this editorial, the FDA is proposing to authorize the use on food labels and in food 
labeling of health claims on the association between soy protein and reduced risk of coronary heart 
disease (CHD)… 
 
Given that the FDA approval is likely to be for soy protein “included in a diet low in saturated fat 
and cholesterol,” might it be irrelevant what is added for a protective effect to be exhibited? Thus, the 
FDA might just as well approve fish, or bananas, or low-fat yogurt, provided they complement a healthy 
diet. 
Which brings us to the major question. How effective might soy protein be in the absence of a 




The Trojan Horse of Menopause Marketing 
Remember the story of the Trojan horse? In Greek mythology a huge, hollow wooden horse, in 
which attacking Greek troops hid, was left at the entrance to Troy as the attacking Greeks surreptitiously 
feigned departure and hid. The Trojans, sensing victory and believing the horse to be a departing gift, 
moved it through the gateway into the walled city, and unsuspectingly allowed the Greeks to capture the 
city of Troy; thus, ending the Trojan war. 
Well, I am deeply disturbed by a similar phenomenon by which our once proud medical 
profession is being “sprung by the same trap,” and is inadvertently doing the same to its patients. In this 
instance the Trojan horse comes in different guises, frequently appearing as slickly marketed packages of 
ostensibly independent CME. But the “troops in the horse” are aggressive marketers of questionable 
“menopausal products,” and the “inhabitants of Troy” are the menopausal women and their pocketbooks. 
It truly troubles me to note once proud names in medicine who, often for no more than the price of 
a fancy weekend in a plush resort, will allow the use of their names, faces or institutions on glossy 
packets of “educational” material, the hidden agenda of which is only to market products. 
 
September/October 1999 
Is There an “Alternate” Menopause Management? 
Ever since 1994, when the “natural products” industry was granted what amounts to a license to 
steal by the US Congress, I have watched with wonder and bemusement as products that are quite 
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obviously pharmaceuticals are labeled “dietary supplements” and, with the FDA sidelined, have been ever 
more aggressively marketed, and accepted by a seemingly gullible public. I have also been fascinated—
and frankly, often disgusted—by the obscene haste with which some healthcare professionals have 
jumped onto this bandwagon… 
 
Logically, therefore, traditional and alternative therapies will, when subjected to scrutiny, either 
pass or fail the test for effectiveness. But the playing field needs to be leveled; the intensity of scrutiny 
needs to be the same. Under these circumstances the public will be protected from ineffective 
alternatives, and the therapies that are actually effective will be recognized as such. There is no 
“alternative” medicine, only good medicine. 
 
November/December 1999 
Preventive Care—Who Pays the Bill? 
My interpretation of events at this time is that unless a portion of the current efforts at legislation 
for healthcare reform include mandated minimum requirements of third-party reimbursers to pay for 
screening and preventive programs with proven benefits, the healthcare profession will be fighting a very 
slow and tedious battle. 
 
March/April 2000 
Hormone Replacement Therapy and Risk of Venous Thrombosis 
Current thinking on the risk of venous thrombosis in association with postmenopausal hormone 
replacement therapy has undergone a radical shift… 
 
May 2000 
Thoughts on Change 
I recently had some personal reasons to ponder the concept of change. After 20 years as a 
director of obstetrics and gynecology departments I have, by choice, resigned my positions as Chairman 
of the academic Department of Reproductive Biology at Case Western Reserve University, Director of 
Obstetrics and Gynecology at University Hospitals of Cleveland, and director of the faculty OB/GN clinical 
practice… 
 
My reasons for drawing this subject of change to your attention is to challenge all of us who are 
developing mechanisms that would allow all women to have a similarly positive “free at last” attitude—free 




Dishonesty in Reporting and Its Negative Impact on Clinical Practice 
A recent major scandal in medical research has once again shaken the foundations of scientific 
integrity. To many of us in academic medicine and medical society administration, as well as in clinical 
practice, this misdirection in science should act as a catalyst to the meticulous and inquiring scrutiny of 




Thoughts on the NIH Consensus Development Conference on Osteoporosis 
Prevention, Diagnosis and Therapy 
 I feel that this consensus statement warrants criticism; in its attempt to be “all things to all 
people,” it presents general statements that fail to reach concrete solutions……Finally, was the question, 
“What are the optimal evaluation and treatment of osteoporosis and fractures?” answered by this panel? 





Hormone Replacement Therapy and Coronary Heart Disease–Where Now? 
 The overall conclusion at this time, pending the outcome of more definitive studies in progress 
(e.g., WHI, RUTH), is that prevention is easier than cure. Thus, clinicians should encourage women with 
no history of heart disease to make healthy lifestyle choices by quitting smoking, improving diet, 
exercising and considering the use of HRT. Once active atherosclerosis is present it is unclear whether 
HRT will have an impact on long-term outcome. 
 
January/February 2001 
NAMS Menopause Clinician and Educator Competency Examinations Explained 
September 6, 2000, represented another milestone in the evolution of The North American 
Menopause Society (NAMS), as the first groups sat for the NAMS/NCC competency examinations for 
Menopause Clinicians and for Menopause Educators… 
 
In essence, the purpose of these competency examinations is to raise the bar of expectation of 
knowledge and quality of care around menopause. 
 
March/April 2001 
OTC Steroids: Time for Government to Act Responsibly 
The federal government must now get off its duff and recognize the potential hazards to which it 
is exposing the citizens it claims to represent. We, as healthcare providers, have a similar responsibility to 
create awareness of the problem among legislators and the public. The time for government to amend the 
1994 law is NOW! 
 
May/June 2001 
Your Letter to Congress 
I have a fantasy that all healthcare providers with concerns about women throughout menopause 
and beyond will be simultaneously energized to, just once, write to their congressmen and senators. The 
following is the sort of letter I hope they will write:… 
 
So, the purpose of this letter is to implore you to take a two-pronged approach to the prevention 
of a very frightening scenario. First, there is an urgent need for legislation forcing all health insurers to 
provide cost-effective, evidence-based preventive health programs to the “pre-Medicare” population. 
Second, there is a need for the federal government to review preventive health care provided under 
Medicare and to set an example for the world. Protocols that could be considered are already available. 
 
July/August 2001 
Recognizing the Clinical Significance of Premature Ovarian Failure 
Current clinical management of young women with premature ovarian failure tends to focus on 
the issue of loss of fertility. This happens at the expense of sufficient recognition of the potential long-term 
adverse health outcomes secondary to the changed hormonal profiles… 
 
September/October 2001 
Precisely Defining the Effects of Long-Term- HRT—The Ultimate Catch-22 
Remember Joseph Heller’s 1961 novel Catch-22? “There was only one catch and that was 
Catch-22, which specified that a concern for one’s safety in the face of dangers that were real and 
immediate was the process of a rational mind. Orr was crazy and could be grounded. All that he had to do 
was ask; and as soon as he did, he would no longer be crazy and would have to fly more missions. Orr 
would be crazy to fly more missions and sane if he didn’t, but if he was sane he had to fly them. If he flew 




Attempts to precisely define the true benefits and risks of long-term hormone replacement 
therapy (LTHRT) after menopause pose an exquisite dilemma, perhaps the ultimate Catch-22… 
 
Obtaining this information necessitates enrolling large numbers of women in studies that, of 
necessity, take many years to plan, complete and report. But by the time such randomized, controlled, 
blinded long-term studies are completed, the drugs, doses, regimens and combinations will almost 
certainly have changed…  
 
The Women’s Health Initiative (WHI) is a perfect example of this problem. WHI was planned in 
the 1990s, is being executed over the course of a decade as one of the most expensive clinical research 
projects ever supported by the NIH, and findings will be reported in detail later this decade. By that time, 
at the very least, the preferred doses and, almost certainly, the preferred progestogen, will have changed. 
 
November/December 2001 
HRT and Cancer 
Are estrogenic steroids carcinogenic? Attempts to answer this perplexing question are beginning to 
resemble those around the question, “When does life begin?”… 
 
January/February 2002 
Thoughts on Fear and Anxiety 
The horrific news of September 11, and after, have already affected all of our lives in more ways 
and to a far greater extent than anything we might have initially expected… 
 
What has all of this to do with Menopause Management? Everything and nothing. The majority of 
women, as demonstrated in NAMS Gallup Surveys, do not have these thoughts and fears as they go 
through the menopause transition, but many women do. Our role as healthcare providers has never been 
more important. We need to step up to the plate as role models and leaders. The remedies for the fear 
created by terrorism are much the same as those for almost any transitional situation in life… 
 
I take every opportunity to counsel women that the best response to fear, whether of terrorism or 
of potential future health problems, is to continue doing what they do best—only more so. Work just that 
much harder. Love your loved ones and offer friendship and charity that much more. Do not give fear and 
terrorism the negative response they seek. I suppose that my message to you is the same, for one 
healthcare provider to many; do the same for your patients —and yourself! 
 
March/April 2002 
Bone Mineral Density Testing: Storm Clouds Rising 
The use and potential for abuse of bone mineral density (BMD) testing are escalating rapidly. 
BMD testing is increasingly being promoted as a universal requirement, with BMD being measured 
centrally or peripherally and the tests being advertised, publicized and charged for. In short, BMD testing 
has become big business. But much of this enthusiasm might well rest on a shaky foundation. My 
concern relates not to the use of BMD in research, but to its application to the individual patient… 
 
May/June 2002 
Scientific “Disinformation” and Media Misinterpretation—Take the Case of the HERS 
Study Group 
Little wonder that women are confused, angry and suspicious about modern medicine. Neither is 
it surprising that many medical practitioners are irritated by the weekly “over-the-top” media circus in 
which the selected article of the moment is highlighted on the evening news and in newspapers and 
magazines. Health science is news, and certain topics are big—postmenopausal HRT currently being an 
Andy Warhol “top ten.” 
 





Managing Menopause After HERS II and WHI: Coping With the Aftermath 
Barely was the long-awaited follow-up of the HERS study published, than the National Institutes 
of Health (NIH) dropped its bombshell of discontinuing the trial of estrogen plus progestin (E+P Trial) in 
women with an intact uterus in the Women’s Health Initiative (WHI). Since then, there has been much 
water under the bridge, but let’s try to consider “Where to now?”… 
 
While the merits and demerits of the data and the wisdom of the decision to terminate this arm of 
the WHI study will be debated for years, the manner in which the study was terminated was poorly 
planned, abrupt and inhumane. 
 
September/October 2002 
The Neglected Symptom: Vaginal Dryness 
Other than the cessation of menstruation itself, the two most specific early symptoms associated 
with menopause are hot flashes and vaginal dryness. The former are the usual reason for women to seek 
help during the perimenopause; vaginal dryness, on the other hand, is frequently not addressed… 
 
The bottom line is to query all patients about vaginal symptoms, including those on ET/HT. 




Weight, Menopause and Hormones 
One of the frequent questions raised in clinical discussions is whether menopause of itself 
influences body weight or body mass index (BMI), or if sex hormone therapy can cause an increase in 
body weight... 
 
What then is the message regarding sex hormones, menopause and BMI? While they are 
probably not related, in that neither menopause nor ET/HT appears to be associated with weight gain and 
BMI does not determine symptomatic response to therapy, BMI is nonetheless an important component 
of menopause management. Of itself, elevated body weight is a negative factor for morbidity and 
mortality. It should therefore be raised as an item for health-related discussion every time an overweight 
patient is seen. 
 
January/February 2003 
Clinical Practice Six Months After the WHI EPT Arm Termination 
There is probably one fact all parties impacted by WHI can agree on: Life has been very hectic 
and confusing since the termination of the EPT arm of the WHI study… 
 
It cannot be overemphasized that WHI is a prevention project, and that hormones can be 
prescribed for preventive or clinical indications, or both. But both the consumer and the provider must 
clearly understand why hormones are being considered and prescribed. 




Integrity of Scientific Clinical Publications and Media Reporting—Credible Information or 
Imaginative Marketing? 
In this new century it is virtually impossible to avoid being a cynic or a total doubter. The media 
feed us daily avalanches of mixed messages: bad news, cautions, warnings, exposures of “evil doers,” 
and unbelievable promises of technological advances or medical breakthroughs. We hear stories of 
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greedy and conniving CEOs, disgraced politicians, fallen priests, a pharmaceutical industry force-feeding 
products via direct-to-consumer advertisements and a rampant health profession placing profits ahead of 
patient care… 
How can we in the health profession deal with the challenge of differentiating scientific credibility 
from imaginative marketing? There is no clear answer. Transparency is obviously essential. Therefore, 
Menopause Management will immediately introduce a policy of full disclosure from authors of future 
articles appearing in this publication that discuss any product or services.  
May/June 2003 
Menopause and Systemic Hormones in the HIV-Infected Woman 
The medical practitioner needs to be prepared to provide appropriate menopause-related care to 
the HIV-infected and at-risk population. The scientific community needs to accelerate its research 
endeavors to help provide practitioners the answers so necessary to handle an increasing number of 
women and an escalating numbers of questions. Here exists a unique opportunity for new young 
investigators to get in on the ground floor of a crucial area of research for which funding really is 
available. NIH is to be commended for getting the ball rolling, but we all need to face the challenge as a 
matter of urgency. 
July/August 2003 
Apples are not Oranges—Prevention and Treatment are Different! 
The aftermath of the abrupt termination of the estrogen-progestogen (EPT) arm of the Women’s 
Health Initiative (WHI) in July 2002, as well as the recent publication of its substudies, has produced at 
least one major benefit—women are having more interactive discussions with their health providers about 
their overall care… 
However, the issue I intend to focus on is that prevention of potential future disease is not 
equivalent to treatment of an existing problem! Let me repeat that. Prevention and treatment are very 
different issues. 
November/December 2003 
Does “Statistically Significant” Always Equate to “Clinically Relevant?” 
There is a widening chasm between the points of view of epidemiologist/research investigators 
and practicing clinicians regarding the appropriate interpretation of major randomized trials and 
observational studies… 
Clinical practitioners should not despair. Nor should they grant excess credence to any one 
research report, meta-analysis, or focused review. Instead, they should consider all facts relevant to each 
individual patient. The unique profile inevitably requires a unique clinical opinion. Provided that a patient 
is given an understandable summary of the balance of risk and benefit, that discussion is documented, 
and that appropriate follow-up is planned, you are practicing good medicine. Ultimately, whether 
“statistically significant” is “clinically relevant” still has to be decided between the woman and her health 
provider, and that remains the challenge of the “practice of medicine!” 
January/February 2004 
Menopause, Hormones and the Eye 
There can be no doubt that a strong relationship exists between endogenous and exogenous 
hormones, menopause and the eye. This relationship adds to the complexity of decision-making 
concerning the benefit-to-risk ratio of hormone usage after menopause. Few women will discuss their 
eyes with you, but eye diseases increase with increasing age. At the very least, menopause-related 
healthcare providers need to draw attention to these potential problems, and apprise women of the need 




Thoughts on Suffering and Dying–Or, is “Disease A”  
Really Equivalent to “Disease B”? 
 
Most healthcare researchers, epidemiologists and clinicians tend to consider morbidity and 
mortality in cold, professional terms until they, themselves, become victims of illnesses involving disability 
and dying… 
 
Clearly, the primary objective of medical research and subsequent healthcare delivery is to 
enhance quality and duration of life… 
 
This entire concept has been largely ignored in the current debate over the use of 
postmenopausal pharmacotherapy… 
 
I cannot emphasize strongly enough that this criticism of current affairs must not be taken as a 
recommendation for or against the use of HT. The QoL and cost-effectiveness analyses are simply 
lacking. Rather, this is an urgent appeal for a more precise and humanitarian approach to data 
evaluation, so that advice given to women facing severe medical problems or making difficult medical 
decisions can be truly “quality”- and “caring”-based. For the clinician helping women to enhance QoL, the 
challenge remains to recognize that each woman has a unique profile that needs to be recognized and 
utilized in medical management. 
 
May/June 2004 
Women and Prostate Cancer 
This editorial is one I wish I had not been inspired to write since much of it relates to a recent 
personal experience… 
 
But this is not an editorial on prostate cancer; it is a call to healthcare providers to recognize that 
this diagnosis has an impact on the life of the spouse/partner that is almost as severe as the impact on 
the individual who has been diagnosed. 
 
July/August 2004 
Women’s Health Initiative Round 2—Is this the Opportunity to Clear the Air on 
Postmenopausal Hormone Use? 
The dogmatic pronouncements of the demise of postmenopausal hormone therapies (the “last 
nail in the coffin”) since the termination of the estrogen and progestogen therapy (EPT) arm of the 
Women’s Health Initiative (WHI) in July 2002 appear to have been premature. The latest data reported 
with the termination of the estrogen-only arm of the WHI have given postmenopausal estrogen therapy 
(EPT) serious revitalization… 
It is clear that, at this time, there have been few winners. My hope is that we can utilize the latest 
WHI estrogen-only data in a more responsible fashion to truly reopen the debate, reduce the confusion 
and fear in our real constituency (women with legitimate health concerns and needs) and banish the 




If Drugs Can Prevent Disease, Why is Continuance so Poor? 
There are some real enigmas in the world of preventive and therapeutic health care. Most experts 
would assert that the cost of treating the complications of an uncontrolled medical disorder far exceeds 
the costs of medication…  
 
Yet, despite patient awareness of the role and importance of their drug therapy, the majority of 





Development and Clinical Application of Guidelines, Consensus Opinions, and Position 
Statements— 
The Need for Clinical Judgment Beyond the Evidence 
 
Reliable, practical, and scientifically substantiated recommendations for current clinical practice 
have become an important guide for our day-to-day clinical decision-making… 
 
…Presumably, using identical databases and published evidence, the process should be 
straightforward for any group developing consensus statements and guidelines. So why then do different 




Osteoporosis-Related Events Negatively Impact Quality of Life, But Does Quality of Life 
Impact the Outcome of Osteoporosis? 
There is an escalating awareness in clinical medicine that self-perceived quality of life (QOL) can 
be a key outcome measure of quality of health care. There is considerable evidence that the 
complications of osteoporosis will have a negative impact on QOL. But less well recognized and of 
enormous potential clinical relevance is the question of whether perceived overall QOL will actually have 
an impact on osteoporosis and its complications… 
 
March/April 2005 
Pregnancy After Menopause and The North American Menopause Society (NAMS) 
It was really inevitable. Given the remarkable sequential breakthroughs in reproductive 
technologies over the past three decades, it was only a matter of time before women could begin to 
consider the option of salvaging fertility, and be able to achieve pregnancy with their own eggs after 
menopause. Who would have thought that pregnancy and menopause would need to be considered a 
single area of health care?... 
 
NAMS, by the very nature of its broad and all-inclusive scientific and multidisciplinary 
membership, has focused on all aspects of perimenopausal transition and beyond. Now that same 
diverse base is admirably situated to add a new dimension to its agenda—all the issues regarding 
pregnancy after menopause… 
 
May/June 2005 
The What and the Who of Contemporary Menopause Management 
We ask a lot of ‘what’s?’ in clinical practice. Consider the most recent new patient you have just 
seen in your office. The front office staff had already asked innumerable questions, like “What is your 
name?”, “What is your age and date of birth?”, “What medical insurance do you have?” So, by the time 
she entered your consulting room you had a pretty good idea of the patient’s demographics. 
Chances are that you started the conversation, after the preliminary courtesies, by asking, “What 
is your main complaint?”, and then proceeded to ask a series of other “what’s”, such as those about 
previous medical history, family history, personal habits, exercise and diet patterns, and so forth. 
But did you ever get around to asking the woman, “WHO are you?” 
 
July/August 2005 
The True Symptoms Associated with Menopause Confirmed after 33 Years: Better Late 
than Never, But Let’s Move on NOW! 
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It is quite extraordinary how frequently in medicine a finding published three, four, or more 
decades ago languishes in obscurity until, voila!—the observation is rediscovered and that idea then 




The days when the definition of “menopause” was a one-liner in medical textbooks (“Menopause 
is physiological amenorrhea”) are long gone. Gone too are the days when the word “menopause” was not 
mentioned in public by any self-respecting woman. Nowadays, the “M word” is a healthcare subject that is 
inspiring musicals, and a ‘title’ launching a thousand opinion-based books and magazine articles. Above 
all, the word “menopause” has, unfortunately, become a selling tool. In simple terms, menopause has 
regrettably graduated into an industry! 
This observation may seem to be particularly hypercritical, coming from someone such as myself, 
who has made a major part of my medical career out of the educational, research and clinical issues 
regarding menopause, and perhaps in my capacity as Executive Director of The North American 
Menopause Society (NAMS), an organization whose very existence is based on menopause. But there is 
indeed a significant difference that needs to be highlighted. It is one thing to attempt to bring scientific 
clarification to all issues about menopause, or to attempt to deliver state-of-the science, high quality, 
preventive and therapeutic health care to all women going through (and beyond) the menopause 
transition. It is quite another thing to use menopausal women as a “market” and to knowingly and 
consciously attempt to industrialize, commercialize, and sell inappropriate “remedies” purely for the sake 
of gathering the almighty dollar… 
 
November/December 2005 
Domestic Violence and Menopause 
A patient of mine committed suicide in the early 1970s… 
My primary objective in writing this editorial is to trigger awareness of intimate partner violence 
(IPV) and domestic violence (DV), and to remind you that these issues might lie behind an unusual or 
persistent presentation in some of your patients. We are the front line and often the only defense for 
victims of abuse. I strongly recommend that you access the resources referred to in this editorial. I 
certainly wish that all those years ago I had an awareness of DV and IPV and that these resources were 
available to me. Perhaps the outcome for my own patient might have been better. 
 
January/February 2006 
Women’s Voices for Change—A New Voice for Women and a  
New Partner for NAMS 
Here is a great new development and a challenge to NAMS members across North America.  
November 21, 2006 marked a new milestone in the accelerating growth and influence of The 
North American Menopause Society. At a glittering event in New York City, attended by over 400 women 
and about six men, welcomed by Liz Smith and Ann Richards and entertained by Bette Midler, a new not-
for-profit partnership organization was launched. Women’s Voices for Change (WVFC) has been 
established to change the meaning of menopause in the 21st century… 
Already, an example of the potential for this organization is a project WVFC is rolling out in 
partnership with New York Presbyterian Hospital. They have started a project to provide free bone density 
screening and follow-up for 1,000 under-served Hispanic women in New York City… 
 
March/April 2006 
The Psychosocial and Socioeconomic Burden of Menopausal Vasomotor Symptoms 
We are constantly informed of the high socioeconomic impact of a number of diseases, from 
osteoporotic fractures, to heart attacks, to various cancers. But disruptive symptoms like headache, 
backache–and yes, hot flushes—are also a source of considerable medical cost and socioeconomic 
impact. I recently reviewed the psychosocial and socioeconomic burden of menopausal vasomotor 
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symptoms (VMS) elsewhere, but in this column would like to draw your attention to some of the most 
significant conclusions of that review… 
 
May/June 2006 
Low Back Pain: Management Dilemmas 
…So, there you have it. Low back pain is a major clinical problem that presents a dilemma for 
management. Current practice would, therefore, suggest a process of comprehensive evaluation, 
counseling, bed rest for a short period of time with short-term analgesic use, and special tests for 
nonresponders and atypical presentations. Above all, patients with low back pain must be given adequate 
information about their symptoms. Allaying a patient’s fears may reduce the utilization of medical 
resources and encourage adherence with treatment. 
 
July/August 2006 
Reconsidering Postmenopausal Estrogen Therapy and Breast Cancer 
 …My personal opinion is that from a breast perspective, women – certainly those with previous 
hysterectomy – and practitioners can breathe more easily. While the outcome for women with an intact 
uterus requiring endometrial protection or observation is less certain, the symptomatic perimenopausal 
woman should feel more secure in her short- to medium-term prescription of estrogen-alone therapy. 
Certainly, CEE treatment alone does increase the need for more frequent mammography screening. 
Whatever the decision, I am convinced that there is a need to reduce exposure to progestin. As always, 
constant vigilance remains mandatory. 
 
September/October 2006 
Is Evidence-Based Medicine a Pipe Dream? 
 Sir William Osler (1849-1919) was credited with presenting the following observation during a 
commencement speech at Johns Hopkins Medical School: “As you complete your rigorous studies and 
graduate today, unfortunately I must inform you that half of what we have taught you is wrong. Even more 
unfortunately, we cannot tell you which half!” 
 In the concerted effort to enhance the quality and outcomes of contemporary health care, 
clinicians, other health providers, medical societies, reimbursers, and the rest, have all scrambled to 
develop guidelines, clinical care paths, protocols, “best practice of medicine” rules, and position 
statements. One of the most emphasized and current of these methodologies is the so-called practice of 
“evidence-based medicine” (EBM). The question I pose is whether EBM is really wishful thinking, a 
fanciful attempt at determining clinical practice on an Osler-defined shaky foundation. 
 
November/December 2006 
 Naturally, developing this material is costly in time, effort, and money. The NAMS Foundation was 
therefore launched in September 2006 as a support organization of NAMS, charged with the challenge of 
raising significant financing for greatly enhanced objectives. With financial support from the Foundation, 
the Society will be able to continue its excellent development of materials and programs, and be well 
positioned for even more growth in the years to come. 
 
January/February 2007 
 George Santayana’s admonition that “those who cannot learn from history are doomed to repeat 
it” is a warning and not a cliché. Feminine Forever: Revolutionary - the amazing new breakthrough in the 
sex life of women, by Robert Wilson, MD was published in 1966. He claimed that “for the first time, a 
leading doctor in the field of menopause prevention explains why no woman – no matter what her age – 
need ever feel a day over forty.”… 
 The 2002 WHI termination of its EPT (estrogen-progestogen) arm was a major speed bump on 
this road of menopause history. But the subsequent massive backlash against use of FDA-approved 
hormonal therapies has had an unanticipated and unfortunate outcome – a shot in the arm for a new 
school of “natural” therapies. We are now in the era of Ageless: the naked truth about bioidentical 
hormones. Written and mega-marketed by a high school graduate, Suzanne Somers, the book claims a 
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foundation of “16 interviews from cutting-edge doctors on how to slow the aging process, for women and 
men.”… 
 There should be an explanatory patient package insert in all hormone prescriptions, whether 
commercial or compounded, that clearly explains to women the benefits and risks associated with the 
product. Nonetheless, you are the advocate for your patients and for safe and effective women’s health 
care. The responsibility to counsel women about risks and benefits of all pharmacotherapies is yours. You 
sign the prescription, you carry the liability. It is time to tell women that “buyers beware!” 
 
SUMMARY SEMINAL CONTRIBUTION #14 
 
As  author or coauthor of nearly 40 major state-of-the-art reviews with clinical 
recommendations for best practice of menopause-related medicine, having written well in 
excess of 120 editorials in medical publications on virtually every facet of the subject, 
authored three books as an individual, and coauthored a further four books, most of 
which have also been translated into other languages, as well as having  personally 
taught or lectured on every continent, I believe this effort and the  extracts presented in 
this section attest to the considerable influence I have exerted on this area of clinical 
practice . 
 
Instead of a narrative summary, selected direct quotations from some of these 
publications are presented as examples of my forward thinking and seminal contributions 
to medical science at the time they were written. These quotations would also best 
represent the evolution of my personal thought processes over the last 40 years.  
 
6.15 SEMINAL IMPACT ON WORLD MEDICINE THROUGH 
 ESTABLISHMENT OF NATIONAL AND INTERNATIONAL 
 MENOPAUSE ORGANIZATIONS, MEDICAL JOURNALS AND A 
 COMPETENCY EXAMINATION 
 
It is one thing in contemporary medicine to undertake and publish basic and clinical 
research findings, to write reviews, editorials, and personal opinions on the current 
literature, to be involved in the development of evidence-based recommendations for 
clinical practice, or to be a teacher. It is quite another thing to create vehicles through 
which all this information can be discussed, distilled, and disseminated to the world at 
large, or by which standards of health care and its delivery can be improved. In judging 
my own personal and seminal major impact on medicine and women’s health, I believe 
it is in the second category that I have made my most significant contribution. 
 
In the role of pioneer in establishing scientific organizations, assisting in their 
development, and launching scientific medical journals, my efforts have been pivotal in 
achieving the following outcomes: 
1. Creating forums for scientific discussion;  
2. Developing vehicles for supporting young and new research investigators;  
3. Establishing professional and consumer education committees which in turn 
have developed professional and consumer education products; 
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4. Enhancing education at medical schools in the area of menopause and women’s 
health;  
5. Improving women’s knowledge about menopause through print, internet, and 
other vehicles; 
6. Initiating an international Menopause Practitioner Competency Certification 
examination. 
 
The outcomes of these accomplishments have raised the “bar of expectations” for 
standards of medical practitioner’s healthcare delivery, and in turn of many women’s 
knowledge about menopause and their expectations from the health system. The 
mechanisms through which I have achieved these objectives, with examples of some of 
the products developed, are summarized below. 
 
6.15.1    ESTABLISHMENT OF NATIONAL AND INTERNATIONAL                
      MENOPAUSE ORGANIZATIONS 
 
6.15.1.1   THE INTERNATIONAL MENOPAUSE SOCIETY (IMS) 
The historical background to the development of the IMS is described in Section 2.1 
above. In summary, two people conceived the idea in 1973, Pieter van Keep and me. 
The idea was honed over the next 3 years, during which time we planned the First 
International Congress on Menopause, which was held at la Grande Motte, France, in 
1976. At that meeting, we refined the ideas about the organization, selected members 
for the first Board of Trustees, and launched the IMS in Jerusalem in 1978. 
 
Since that time, I have served at various periods on the Board of Trustees, and am an 
Honorary Past President. 
 
The nature, scope and activities of the IMS are described on its web site at 
www.imsociety.org.  
 
6.15.1.2   OTHER NATIONAL MENOPAUSE SOCIETIES 
Following the launch of the IMS and the successful first world meetings in 1976 and 
1978, I was invited by colleagues with interests in their own countries to help in the 
development of their own national organizations. This invariably involved a lengthy 
correspondence with assistance in writing initial statutes based on their national 
objectives (mission/vision). Following that my routine recommendations included that  a 
national menopause meeting  be held, at which time the organization would be formally 
approved. Again, invariably, I would attend those meetings, assist in committee 
deliberations, and give a keynote lecture at the meeting. The following is a list of 
countries with which I was involved and, for many, the lectures I presented are listed in 
my full curriculum vitae (Section 8). The years represent year of launch or of initiation of 





















United Kingdom (1993) 
Taiwan (1995) 




Czech Republic (1998) 
Jamaica (1998) 
Turkey (2000) 
Caribbean Menopause Society (2000) 
Asia Pacific Menopause Federation (2001) 
 
6.15.1.3   THE NORTH AMERICAN MENOPAUSE SOCIETY (NAMS) 
The background and history to my starting The North American Menopause Society 
(NAMS) is detailed in Section 2.1. The growth and success of this organization has 
been phenomenal and a detailed description of every aspect of the organization and its 
programs can be accessed at www.menopause.org.  Some examples of its milestones, 
accomplishments, and activities follow. 
  
• Founded in 1989, NAMS is North America’s leading nonprofit organization 
dedicated to promoting women’s health and quality of life through an 
understanding of menopause. NAMS organizes meetings and congresses, and 
advances the interchange of research plans and experience between individual 
members of the Society. Its multidisciplinary membership of leaders in the field—
including clinical and basic science experts from medicine, nursing, sociology, 
psychology, anthropology, pharmacy, epidemiology, nutrition, and education—
allows NAMS to be the preeminent resource on all aspects of menopause to both 
healthcare providers and the public. 
 
• The annual scientific meetings confirm our diversity, with members drawn from 
the basic and clinical sciences, physicians, nurses, and all the others listed 
above. By avoiding concurrent sessions, the annual meetings have been 
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extraordinarily successful in fostering increased collaboration and elevating 
knowledge. The scientific programs are attended by thought leaders from over 50 
countries. 
 
• NAMS provides guidance for healthcare providers through its development of 
position statements on key clinical issues, printed and Web-based educational 
programs, and its popular textbook, Menopause Practice: A Clinician’s Guide. 
Members also receive expert advice through our Webinars and quarterly 
Menopause e-Consult e-newsletter. Many of these programs allow participants to 
earn continuing education credits from NAMS, an ACCME-accredited 
organization.  
 
• The abrupt pronouncements on the termination of the estrogen/progestin arm of 
the WHI study in July 2002 caused real confusion for women and health 
providers. But it contributed to the my launching of our highly acclaimed First to 
Know® monthly e-newsletter in which experts cull the current and about-to-be-
released literature for important news. The best are summarized and e-mailed to 
members with expert commentary. The file is then posted to the NAMS web site 
for open access. 
 
• NAMS established multiple awards for significant accomplishments in scientific 
research, clinical care, teaching, and consumer information and education. 
 
• NAMS provides startup research grants to new investigators for pilot research 
projects. 
 
• A decade ago, recognizing our strengths and the demand for reliable information 
for the public, NAMS added consumer education to its broader mission. Major 
accomplishments in this arena include: 
 The award-winning NAMS Web site (www.menopause.org), currently 
drawing in excess of 5 million hits per month. 
 Two primary print resources, the Menopause Guidebook and the Early 
Menopause Guidebook, provide factual information to hundreds of 
thousands of women. 
 Now in its third year is Menopause Flashes, a complimentary monthly e-
newsletter for women that translates the most current scientific information 
into consumer-friendly language. 
 And just launched in 2006 with an initial print run of one million is 
Changes, the NAMS-endorsed magazine distributed to patients through 
U.S. physicians’ offices.  
 
6.15.1.4   THE COUNCIL OF AFFILIATED MENOPAUSE SOCIETIES (CAMS)   
  
CAMS is one of the Organs of the International Menopause Society. I launched CAMS 
during my tenure as President of the IMS in 1996 with several specific objectives in 
mind. The first was to provide a democratic forum for all national societies affiliated with 
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the IMS. The controlling committee of the IMS (the Board) by virtue of its limited size 
could not have a member from every country on its rostrum. CAMS on the other hand, 
irrespective of the size or number of members of a national or regional society, allows 
one member from each onto its Board. The second main objective of CAMS was to 
develop ideas for projects that would have international pertinence to the scientific basis 
and healthcare delivery aspects of menopause.4  
 
The first four projects that were approved serve as examples of these objectives: 
 
1.DEFINITIONS PROJECT 
This project was assigned the task of modernizing the terminology associated with 
menopause, taking into account the definitions developed at the First International 
Menopause Congress at La Grande Motte in 1976, as well as WHO and other previous 
definition projects. I was assigned the task, and working with a committee that I enrolled 
to be representative of our family of nations, completed the task, and the final report 
was widely disseminated, and also published in our official journal, Climacteric (2,284-
286, 1999). 
2. MINIMAL STANDARDS FOR BEST HEALTH CARE PROJECT 
 
Discussions between many IMS members over the years had highlighted the need for 
the IMS to come out with a clear set of guidelines as to what would comprise the 
minimum level of health care that should be delivered to women worldwide. Such a 
document would be useful to both healthcare providers in day-to-day practice as well as 
to controlling authorities such as local or central governments and reimbursing agencies 
in setting their priorities and budgets. 
 
3. ESSENTIALS FOR MEDICAL EDUCATION PROJECT 
A project was approved by the CAMS for the development of a curriculum of essential 
criteria for menopause education that should be included in the women’s health 
teaching programs at medical schools.  
 
4. WORLD MENOPAUSE DAY 
A project to declare October 18th every year as World Menopause Day was approved by 
the CAMS Board and subsequently by the World Health Organization (WHO). For the 
first 6 years, I personally developed appropriate materials and circulated them to all 
CAMS members for use in their home countries. 
 
6.15.1.5   WOMEN’S VOICES FOR CHANGE (WVFC) 
 
The NAMS Board recognized the need to develop a grassroots women’s organization to 
partner in its efforts to disseminate good information. I was given the go-ahead to work 
with a group of eminent women in New York City to establish such an organization.  
 
On November 21, 2005, a new not-for-profit partnership organization was launched. 
Women’s Voices For Change (WVFC).The organization’s mission is to provide 
education, advocacy, and support to the estimated 50 million North American women of 
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menopausal age through a collaborative partnership with NAMS. WVFC will rely on 
NAMS for the scientific content of its initiatives, and will donate half of its annual 
proceeds to NAMS, specifically for the mutual development of projects. The new 
essential component now activated is a voice for women through the power of a strong 
grassroots organization in partnership with a strong scientific organization. An example 
of the potential for this organization is a project WVFC has undertaken in partnership 
with New York Presbyterian Hospital. This is  a project to provide free bone density 
screening and follow up to 1,000 underserved Hispanic women in New York City. Each 
participant will receive free bone density testing, a free Spanish-language version of the 
NAMS guidebook  Menopause: A New Beginning, one year’s supply of calcium and 
vitamin D, and free transportation to the hospital for the testing. 
 
6.15.1.6   THE NAMS FOUNDATION 
 
Developing NAMS material is costly in time, effort, and money. The NAMS Foundation 
was therefore launched in September 2006 as a support organization of NAMS, 
charged with the challenge of raising significant financing for greatly enhanced 
objectives. With financial support from the Foundation, the Society will be able to 
continue its ambitious agenda for development of materials and programs, and will be 
well positioned for even more growth in the years to come. I have been appointed 
President of The NAMS Foundation for the years 2006 through 2009. 
 
6.15.2   FOUNDING OF MEDICAL JOURNALS  
 
I have also been privileged to have been involved in the conception, planning, 
launching, and editing, of three major medical publications: 
 
6.15.2.1 MATURITAS 
Maturitas was the first official medical journal of the IMS. For years, I coedited this 
journal with Peter van Keep MD, PhD, who at that time was Director General of the 
International Health Foundation. Before I launched NAMS in 1989, I stepped down from 
that responsibility, as there would have been a conflict of interest when NAMS planned 
to initiate its own scientific publications. 
 
6.15.2.2 MENOPAUSE MANAGEMENT 
Menopause Management is a practical, peer-reviewed clinical publication, mailed 
bimonthly throughout North America and internationally, with a circulation of just under 
35,000. The evidence-based, clinically relevant, and practical articles have resulted in 
the wide acceptance and popularity of this publication. I have been the Medical Editor 
since the onset of publication in the fall of 1988. I write the editorial for every issue. 
 
6.15.2.3   MENOPAUSE: THE JOURNAL OF THE NORTH AMERICAN              
MENOPAUSE SOCIETY 
Menopause was launched in 1994 under the stewardship of Isaac Schiff, MD, and me 
as a journal to serve as a vehicle for transmitting peer-reviewed scientific information 
that would be helpful to the NAMS membership, the healthcare profession, and society 
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in general. Menopause is now ranked in the top three of OB/GYN journals listed by the 
Library of Congress, as measured by Science Citation Index, and universally accepted 
as the scientific journal on the subject. 
 
6.15.3   THE FIRST AND ONLY MENOPAUSE COMPETENCY         
EXAMINATION 
 
With the Mission of NAMS to promote the health and quality of life of women through an 
understanding of menopause, we recognized the need to set essential standards for 
health providers, thereby assuring high-quality care for women. To meet this need, the 
Society in 2000 developed an opportunity for licensed healthcare providers from 
multiple disciplines to demonstrate their expertise though passing a 100-question 
multiple-choice competency examination and becoming credentialed as a NAMS 
Menopause Practitioner. Currently, healthcare providers throughout the world hold this 
prestigious 3 year credential. 
 
Those who pass the examination receive a certificate suitable for framing, plus 
suggestions on how to promote the accomplishment within the community. NAMS 
assists in announcing this accomplishment by posting all Menopause Practitioners 
names on the Society’s Web site. In turn, this allows women searching the NAMS Web 
site for a competent practitioner near home, with the names of those who have received 
the credential. 
 
SUMMARY SEMINAL CONTRIBUTION #15 
 
This section provides a detailed summary of my pioneering efforts in organizing the 
medical profession into societies and foundations, all established with the prime 
objective of enhancing the quality of health care provided to women worldwide. One of 
the original three founders of the International Menopause Society, I assisted about 20 
countries establish national societies, before founding The North American Menopause 
Society in 1989. 
 
In this endeavor of establishing scientific organizations, assisting in their development, 
launching scientific medical journals, and initiating a competency examination to set the 
minimal standards of knowledge required for this area of health care, my efforts have 
been pivotal in achieving the following outcomes: 
1. Creating forums for scientific discussion;  
2. Developing vehicles for supporting young and new research investigators;  
3. Establishing professional and consumer education committees which in turn 
have developed professional and consumer education products; 
4. Enhancing education at medical schools in the area of menopause and women’s 
health;  
5. Improving women’s knowledge about menopause through print, Internet, and 
other vehicles; 









SUMMARY STATEMENT ON THE NATURE AND VALUE OF THE 
CONTRIBUTIONS TO MEDICAL SCIENCE 
 
 
CONTRIBUTION #1 – HISTORICAL PERSPECTIVE 
 
3. My first significant contribution to medical science was the recognition of the 
female menopause as being a health-related issue beyond simple loss of 
menstruation. In drawing attention to this issue, I was also one of the pioneers in 
identifying the key questions for future research. 
4. Another major pioneering contribution to medical science and women’s 
healthcare was to recognize the need to establish national and international 
scientific organizations, peer reviewed medical journals, and mechanisms both 
for researchers to share and interact in programs for scientific progress, and 
clinicians to be apprised of current standards and recommendations for practice. 
 
 
CONTRIBUTION #2 – TERMINOLOGY AND DEFINITIONS 
 
Over a period of 30 years I was the first to introduce a standard set of definitions on 
menopause-related terminology, and then to work with international working groups and 
medical organizations to further develop this process. By helping standardize the 
semantics and the staging of reproductive aging this represents a significant 
achievement in comparing research and evaluating clinical standards of care. 
 
 
CONTRIBUTION #3 – RESEARCH METHODOLOGY,  
 TECHNIQUES, AND INSTRUMENTS 
 
Faced with a lack of methods to quantify the potential physical and clinical impact   of 
the menopause transition, I was forced to develop techniques for accurate quantification 
of change. The areas I have made a contribution to, in this respect, include: 
7. Documenting the role of the parabasal cells of the vaginal smear as being 
adequately reflective of the level of estrogenicity of the postmenopausal woman. 
Thus a simple vaginal smear was recognized as a good clinical instrument in 
determining therapeutic indications for estrogen therapy. 
8. Identifying the relationship between plasma calcium levels and estrogenicity 
presented an early potential marker of change in bone metabolism. 
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9. Involvement in the evaluation and determination of the role of successive 
technologies for measurement of bone density. 
10. The development and validation of a precise instrument for measuring and 
following global quality of life. The UQOL is established in contemporary 
research as a good instrument for following 4 inter-related domains of quality of 
life. 
11. Development of a laboratory cell line of ectocervical epithelial cells that can serve 
as a system for studying the effects of a variety of agents, including the sex 
steroids, on the female ectocervix. 
12. Helping develop and test instruments to measure vasomotor symptoms and 
domains of sexual function. 
 
 
CONTRIBUTION #4 – PHYSIOLOGY AND MECHANISMS 
 
Working alone or with co-investigators I have been able to contribute some significant 
basic research findings towards explaining the fundamental physiology and 
mechanisms of disease, and the pharmacologic function of female hormones. These 
contributions include: 
5. I was the first investigator to suggest that different estrogens demonstrate 
different properties and effects. Studies with the non-steroidal estrogenic product 
P1496 might also represent the first study with a SERM. 
6. The prevailing dogma that hormone replacement therapy dosage should be 
titrated to gonadotropin levels was shown to be incorrect. Moreover, low dosages 
of estrogen were shown to be potentially effective, presaging the advent of low 
dose hormone therapy. 
7. We were amongst the first investigators to explain changes in human vaginal and 
cervical epithelium at a molecular biological level. 
8. Through a series of studies and experiments a window has been opened into 
explaining the role of estrogens and progestogens in potential protection from 
and pathogenesis of cardiovascular disease. 
1) The impact of bilateral oophorectomy and replacement estrogen was 
studied and “these findings considered sufficient evidence for questioning 
the empirical use of estrogenic hormones for the prevention of ischemic 
heart disease in postmenopausal women”.27 
2) Our studies of unesterified deposits in human arteries demonstrated 
correlation with the severity of the atherosclerotic lesion. This allowed a 
working two-stage hypothesis involving a reversible first stage in which 
there is small particle aggregation, and a  second irreversible stage with  
more massive agglomeration of irregularly shaped particles containing 
unesterified cholesterol and calcium phosphate. These findings are 
particularly important because of the current suggestion from clinical 
studies that exogenous estrogen therapy commenced early in the process 
of atherogenesis in postmenopausal women may be cardioprotective, 
whereas therapy started several years after menopause may in fact be 
deleterious and result in increased risk of heart attack. 
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3) Our early experiments demonstrated modulation effects by sex hormones 
on flow velocity in the parametrial artery of pregnant rats.37  Following on 
this we showed coronary blood flow to increase by an order of about 50% 
and to be virtually abolished by NG-nitro-L-arginine, an inhibitor of nitric 
oxide synthase. We were able to conclude that estrogen regulates 
coronary blood flow, in part by upregulating nitric oxide synthase in the 
coronary vasculature. 
4) Puzzled by our observations in pregnant rats that estrogen and 
progesterone may have opposing effects on blood flow  we were the first 
to prove that when administered with estradiol, all progestogens and 
progesterone abrogated the estradiol-related increase in coronary flow.40  
These studies may be evidence of a potential mechanism to explain later 
clinical studies suggesting that administration of combined estrogen and 
progestogen might be associated with an increased risk of heart attack in 
the first year of therapy. 
5) To investigate whether estrogens might act directly on the cardiac 
myocytes and in this way affect the mechanical performance of the heart 
we demonstrated that the overall influence of estrogen on the coronary 
circulation and its influence on the contractile function of the heart 
combine synergistically to exert a cardioprotective effect. The results 
confirmed that estrogens are cardioprotective agents in females. 
6) Because that cardioprotective effect could result from modulation of 
endothelial permeability, we investigated and effectively demonstrated that 
the net effect on transendothelial permeability depends  on the relative 
contributions of each of two systems. This has current  relevance because 
understanding the mechanisms by which estrogens modulate endothelial 
permeability may be important for development of drugs that can target 
the specific mechanisms involved in the actions of estrogen and may 
provide the pharmacological means to selectively regulate the 
permeability 
 
In summary then, my seminal contribution in investigating the potential relationship 
between female hormones, ovarian function and heart disease has been to identify the 
areas in need of study, and to work closely with colleagues in attempting to clarify those 
relationships. The outcome has been to open a window into some of the mechanisms 




CONTRIBUTION #5 – CHARACTERIZING MENOPAUSE, SPECIFIC 
 SYMPTOMS, AND CHRONIC CONDITIONS 
 
7. The menopause transition was shown to represent a potential endocrinopathy. 
8. The definitive symptoms and physical signs directly related to the change in 
endocrine profiles were defined and classified. 
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9. Those symptoms responsive to estrogen replacement therapy were differentiated 
from those responding to general supportive and placebo therapy. This finding 
has formed the foundation for national and international evidence-based 
guidelines for symptomatic indications for estrogens after menopause. 
10. The mental tonic effect of estrogens, or ability to produce a feeling of wellbeing, 
was scientifically documented and established for the first time. 
11. The significant response of vasomotor symptoms to placebo in randomized 
placebo-controlled clinical research studies of estrogen therapy was recognized 
and reported for the first time.  
12. The continued function of ovaries conserved at the time of hysterectomy in 
premenopausal women was confirmed, and a plea made for their conservation. 
 
CONTRIBUTION #6 – NEW DRUGS AND DELIVERY SYSTEMS 
 
6. Different estrogens were shown to induce different clinical and metabolic effects. 
This seminal finding has influenced my search for safer and more effective 
hormonal products and routes of administration. 
7. I initiated, completed, and published the world’s first randomized placebo-
controlled blinded study, including head to head comparison of bioequivalent 
doses of different estrogens. 
8. I have been the first, and sometimes only, investigator to evaluate and report on 
new products. 
9. I have been one of the initial investigators to promote scientific comparisons of 
lower doses of hormone products.  
10. I was one of the first investigators to evaluate non-oral routes of administration of 
hormones through technologies such as the   transdermal patches and gels. 
 
CONTRIBUTION #7 – SEXUAL FUNCTION 
 
4. My oophorectomy studies in women of reproductive age, and assessment of  the 
role of exogenous estrogen replacement, were the first of this type in this 
population, and brought attention to an area in need of research. 
5. I have worked as part of collaborative groups in developing and testing validated 
instruments for measuring female sexual response. 
6. Estrogen therapy after surgical menopause was shown to be of no value in 
restoring or enhancing libido. But in later studies of testosterone in estrogen-
replete surgically menopausal woman, the testosterone was shown to 
significantly improve sexual desire. Studies are on-going. 
 
CONTRIBUTION #8 – BODY WEIGHT 
 
3. I was the first to report that exogenous hormone therapy to the postmenopausal 
woman does not induce an increase in body weight 
4. We were able to report from a large multicenter study, that BMI is not an 






CONTRIBUTION #9 – QUALITY OF LIFE 
 
Perhaps my greatest contribution in this area has been to bring medical attention to the 
importance of defining, recognizing, accurately measuring, and enhancing quality of life 
in women through and beyond menopause. This has been accomplished through: 
5. Development of a validated instrument, the UQOL.  
6. Contributions of specific research in therapy for reducing or alleviating specific 
menopause-related symptoms and consequent enhancement of health related 
QOL. 
7. Application of the UQOL in clinical research to demonstrate the impact of specific 
treatments on global QOL. 
8. Multiple reviews and other educational activities. 
 
CONTRIBUTION #10 – POPULATION SURVEYS 
 
My key contribution under this section was the design and implementation of health 
surveys on population knowledge, attitudes, and experience regarding menopause and 
hormone therapies. That provided recognition of what the population was telling us 
about their health concerns and the health care system, and enabled translation of that 
need into appropriately designed and distributed materials that were informative and 
understandable to that target population. 
 
CONTRIBUTION #11 - COST-EFFECTIVENESS ANALYSIS AND  
        PHARMACOECONOMICS 
 
Pioneering the concept of balancing the risks and benefits of menopause-related 
hormone therapies, I was the first to introduce the application of cost-effectiveness 
analysis to this area of medicine. This emphasized the need for incorporating risk, 
benefit, the costs incurred or saved with each, as well as quality of life, into a 
measurable analysis. In turn this will allow for impartial selection of such therapies in 
both individual and overall health planning. Most importantly, such analyses allow for 
the ranking and comparison of the cost-effectiveness of other therapeutic modalities for 
other health problems, and placing postmenopausal hormone therapies in perspective 
within the big picture. 
 
CONTRIBUTION # 12 – HEALTHCARE DELIVERY AND  MENOPAUSE 
CLINICS 
 
The original Groote Schuur Hospital Menopause Clinic was the first such facility in the 
world. Following publications on the role of such a facility, the clinic became a role 
model for similar clinics world wide. Thus I was the first person to start a menopause 
research clinic and then a comprehensive menopause clinic, and later to describe the 




I educated clinicians from across North America and internationally in the details of 
establishing these centers, or developing a menopause management component within 
their existing medical practices. I advised on the establishment of such clinics in South 
Africa, the United Kingdom, the United States, Europe, and Asia. 
 
An indirect result was that I was a pioneer in establishing the sub-specialty of 
“Menopause Medicine”. 
 
CONTRIBUTION #13 – CLINICAL PRACTICE GUIDELINES 
 
I have initiated, coordinated, and disseminated evidence based guidelines for best 
medical practice utilizing international panels of medical experts in multiple disciplines 
pertinent to the topic under consideration. These position statements have consequently 
had a major impact on medical management of the menopause. 
 
CONTRIBUTION #14 - CONTRIBUTION TO INTERNATIONAL                   
         PRACTICE THROUGH STATE OF THE ART REVIEWS,  
         EDITORIALS, AND CLINICAL RECOMMENDATIONS  
 
As  author or coauthor of nearly 40 major state-of-the-art reviews with clinical 
recommendations for best practice of menopause-related medicine, having written well in 
excess of 120 editorials in medical publications on virtually every facet of the subject, 
authored three books as an individual, and coauthored a further four books, most of 
which have also been translated into other languages, as well as having  personally 
taught or lectured on every continent, I believe this effort and the  extracts presented in 
this section attest to the considerable influence I have exerted on this area of clinical 
practice . 
 
Instead of a narrative summary, selected direct quotations from some of these 
publications are presented as examples of my forward thinking and seminal contributions 
to medical science at the time they were written. These quotations would also best 
represent the evolution of my personal thought processes over the last 40 years.  
 
CONTRIBUTION #15-SEMINAL IMPACT ON WORLD MEDICINE 
 THROUGH ESTABLISHMENT OF NATIONAL AND 
 INTERNATIONAL MENOPAUSE ORGANIZATIONS, MEDICAL 
 JOURNALS AND A COMPETENCY EXAMINATION 
 
This section provides a detailed summary of my pioneering efforts in organizing the 
medical profession into societies and foundations, all established with the prime 
objective of delivering quality health care to women world wide. One of the original three 
founders of the International Menopause Society, I assisted about 20 countries 





In this endeavor of establishing scientific organizations, assisting in their development, 
launching scientific medical journals, and initiating a competency examination to set the 
minimal standards of knowledge required for this area of health care, my efforts have 
been pivotal in achieving the following outcomes: 
7. Creating forums for scientific discussion,  
8. Developing vehicles for supporting young and new research investigators,  
9. Establishing professional and consumer education committees which in turn 
have developed professional and consumer education products, 
10. Enhancing education at medical schools in the area of menopause and women’s 
health,  
11. Improving women’s knowledge about menopause through print, internet, and 
other vehicles, 
























CLOSING STATEMENT ON SEMINAL CONTRIBUTION  
TO MEDICAL SCIENCE 
 
“Anyone who believes you can’t change history has never tried to write his memoirs.” 
      David Ben Gurion 
 
During a professional career spanning over four decades, I believe I have made seminal 
contributions to both the science and understanding of menopause, and to the 
organization of the medical profession in setting standards for research, education, and 
healthcare delivery. In the process, I started with the unusual opportunity of identifying 
the significance of an unrecognized area in medicine that ultimately affects all women. 
My contribution beyond the recognition phase was to identify or be at the beginning of 
virtually every aspect related to the research into, and management planning of, the 
female menopause. This has included, inter alia, defining the menopause transition, 
establishing instruments for evaluation and identification of the menopause as a 
potential endocrinopathy, stimulating and undertaking basic and clinical science 
research, characterizing the condition, determining  women’s own perceptions of the 
transition, describing and developing appropriate healthcare delivery systems, 
quantifying cost-effectiveness of therapies, producing evidence based clinical 
guidelines, and founding national and international menopause societies to further all 
these activities. Beyond this, I have edited the major medical journals in the subject, 
used my editorials as a bully pulpit to drive enhanced health care and question outdated 
dogma, and taught and lectured on the subject worldwide. 
 
In humbly submitting this body of work for consideration for the prestigious degree of 
Doctor of Science at the University of Cape Town, I truly believe that my life’s work has 
had a positive impact on the health and quality of life of millions of women worldwide. I 
am conscious of my good fortune in having been able to do what I have done, and the 
debt I owe to the many research and clinical collaborators I have worked with around 
the world. Above all, I am deeply grateful to the many thousands of women I have seen 
in consultation, and for what they have confided in me and taught me.  
 
 
“I have but one lamp by which my feet are guided, and that is the lamp of experience. I 
know of no way of judging of the future but by the past.” 





















WULF H. UTIAN 
































NAME AND CURRENT TITLES  
 
Wulf H. Utian, MB, BCh, PhD, FRCOG, FACOG, FICS 
 
 Executive Director and Honorary Founding President 
 The North American Menopause Society  
 
 The Arthur H. Bill Professor Emeritus 
 Department of Reproductive Biology 
 Case Western Reserve University  
 
 Chairman, Board of Advisors, Rapid Medical Research Inc. 
 
 Consultant, Obstetrics and Gynecology and Women’s Health 
The Cleveland Clinic Foundation 
 
Visiting Professor, Faculty of Health Sciences,  





Home: 27500 Cedar Road, Point East P-7 
Beachwood, OH  44122 
Office:  The North American Menopause Society 
5900 Landerbrook Drive 




Home:  216/378-1840 
Office:  440/442-7680 NAMS 
Fax:  440/442-2660 
Cell:  216/272-7751  
 
 Home:  utian@attglobal.net  




Date of Birth:  September 28, 1939 
Place of Birth: South Africa 
Wife:   Moira 
Children:  Brett  




                  
EDUCATIONAL BACKGROUND 
 
1956  Highlands North High School 
   Johannesburg, South Africa 
 
1962  University of Witwatersrand 
             Johannesburg, South Africa 
             MB.BCh 
 
1970  University of Cape Town 
             Cape Town, South Africa 
             PhD 
 Thesis: Clinical and Metabolic Effects of the Menopause and the Role 
   of Replacement Oestrogen Therapy 
 
    
CERTIFICATION 
 
 MRCOG (London), 1967 
 FACOG, December 1976 (Elected Life Fellow, November 2005) 
 ECFMG Written and passed May 1963 (033-629-7) 
 FLEX passed December 1976 (FLEX avg. 81.8; OB-95) 
 American Board of Obstetrics and Gynecology, March 1979 
 American Board of Obstetrics and Gynecology, Division of Reproductive 
Endocrinology, February 1980 
 Fellow, Royal College of Obstetrics and Gynaecology, Elected 1980 
 Fellow, International College of Surgeons, Elected 1980 
 Certified Clinical Densitometrist (CCD), International Society for Clinical 
Densitometry, October 15, 2001 (valid through October 15, 2009) 




 1963 South African Medical Council, Medical Practitioner (MP9514) 
 1963 General Medical Council, London, England (1105614) 
1970 South African Medical Council, Specialist Obstetrician and  
 Gynaecologist 
 1977 Ohio State License by FLEX (40409) 
 1979 Medical Board of South Australia 




PREVIOUS HOSPITAL ADMITTING PRIVILEGES 
 
 Part-time lecturer to the University of Cape Town and Consultant in Obstetrics 
and Gynaecology, Groote Schuur Hospital.  
 Part-time Consultant Obstetrician, Mowbray Hospital, Cape Town  
 Honorary Gynaecologist, Highland House Home for the Aged, Cape Town 
 Medipark Clinic, Cape Town 
 Vincent Palotti Hospital, Cape Town 
 New Somerset Hospital, Cape Town 
 Rondesbosch Cottage Hospital, Cape Town 
 Victoria Hospital, Cape Town 
 The Mt. Sinai Medical Center, Cleveland 
 University Hospitals of Cleveland, Cleveland 




 American Board of Medical Specialties 
 Personalities of the West and Midwest 
 Personalities of America (4th Edition) 
 Who's Who in the Midwest (20th Edition) 
 Directory of Medical Specialists, 1976 to Present 
 ABMS Director of Certified Obstetrics and Gynecologists 
 Who's Who in the Midwest (21st Edition) 
 Men of Achievement, (13th Edition) 1988 
 The International Directory of Distinguished Leadership, 1988 
 Personalities of the Americas, First Commemorative Edition, 1988 
 Personalities of America (5th Edition) 1988 
 Who's Who in America, 1988 
 Five Thousand Personalities of the World, 1988 
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 International Leaders in Achievement (2nd Edition) 1990 
 Directory of Distinguished Americans (5th Edition) 1989 
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 Who’s Who in America (60th Edition) 2006 
 Who’s Who in Medicine and Healthcare (6th Edition) 2006-2007 




 Fellow, Royal College of Obstetricians and Gynaecologists 
 South African Society of Obstetricians and Gynaecologists 
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 South African Society of Endocrinology, Diabetes and Metabolism 
 International Society of Psychosomatic Obstetrics and Gynaecology, Founding 
Member 
 Fertility Society of South Africa 
 South African Medical Association 
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 The International Society for Clinical Densitometry 
 International Society for the Study of Women’s Sexual Health (ISSWSH) 




 CARE Committee, University Hospitals (1977-1980) 
 Human Investigation and Clinical Research Committee, University Hospitals 
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 Chairman, MacDonald House Human Research Review Committee 
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 CWRU Executive Committee (1990-1999) 
 University Hospitals Medical Council (1990-1999) 
 Council of Clinical Chairman CWRU (1990-1999) 
 CWRU Task Force on Endocrinology and Metabolism (1990-1992) 
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 National Scientific Advisory Committee, First Annual CCF Speaking of 
Women’s Health Summit (April 16-17, 2005) 
 Steering Committee, CCF Speaking of Women’s Health (2006) 
 
MEDICAL TEACHING EXPERIENCE 
 
 66-67 Undergraduate Medical Teaching, University of Cape Town Medical 
School 
 
 68-71  Undergraduate and Postgraduate Teaching. Lecturer and consultant in 
charge of the Postgraduate Teaching Program in Obstetrics and 
Gynaecology at the University of Cape Town and the Groote Schuur 
Hospital 
  
 67-73 University of Cape Town School of Physiotherapy, Course in Obstetrics 
and Gynaecology 
 
 71-76  Lecturer, Part-time, Department of OB/GYN, UCT. 
 
71-76 Carinus Nursing College, Cape Town 
 
 75-76  Lecturer, Advanced Course in Midwifery, Mowbray Maternity 
 Hospital, Cape Town 
 
76-79 Assistant Professor, Case Western Reserve University School of 
 Medicine, Undergraduate and Postgraduate teaching 
   
79-89 Associate Professor, Case Western Reserve University 
 







  67-68  Consultant in Charge, Maternity Block, Groote Schuur Hospital 
 
 69-71  Consultant in Charge, Peninsula Maternity Hospital, Cape Town 
 
 80-89  Director, Obstetrics and Gynecology, Mt. Sinai Medical Center, 
Cleveland 
    
 89-99  Director, Obstetrics and Gynecology, University Hospitals of Cleveland 




 70-76  Private Practice, Medipark, Cape Town, South Africa 
    
 78-79  Practice Manager, MacDonald Hospital Associates, Cleveland, Ohio 
    
 79-00  President, University OB/GYN Specialties, Inc., Cleveland, Ohio 
    
 94-99  Board Member, University Faculty Practice Association, Cleveland, Ohio 
 
RESEARCH  INTERESTS 
General: 
 Estrogens and menopause - metabolic and psychosocial aspects 
 Premenstrual Syndrome 
 In Vitro Fertilization - successful program established 1983 
 
Specific: 
 Metabolic aspects of the perimenopausal female, the effects of 
oophorectomy, and the use of pharmacologic agents, in particular on 
bone, cardiovascular and hypothalamic pituitary physiology 
 Determining “Quality of Life’ through instrument validation and 
application  
        
Groote Schuur Menopause Research Clinic: 
   I was responsible for establishing this clinic in 1967 and was consultant 
in charge until leaving in May 1976.  Numerous scientific reports 
emanated from this clinic   
  
Rapid Medical Research Inc.: 
   In 1997, I was responsible for establishing this independent Clinical 
Research Center with the objectives of expediting and facilitating the 
above types of research 
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MEDICAL JOURNAL REVIEWER/EDITOR AND MEDIA POSITIONS 
South African Medical Journal, Referee and Reviewer 1972-1976 
South African Medical Journal, Editorial Contributor 1974-1976 
Examiner in Obstetrics and Gynaecology, University of Cape Town 
1971-1976 
Maturitas, Manuscript Referee 1978- 
C.V. Mosby Publishing Company, Manuscript Referee 1980-
American Journal of Obstetrics and Gynecology, Manuscript Referee 1980-
Fertility and Sterility, Special Reviewer 1981-
Obstetrics and Gynecology, Special Reviewer 1981-
Maturitas, Co-Chief Editor 1983-1993
Journal of Psychosomatic Obstetrics and Gynaecology, Referee 1985-1990
NIH Bioengineering Study Section Project Review 1987
American Fertility Society, Media Spokesperson on "Menopause" 1988-1996
Menopause Management, Editor 1988-
Medical Advisory Board, Producers Group, Inc., New York 1988-1990
Honorary Research Board of Advisors, American Biographical Institute 1988-
OB/GYN Digest, International Advisory Committee, 1988-1996
Resident & Staff Physician, Special Reviewer 1988-
Neurology, Reviewer 1989-
Journal Clinical Endocrinology and Metabolism, Reviewer 1989-
Drugs, Reviewer 1990-
OB/GYN Management, Monthly Editorial Column "Climacteric Practice"
11/90-2/93
Gynecologic Endocrinology, Advisory Board 1986-1996
Journal of Endocrinological Investigation, Reviewer 1992-
Search Your Colleague's Practice on Gynecology, Editorial Board 1992-1995
Chest, Reviewer 1992-
Health Words for Women, Editor 1992-
Osteoporosis International, Reviewer 1992-
Drug Evaluations, American Medical Association, Consultant, 1992-
Journal of Musculo-Skeletal Medicine, Reviewer 1993
Journal of Women’s Health, Reviewer 1993
Journal of Reproductive Medicine, Reviewer 1993
University Hospitals Magazine, Editorial Advisory Board 1993
MENOPAUSE - The Journal of the North American Menopause Society,
Founding Co-Editor, 1993-
Medical Tribune for the OB/GYN, Editorial Advisory Board 19941999
Pharmaco Economics, Reviewer 1994-
American Journal of Epidemiology, Reviewer 1994-
American Journal of Human Biology, Reviewer 1994-
New England Journal of Medicine, Reviewer 1996-
United States Pharmacopeial Convention, USP Drug & Disease Therapy
1996-
Gynecology Digest, International Scientific Editorial Committee 1997-
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Medical Tribune for the Obstetrician/Gynecologist, Medical Editor 1997-1998 
Climacteric, Journal of the International Menopause Society, Editorial Board 
1997-2004 
Annals of Internal Medicine 1998- 
British Journal of Obstetrics and Gynaecology 1998 – 
Patient Care 1999- 
Women and Health 1999- 
Journal of General Internal Medicine 2000- 
NBC Cleveland TV Women’s Health Expert Morning News 2000-2002 
Women’s Health & Urban Life (WH&UL) 2001- 
Human Reproduction Updates 2001- 
Treatments in Endocrinology 2002- 
Journal of Women’s Health and Gender-Based Medicine 2003- 
Quality of Life Research 2003- 
BioMed Central 2004- 
International Journal of Impotence Research (The Journal of Sexual 
Medicine) IJIR 2004- 
International Journal of Gynecology and Obstetrics 2006-  
SPECIAL INTERNATIONAL APPOINTMENTS AND NATIONAL 
ORGANIZATION OFFICES 
South African Representative on the International Society of Psychosomatic 
Obstetrics and Gynaecology, Elected December 1971 
South African Council of the Royal College of Obstetricians and 
Gynaecologists, Representative for Members of the College, 1972-1974 
Chairman, South African Council of ISPOG, 1972-1976 
Chairman and Founding Member, South African Inherited Disorders 
Association, Cape Western, 1974-1975 
Medical Advisory Panel, SAIDA (W.P.), 1974-1976 
Fertility Society of South Africa, Executive Committee, 1977 
Appointed to Advisory Panel, International Health Foundation, Geneva and 
Brussels, 1976 
Appointed to the Permanent Scientific Advisory Panel, Society for the Study 
and Therapy of the Menopause, 1977 
Editorial Advisory Board of Maturitas (Elsevier/North Holland Biomedical 
Press), 1977 
Consultant Flinders University (Adelaide, Australia) Long-term Collaborative 
Menopause Research Project, 1979 
Panel of Independent Assessors, National Health and Medical Research 
Council, Canberra, Australia, 1979 
Executive Committee, International Menopause Society, 1980-1996 
International Menopause Society, Executive Committee, 1981 
Consumer Reports, New York, Consultant, 1981 
Vice Regent for Ohio, International College of Surgeons, 1981 
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Chairman, OB/GYN Surgical Specialty Group Executive Committee, 
International College of Surgeons, 1981 
International College of Surgeons, United States Section, Executive Committee 
of the Obstetric and Gynecologic Surgical Specialties Group, 1981-1990 
Board of Advisors, RESOLVE, 1983-1986 
Vice President, International College of Surgeons, United States Section, 1983 
Executive Committee, International College of Surgeons, United States 
Section, 1984-1989 
Board of Regents, International College of Surgeons, United States Section 
1984- 1995 
International Menopause Society, Executive Committee - Re-elected, 1984 
Re-elected Vice President, International College of Surgeons, United States 
Section, 1985 
International Society of Gynecological Endocrinology, Founding Committee, 
1986 
Re-elected Vice President, International College of Surgeons, United States 
Section, 1986 
Executive Committee, International Society of Gynecological Endocrinology, 
1986-1992 
CME Program and Membership Committees - International College of 
Surgeons, 1987-  
Advisor on Menopause and Infertility to the International Health Foundation, 
Geneva and Brussels, 1987 
Vice President, International College of Surgeons, United States Section, 
1987-88 
Re-elected Vice President, International College of Surgeons, United States 
Section, 1988-89 
The North American Menopause Society, Founding President, 1989-92 
Treasurer, International Menopause Society, 1990-93 
International Menopause Society, 1990, Elected President-Elect for 1993-
1996 
The North American Menopause Society, Executive Director, 1992- 
President, International Menopause Society, 1993-1996 
American Representative Committee of the Royal College of Obstetricians 
and Gynecologists 1994-1997, Re-elected 1997 for 1997-2000 
Board of Trustees, Turner’s Syndrome Society of the United States, 1995-97 
Council of Affiliated Menopause Societies of the International Menopause 
Society, U.S. Representative, 1996-1999 
Chairman, Steering Committee, National Menopause Education, Program 
Association of Academic Health Centers, Washington, DC, January-July, 
1996 
Visiting Professor, University of Ferrara, Italy, May-June, 1997 
Medical Health Advisory Board, Society for the Advancement of Women’s 
Health Research, 1997- 
Council of Affiliated Menopause Societies of the International Menopause 
Society, Secretary 1996-1999 
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 Coalition on Women’s Health and Aging, National Council on Aging, 1998- 
 Council of Affiliated Menopause Societies of the International Menopause 
Society Chairman 1999-2002 
 International Advisory Board, the YVY-QOL Institute, Seoul, Korea 1999- 
 Women’s Health Advisory Council of the National Women’s Health Resource 
Center 2000- 
 Honorary President, Satellite Symposium 5th European Congress on 
Menopause, Sardinia, Italy, June 18-20, 2000 
 Steering Committee, 10th World Menopause Congress, Berlin, Germany. 10-14 
June, 2000-2002 
 Medical Health Advisory Board Executive Committee, Society for Women’s 
Health Research, Washington DC, Elected October 26, 2000-2001 
 The Helen Moss Breast Cancer Research Foundation Advisory Board, 2000-  
 Council of Affiliated Menopause Societies of the International Menopause 
Society Chairman 2002-2005 
 Steering Committee, 11th World Congress of the International Menopause 
Society, Buenos Aires, Argentina. 2002-2005  
 Chair, Editorial Advisory Board OB.GYN.Net Menopause, 2005- 
 Executive Committee of the North American Women’s Healthcare Forum, 
2003- 
 Council of Past Presidents, International Menopause Society, 2005- 
 Co-secretary for North America, Scientific Committee 2008 World Congress on 
Menopause, Madrid, Spain. 2006-2008. 
 
PAST RESEARCH GRANTS  
 
 1968  The Herman Bequest, University of Cape Town 
 1969  Atomic Energy Board, South Africa 
 1970  Atomic Energy Board, South Africa 
 1971  Atomic Energy Board, South Africa 
           Round Table Association, South Africa 
National Institutes of Health, Washington (Chemicals and purified 
hormones and antibodies) 
           Medical Research Council (with Dr. C. Beardwood) 
 1972  Atomic Energy Board, South Africa 
 1973  Medical Research Council (with Dr. P. Beaumont) 
 1974  University of Cape Town 
           Ayerst Laboratories, New York 
 1975  Ayerst Laboratories, New York 
 1976  University of Cape Town 
           Ayerst Laboratories, New York 
 1977  NIH Award No:  RR-05410-16 
 1980  NIH Pharmacia Joint Award, Project Co-Director, Hyskon Adhesion Study 
1983  CIBA Geigy, New York 
1986  Organon, New York 
1989  Wyeth-Ayerst, New York 
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1989  NIH/NIA:  1 R13 - AG086-16 - Multidisciplinary perspectives on 
reproductive aging (with F. Kronenberg) 
1991  Mead Johnson, Evansville, Indiana 
1992  Solvay Pharmaceuticals, Estratab/Estratest Study 
1992 Noven Pharmaceuticals, Estrogen Patch Study 
1992 NIH RO1-AR4-3003-01 Co-Investigator 
1994-  Multiple multicenter drug trials, proprietary in nature and not specifically 
detailed here (Available on request). 
 
PRINCIPAL INVESTIGATOR – NATIONAL MULTICENTER STUDIES 
 
1995-98 Fournier, TS 17 Estradiol Transdermal System  
 1996-  Lipha/Merck AG, Continuous E2/LNG TDS – Hot Flashes 
 1998-  Solvay, Continuous E2/LNG TDS – Endometrium 
 1999-  Solvay, Protocol S1673003. Multicenter Efficacy Study Continuous EP 
Patch -Vasomotor 
 2000-  Endeavor Pharmaceuticals Estrogen vasomotor symptoms study 
 
HONORS AND AWARDS 
 
1979 Organon Australian Visiting Professorship for 1979 
1981 Elected Honorary Member Kansas City Gynecologic Society 
1981 Diploma of Medical Achievement, Venezuelan Society of OB/GYN 
1997 Ruth Gray Lecture Award, Evanston Hospital, Illinois 
1989  The New York Academy of Sciences Certificate of Appreciation 
1992  The North American Menopause Society, Honorary Founding President  
1993  Honorary Fellowship, TSI Foundation, London, England 
1993  Honorary Member, Argentine Association for Study of Climacteric 
1995  Awarded Honorary Membership, Pacific Northwest Obstetrical and 
   Gynecological Association 
 1995  Honorary Membership, FLASCYM, Federation of Latin 
    American Societies of Climacteric and Menopause 
1996   Awarded Honorary Membership, Polish Menopause Society, Warsaw, 
    Poland 
1996   NAMS Award in recognition of “vision and dedication as Founding 
Trustee 1989-1996” 
1996   Life Honorary Past President, International Menopause Society 
1996  Awarded Honorary Membership Chilean Menopause Society 
1997  Elected to Academy of Medical Sciences of Kazakhstan 
1998   The Best Doctors for Women, Good Housekeeping Magazine, Citation 
1998  Czech Medical Association, J.E. Purkyne Medal of Honor and Honorary 
Life Membership for Career-Long Contributions to Women’s Health, 
Prague, Czech Republic 
1999  North American Menopause Society first “Lifetime Achievement Award” 




 1999  Faculty and Staff of University MacDonald Women’s Hospital.  “In 
recognition of your outstanding leadership, achievement and 
commitment, we dedicate the Wulf H Utian OB/GYN Fund for Surgical 
Excellence” 
2000      Appointed Arthur H. Bill Professor Emeritus of Obstetrics and  
   Gynecology, effective January 1, 2000 
2000  Award of recognition for service to the College and contributions in the 
field of menopause, Royal College of Obstetricians and Gynaecologists, 
Sept. 4, 2000 
2001  The 2001 Historical Lectureship, Royal College of Obstetricians and 
Gynaecologists, London 
2003  Appointed Visiting Professor, Department of Obstetrics and 
Gynaecology, Faculty of Health Sciences, University of Cape Town for 
2003 
2003  Key to Miami Beach and “every women’s heart” for services to women’s 
health, the Mayor of Miami Beach, September 17, 2003 
2004  Awarded Honorary Membership to the South African Menopause 
Society, Port Elizabeth, South Africa 
2004  Food and Drug Administration’s Commissioner’s Special Citation “for the 
collective outstanding performance of the “Menopause and Hormones 
Information Campaign” that resulted in the launch of a national public 
awareness outreach campaign” 
2004  Case Western Reserve University School of Medicine, certificate of 
deep appreciation for superb efforts on Campaign for the Future of 
Academic Medicine 
2006  Lifetime Endowment for Wulf H Utian/Wyeth NAMS Annual Lecture to 
be presented at NAMS Annual Scientific Meeting 
2007-10 Appointed Visiting Professor, Department of Obstetrics and 
Gynaecology, Faculty of Health Sciences, University of Cape Town. 
 
MICROSURGICAL FALLOPIAN TUBE REPAIR DEMONSTRATIONS 
 
 1978  Park Lane Hospital for Women, Johannesburg, South Africa 
 1979  Flinders University Medical Centre, Adelaide, Australia 
 1981  Park Lane Hospital for Women, Johannesburg, South Africa 
 1984  Park Lane Hospital for Women, Johannesburg, South Africa 
 
SEARCH AND EVALUATION COMMITTEES 
 
 1984  Appointment Committee, Chair in Obstetrics and Gynecology, University 
of Turku, Finland 
 1996  American Medical Writers Association(AMWA), Margaret Mead 
Journalism Award Committee 
 1997  AMWA Margaret Mead Journalism Award Committee 
 1998  AMWA Margaret Mead Journalism Award Committee 
 1999  AMWA Margaret Mead Journalism Award Committee 
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OTHER SPECIAL COMMITTEES 
1985 Special Study Section Committee for Review of Menopause 
Research Grants, Department of Health and Human Services (NIH) 
1986 Special Site Visitor, NIH Program Project, Harvard Medical School and 
American Institute for Research, Menopause Project, Boston 
1986 Medical College of Virginia, Consultant to Climacteric Study Group, 
Department of Maternal Child Nursing 
1991 Medical Policy Committee, Qualchoice, Cleveland 
1992 Consultant on NIMH Proposal and Research, School of Nursing, 
Georgia State University 
1994 Invited member of International Expert Panel on "Detection and 
Interpretation of Low Bone Mass in the Adult Population" Society for 
Clinical Densitometry, 3/06/94 
1994-6 WHO Scientific Group on Research on the Menopause, Geneva, 
Switzerland 
WHO Technical Report Series #866, “Research on the Menopause in 
the 1990’s” 
1997 Perimenopause Committee for Research on Women’s Health for the 
21st Century, National Institutes of Health Office on Women’s Health 
Research 
1997 Office on Women’s Health Research, N.I.H., Co-Chairman of 
Reproduction Committee for Agenda for Women’s Health Research into 
the Next Century, Washington, DC 
1995 Steering Committee for 10th World Congress on the Menopause, 10-14 
June 2002, Berlin, Germany 
1995 Planning Committee for Workshop on Reproductive Staging, National 
Institutes of Health, Washington DC, planned for July 2001 (STRAW 
Conference) 
1995 Executive Planning Committee, The Foundation for Better Health Care, 
North American Women’s Health Care Forum, 2000, 2001, 2002, 2003 
2003 FDA Menopausal Hormone Therapy Outreach Education Committee, 
Washington  
2003 WHO/ICUD (International Consultation on Urological Diseases), 
Committee on female sexual desire, arousal and pain disorders; 
pathophysiology and treatment 
2005 Vice Chair, Israel Health Advancement for Women/Jewish Community 
Federation of Cleveland  Committee (ISHA) 
2005 International Advisory Board of the 7th European Congress on 
Menopause, June 3-7, 2006, Turkey (EMAS) 
2006   Planning Committee for the 12th World Congress on the Menopause,  
  Madrid, June 2008. 
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PHARMACEUTICAL ADVISORY COMMITTEES/CONSULTANCY (PAST) 
CIBA-GEIGY USA 
Organon Steering Committee 
Mead Johnson Laboratories/Bristol Myers Squibb 
Noven Pharmaceuticals 
Upjohn Worldwide Advisory Board on Women's Healthcare 
Merck-Medco Advisory Board on Partners for Women's Health 
Solvay East Coast Advisory Board 
Hoechst Marion Roussel 
Lipha Pharmaceuticals 
Merck KGaA/Solvay International HRT Advisory Board 
Eli Lilly National Scientific Advisory Board 
Solvay Pharmaceuticals 
Johnson & Johnson Leadership Council on Women’s Health 
Parke-Davis Advisory Board 
Roche Pharmaceuticals Advisory Board 
Endeavor Pharmaceuticals Advisory Board 
TAP Pharmaceuticals Consultant 
Pfizer Lasofoxifene Global Strategic Advisory Panel 
Berlex Female Health Care National Advisory Board 
Galen/Warner Chilcott Advisory Board 
Aventis Pharmaceuticals Advisory Board 
Nexcura Inc. Medical Editorial Board 
Merck Medical Advisory Board 
Novogyne Advisory Board 
KV Pharmaceuticals 




PHARMACEUTICAL ADVISORY COMMITTEES/CONSULTANCY (PRESENT) 
Depomed 
Novartis Zoledronic Acid Consultant Advisory Board 
Johnson & Johnson Pharmaceutical Research and Development, Consultant 
Roche/GlaxoSmithKline Boniva OB/GYN Advisory Board 
Pfizer Consultant 
Berlex 
Johnson and Johnson Internal Medicine Therapeutic Advisory Board 
Organon 
Barr/Duramed 
Merck Gynecology Advisory Board 
GSK SERM Global Advisory Board 
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 ELI Lilly Breast Cancer Risk Reduction Advisory Board 
 Novo Nordisk 
 
U.S. CONGRESS ACTIVITIES 
 
 03/22/91  Chairman, U.S. Congress Office of Technology Assessment 
Workshop, Dirkson  Senate Building, Washington, D.C. 
     "Hormone Replacement Therapy:  Policy and Practice" 
Report Released 5/19/92 - The Menopause, Hormone Replacement 
Therapy & Women's Health (U.S. Government Printing Office #052-
003-01284-7)  
     ISBN 0-16-037912-1 
 
 05/30/91  A Hearing of the Subcommittee on Housing and Consumer Interests 
Select Committee on Aging, United States House of 
Representatives, Rayburn House  Office Building 
     “Women at Midlife:  Consumers of Second-Rate Health Care?"  
Expert Testimony Assisted in development of HR 1020 Introduced to 
Congress 2D Session 6/01/92 as "Women's Midlife Health Research 
Act" by Rep. Marilyn Lloyd 
 
 09/07/05  Town Hall Meeting on Menopause, Hart Senate Building. Opening 
keynote address, and session moderator 




Play Development Advisor, Plays for Living, New York - "The Birthday Club" - 
Premiere, New York, February 23, 1995 
 
INVITED FORMAL LECTURES 
 
 1967 Medical Association of South Africa, Cape Western Branch. 
      "Teenage Pregnancy" 
1969   South African Society of Obstetrics and Gynaecology, Cape Western 
Branch, Karl Bremer Hospital 
"Pros and Cons of Long-term Oestrogen Admin. to Postmenopause 
Female" 
1970   University of Natal, Durban 
       "Oestrogens and Menopause" 
1970   Medical Association of South Africa, Natal Inland Branch, 
Pietermaritzburg 
       "Menopause" 
1970   University of Tel Aviv, Tel Hashomer Hospital, Israel 
       "Oestrogens and Menopause" 
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1971   South African Society of Physiotherapists Annual Mtg., Cape Town, 
South Africa 
       "Role for Physiotherapy in Obstetrics and Gynecology" 
1971   University of Cape Town, Postgraduate Refresher Course 
       "Induction of Ovulation" 
1972   Charing Cross Hospital Medical School, London 
       "Calcium Metabolism, Oestrogens and Osteoporosis" 
1972   University of Ohio, Cincinnati School of Medicine 
       "Estrogens, Oophorectomy and Menopause" 
       "Induction of Ovulation with Limited Laboratory Facilities" 
1972   Medical Association of South Africa, Natal Coastal Branch, Durban 
       "Management of the Menopause" 
1972   University of Witwatersrand, Department of OB/GYN, Johannesburg, 
South Africa 
       "Management of the Menopausal Patient" 
1973   South African Nursing Association, Cape Western Branch 
       "Recent Advances in Gynaecological Endocrinology" 
1973   South African Medical Congress, Cape Town, South Africa 
       "Endocrine Aspects of Menopause" 
1973    University of Witwatersrand, Dept. of Medicine, Neurology Unit  
       "Oestrogen, Headache and the Contraceptive Pill" 
1973   South African Medical Association, East London Branch 
       "The Role of Oestrogen in the Treatment of the Menopause" 
 1974 International Health Foundation, Oestrogens in Menopause ,Geneva 
  "Definitive Symptoms of Postmenopause - Parabasal Cell Index" 
1976   International Congress on Menopause, La Grande Motte, France, June 
Chairman Workshop on Climacteric Syndrome 
1976    International Symposium on Oestrogens, Bordeaux, France 
       "Oestrogens and Menopause" 
1976   University of Utrecht, Departments of Gynecology and Medicine 
       "Recent Advances in Oestrogens and Menopause Research" 
1977   Cleveland Society of Obstetricians and Gynecologists 
       "Menopause:  The Estrogen Controversy" 
1977   Akron Visiting Professor Program, St. Thomas Hospital 
       "Infertility - Diagnosis and Treatment" 
1977   Case Western Reserve University, Current Concepts in Reproductive 
Endocrinology 
       "Menopause" 
1977   Cleveland Metropolitan General Hospital 
 "Therapy Oriented Cost/Effect Diagnosis of Secondary Amenorrhea" 
1977   International Health Foundation Workshop on Estrogens, Geneva 
"Application of Cost-Effectiveness Analysis to Postmenopausal 
Estrogen Therapy" 
1977   University of Athens, Greece and Hellenic Fertility and Sterility Society, 
Symposium on Menopause 
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"The Climacteric Syndrome:  Rationale for Curative and Preventative 
Therapy" 
1977 University of Cape Town, South Africa 
"Current Gynecologic Trends in the United States" 
"Cost-Effectiveness Analysis and Estrogen Therapy" 
1978 University of Louisville, Kentucky 
"Cost-Effectiveness Analysis and Estrogen Therapy" 
1978 University of Milwaukee, Milwaukee County General Hospital, 
Milwaukee, Wisconsin 
"Streamlining the Infertility Work-Up" 
1978 St. Joseph's Hospital, Milwaukee, Wisconsin 
"Menopause" 
1978 Diabetes Association of Greater Cleveland 
"Menopause and Diabetes" 
1978 Akron Visiting Professor Program, St. Thomas Hospital 
"Surgical Correction of Infertility" 
1978 Youngstown Visiting Professor Program, St. Vincent's Hospital 
"Menopause" 
1978 Medicine 1978 - Postgraduate Course of Case Western Reserve 
University 
"Glands are Necessary" 
1978 Akron Visiting Professor Program, St. Thomas Hospital 
"Recent Advances in Menopause Research" 
1978 University of Witwatersrand, Johannesburg, South Africa 
"Recent Advances in Menopause Research" 
1978 2nd International Congress on Menopause, Jerusalem, Israel 
Chairman:  Workshop on Metabolic Effects 
  Workshop on Menopause Clinics 
1978 Societa Italiana di Ostetrica e Ginecologia and International Health 
Foundation, International Symposium on Menopause, Rome, Italy 
"Vantaggi e limiti della terapia estrogenica" 
1978 Central New York Academy of Medicine, Utica, New York 
"Estrogen Therapy in Perspective" 
1978 Youngstown Visiting Professor Program, St. Elizabeth's Hospital 
"Management of Menopause" 
1979 American Society of Abdominal Surgeons, Tampa, Florida 
"Use and Misuse of Estrogens" 
1979 Akron Visiting Professor Program, St. Thomas Hospital, Akron, OH 
"Hirsutism" 
1979 University of Southern California, Los Angeles, Grand Rounds 
"Menopause" 
1979 Royal Australian College of General Practitioners (Victoria Branch) and 
University of Melbourne 
"Clinical Presentations and Therapy of Menopause" 
1979 University of Queensland, Brisbane, Department of Gynaecology 
"Current Work on Tubal Microsurgery" 
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1979 Royal Women's Hospital, Brisbane 
"Amenorrhea:  Investigation and Treatment" 
1979 Royal Australian College of General Practitioners (Sydney Branch), 
Prince of Wales Hospital, Sydney 
"Gynecology and the General Practitioner" 
1979 School of Obstetrics and Gynecology, Royal Hospital for Women,  
University of New South Wales, Postgraduate Symposium on 
Menopause 
"Organ Changes During Climacteric" 
1979 University of Sydney, St. George's Hospital Reunion Week 
"Endocrinology of Menopause" 
1979 Flinders University School of Medicine, Adelaide, Visiting Professorship 
Lectures 
"Amenorrhea" 
"Current Status of Postmenopausal Estrogen Therapy" 
"Abnormal Uterine Bleeding" 
"Hirsutism" 
"Current Status of Fallopian Tube Surgery" 
"Hormonal Management Around Menopause" 
1979 University of Adelaide, Queen Elizabeth Hospital 
"Cost-Effective Therapy-Oriented Diagnosis of Amenorrhea" 
1979 Waterbury Hospital Grand Rounds, Connecticut (Yale University 
affiliate) 
"Recent Surgical Advance in the Treatment of Infertility" 
1979 Seminar on Current Views on Estriol, Oss, Holland 
"The Place of Estriol Therapy After Menopause" 
1979 Northern Ohio Pediatric Society, Cleveland 
"Teenage Pregnancy" 
1979 Mt. St. Mary's Hospital of Niagara Falls and State University of New 
York at Buffalo 
"Estrogen" 
1979 Cleveland Society of Obstetricians and Gynecologists 
"Endocrinology of the Menopause" 
1980 American Society of Abdominal Surgeons, Postgraduate Course,  
Chicago, IL 
"Rational Hormonal Therapy" 
"Surgical Treatment for Sterility" 
1980 University of Missouri, Kansas City, Postgraduate Course 
"Update in Ob/Gyn - Macro vs. Microsurgery:  New Frontiers for 
Gynecologists" 
1980 St. Thomas Hospital, Akron, Ohio - Visiting Professor Program 
"The Female Climacteric" 
1980 Medicine, Postgraduate Course, Case Western Reserve University 
"Current Dilemma in the Use of Estrogen in the Menopausal Period" 
1980 Fairview General Hospital, Cleveland, Visiting Professor Program 
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"Applications of Cost-Effectiveness Analysis to Estrogens After 
Menopause" 
1980   St. Luke’s Hospital, Cleveland 
       "Modern Trends in Tubal Surgery" 
 
1980   West Virginia School of Medicine, Wheeling Division 
       "Evaluation of Infertility" 
       "Recent Advances in Tubal Surgery" 
1980 College of Medicine and Dentistry of New Jersey, Rutgers Medical  
       School, 2nd Annual Dorothy Marvin Lecture 
       "The Treatment of Menopause" 
1980 The Mt. Sinai Hospital of Cleveland, 12th Annual Shirley and Maurice 
Saltzman Lecture 
 "The Endocrine Background to the Clinical Management of Menopause" 
1981 University of the Witwatersrand, Johannesburg 
   "Aspects Relating to the Menopause" 
1981 Barberton Citizen's Hospital, OH 
  "Controversy in Estrogen Therapy" 
1981   Northeastern Ohio University College of Medicine, Visiting Professor, St. 
Elizabeth's Hospital, Youngstown, Ohio 
       "Menopause - Normal Physiology or Endocrinopathy" 
1981   Youngstown Osteopathic Hospital Association, Cafaro Memorial 
Hospital, Youngstown, OH 
       "Estrogen Therapy" 
1981 Brandeis University Women's Committee, Cleveland Branch 
       "Life Cycle of a Woman" 
1981   Parma Community Hospital and Case Western Reserve University 
       "Controversies in Estrogen Therapy" 
1981   Kansas City Gynecologic Society, Kansas City 
       "Microtubal Surgery - A Philosophy or a Technique" 
1981   Lakewood Hospital Medical Grand Rounds, Lakewood, OH 
       "The Consequences of Ovarian Aging" 
1981    University of Arkansas for Medical Sciences, Postgraduate Symposium 
       "Menopause and its Management" 
       "The Menopause Syndrome - Symptom Formation" 
       "Choice of Hormone, Indications, Monitoring" 
1981   Marymount Hospital Grand Rounds, Cleveland 
       "Macro vs. Microsurgery in Infertility" 
1981   Family Practice Center of Akron, Day of Education 
       "Problems of the Female Menopause" 
1981   St. Vincent’s Charity Hospital, Cleveland 
       "Estrogens and Osteoporosis" 
1981   University of Utrecht, The Netherlands 
       "Advances in Infertility Microsurgery" 
1981    Mt. Sinai Medical Center, Cleveland, First Workshop in Infertility Surgery 
       "Principles of Conservative Pelvic Surgery" 
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       "Prophylaxis of Pelvic Adhesion Formation" 
       "Reversal of Sterilization in the Female" 
 
 
1981 Desert Springs Hospital, Third Annual Medical Symposium on 
Endocrinology and Metabolic Disease, Las Vegas, NV 
       "Menopause" 
       "Amenorrhea" 
       "Microsurgical Techniques in the Treatment of Infertility" 
1981   Licking Memorial Hospital, Newark, OH 
       "Estrogens and Osteoporosis" 
1981   Albany Medical College and New York State Department of Health, 
Albany, New York, Symposium on Controversies in the Management of 
the Menopause 
 “The Menopause, A Physiological or Pathological Phenomenon?" 
       "Patient Management:  What's Appropriate?" 
1981 Evansville, Indiana, St. Mary's Medical Center 
       "Menopause, Osteoporosis and Estrogens" 
1981  Case Western Reserve University, University Hospitals, Family Practice 
Grand Rounds 
       "Osteoporosis" 
1981  Suburban Hospital, Cleveland, Grand Rounds 
       "Current Status of Menopause and HRT" 
1982   VIII Venezuelan Congress of Obstetrics and Gynecology, Caracas, 
Venezuela, Special Invitation Keynote Lecturer 
 "Recent Advances in Understanding and Treatment of Menopause" 
1982   Northern Transvaal Branch of SASOG and University of Pretoria, South 
Africa 
      "Estrogens and the Menopause" 
1982   SASOG Southern Transvaal Branch, College of Medicine, 
Johannesburg, South Africa 
       "Advances in Estrogen Therapy" 
1982   SASOG Cape Province Branch, University of Cape Town Postgraduate 
Medical Center, Cape Town, South Africa 
       "Effect of Progestins on Estrogen Therapy" 
       "Recent Progress in Infertility Microsurgery" 
1982   Addington Hospital, Durban, Grand Rounds, Durban, South Africa 
       "Advances in Gynecology” 
       “Estrogens and the Menopause” 
     “Recent Developments in Infertility Surgery" 
1982  University of Natal and King Edward VIII Hospital, Durban, South Africa 
 "Recent Advances in Hormone Replacement Therapy after Menopause" 
1982   Sharon General Hospital, Sharon, PA 
       "Estrogen Therapy after Menopause" 
1982   American Association of University Women, Painesville, OH 
       "Research in Female Reproductive Endocrinology" 
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1982 Michael Reese Hospital and Pritzker Medical School, Chicago 
"Menopause as an Endocrinopathy" 
"Recent Surgical Advances in Treatment of Infertility" 
1982 Youngstown Obstetrical & Gynecologic Society, Squaw Creek, 
Youngstown, OH 
"Recent Advances in Infertility Surgery" 
1983 Wayne State University School of Medicine, Detroit, MI, Visiting 
Professor 
"Recent Advances in Infertility Surgery" 
"Premenstrual Syndrome - Current Perspective" 
1983 Cleveland Metropolitan General Hospital, OB/GYN Grand Rounds 
"Practical Treatment of Menopause" 
1983 Mt. Sinai Hospital of Hartford, Connecticut, Visiting Professor 
"Is Menopause Physiological or Pathological?" 
1983  Cleveland Society of Obstetricians and Gynecologists 
"The Logistics of In-Vitro Fertilization" 
1983  Bloomington Hospital and University of Indiana, Bloomington, IN 
"Estrogens, Menopause and Osteoporosis" 
1983 Planned Parenthood of Great Lakes Regional Meeting, Cleveland 
"In Vitro Fertilization" 
1983 11th World Congress on Fertility and Sterility, Dublin, Ireland 
"Prevention of Postoperative Adhesions" 
1983 Jan Palfijn European Congress on Menopause, Antwerp, Belgium 
"Problems of the Untreated Menopause" 
1983 St. Michael Hospital, Milwaukee, WI 
"Estrogen Replacement Therapy - Pros and Cons" 
1983 Fairview General Hospital, Cleveland, OH 
"PMS - Diagnosis and Treatment" 
1984 University of Stellenbosch, Cape, South Africa 
"Logistics in In Vitro Fertilization" 
1984 University of Cape Town, Cape, South Africa 
"In Vitro Fertilization" 
1984 Bloomington Hospital, Bloomington, IN, Community Education Program 
"Menopause - A Woman's Transition" 
Visiting Professor Conference 
"Menopause" 
1984 Massillon Community Hospital, Massillon, OH 
"Estrogen Replacement Therapy" 
1984 First Annual MacDonald House Conference on Reproductive 
Endocrinology, Cleveland, OH, Hilton South Hotel 
"The Fate of the Untreated Climacteric" 
"In Vitro Fertilization" 
1984 Special Invited Delegation of American Fertility Society to Peoples 
Republic of China Hosted by China Association for Science and 
Technology (CAST), May 26 through June 14, 1984 
1984 Capital Hospital, Beijing 
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"Menopause - Meaning, Treatment and Menopause Clinics" 
1984 Tianjing Central Hospital, Tianjing 
"Menopause" 
"In Vitro Fertilization" 
1984 Shanghai Obstetrical-Gynecologic Hospital of #1 Medical School, 
Shanghai 
"Menopause Clinics and Treatment" 
“In Vitro Fertilization" 
1984 First Hospital of Kuenming, Kuenming 
"Menopause - Current Status" 
1984 #2 Peoples Hospital, Guangzhou (Canton) 
"Menopause and Osteoporosis" 
1984 Medical School of Guangzhou (Canton) 
"Microsurgery" 
1984 Youngstown Hospital Grand Rounds, Youngstown, OH 
"In Vitro Fertilization" 
1984 University Hospitals of Cleveland, Endocrine Grand Rounds 
"In Vitro Fertilization" 
1984 University of Toledo, Toledo, OH 
"Menopause in Modern Perspective" 
1984 Fairview General Hospital, Cleveland, OH, Seminar on New 
Approaches to Geriatric Care 
"Prevention of Osteoporosis" 
1984 Akron Obstetrical and Gynecologic Society, Akron, OH 
"Microsurgery in an Expanding World of In Vitro Fertilization" 
1984 Cleveland Metropolitan General Hospital, Grand Rounds 
"Premature Ovarian Failure" 
1984 Alpha Omega Dental Fraternity, Annual Meeting, Cleveland, OH  
"In Vitro Fertilization" 
1985 Mt. Sinai Medical Center of Cleveland 
"Update on IVF" 
1985 University of Bologna, Bologna, Italy 
"Therapeutic Approach to Climacteric and Postmenopause" 
1985 Hospital Sant'Anna and Gruppo Piementese e Valdostana di Ostetrica e 
ginecologia, Turin, Italy 
"Detection & Prevention of Osteoporosis: A Gynecologic Responsibility" 
1985 The University of Kansas, Department of OB/GYN at Wesley Medical 
Center, Wichita, KS 
"Natural History of Female Menopause" 
"In Vitro Fertilization and its Spin-Offs" 
1985 Memphis Obstetrical and Gynecological Society, Memphis, TN 
"Recent Advances in Infertility Surgery" 
1985 The University of Tennessee, Memphis, TN 
"Menopause and Estrogen Therapy" 
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1986 21st Annual Postgraduate Seminar, Cleveland Academy of Osteopathic 
Medicine, Cleveland, OH 
"Recent Advances in Estrogen Therapy" 
1986 Wright State University, Dayton, OH, Postgraduate Course on 
Osteopenia 
"Postmenopausal Osteoporosis" 
1986 B'Nai Jeshurun Temple on the Heights, Cleveland, OH 
"Social and Moral Dilemmas of Modern Infertility Treatments" 
1986 The Winterlude Update in Reproductive Endocrinology, University of 
Ottawa School of Medicine, Ottawa, Canada 
"The Climacteric" 
1986 The Cleveland Clinic Foundation, Endocrinology Grand Rounds 
"An Approach to Infertility" 
1986 Lake County Bar Association Family Law Program, Mentor, OH 
"The Meaning of Menopause" 
1986 Missouri State Medical Assoc. 128th Annual Convention, St. Louis 
"Postmenopause - The Place of Estrogen and Progesterone" 
1986 Center for Biomedical Ethics, Symposium on the Business of Health 
Care, Bond Court, Cleveland 
"The Business of Reproduction" 
1986 Medicine 1986 Postgraduate Course, Case Western Reserve University 
"The Status of Estrogen Therapy" 
1986 New and Evolving Concepts on the Menopause, Cancun, Mexico, CIBA 
Foundation Symposium (Co-Chairman) 
"Overview - Defining and Understanding Menopause" 
"The Endometrial Effects of Transdermal Estrogen" 
1986 Flower Hospital, Toledo, OH, Combined Grand Rounds 
"Estrogens, Menopause and Osteoporosis" 
1986 Stark County Medical Society, Keynote Speaker, Canton, OH 
"Recent Advances in Estrogen Therapy" 
1986 Israel Society of Gynecologic Endocrinology, Tel Aviv, Israel 
"Modern Management of the Menopause" 
1986 CIBA-GEIGY Estraderm Launch, San Francisco 
"The Climacteric Syndrome" 
1986 Western Pennsylvania Osteopathic Association 27th Annual Meeting, 
West Middlesex, PA 
"Contemporary Management of the Menopause" 
1986 Akron OB/GYN Society AGM Dinner Lecture, Akron, OH 
"Contemporary Management of the Menopause" 
1986 Current Perspectives in the Management of the Menopausal and 
Postmenopausal Patient, Banff, Alberta, Canada 
"Overview on the Menopause" 
“TTS Estradiol Overall Safety Profile 
“Summation” 
1986 Brentwood Hospital, Warrensville Heights, OH 
"Hormonal Replacement Therapy in Postmenopausal Women" 
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1986 The College of Wooster, Wooster, OH, Women's Health Day 
"Your Middle Years" 
1986 University of New Mexico, Albuquerque, New Mexico 
"A Present Overview of Estrogen Replacement Therapy" 
1986 University of California at Irvine, Departmental Grand Rounds 
"Current Insights Into Menopause" 
1986 TRW World Headquarters, Cleveland, OH, Wellness Program 
"Osteoporosis and Menopause" 
1987 Michael Reese Hospital and Pritzker Medical School, Chicago, IL 
"Menopause - Perspective and Treatment" 
1987 The 23rd Ruth Gray Lecture, Evanston Hospital, IL 
"Menopause - Physiology and Medical Management" 
1987 University of Chicago, Gyn Departmental Grand Rounds, IL 
"Hormone Replacement Therapy" 
1987 St. Mary's of Nazareth Hospital, Chicago, IL 
"Menopause" 
1987 Cleveland Clinic Foundation, Endocrine Grand Rounds, Cleveland 
"Understanding the Menopause" 
1987 St. Elizabeth Hospital, Youngstown, OH, Family Medicine Grand 
Rounds 
"Hormone Replacement Therapy in the Postmenopausal Woman" 
1987 Mt. Sinai Medical Center of Cleveland, Department of Anesthesia Grand 
Rounds 
"Infertility Update" 
1987 St. Thomas, U.S. Virgin Islands, Current Perspectives in the 
Management of the Postmenopausal Patient 
"Overview on Menopause" 
"Safety and Efficacy of TTS Estradiol" 
1987 Cleveland Society of Obstetricians and Gynecologists 
"Transdermal Estrogen Therapy" 
1987 TRW World Headquarters, Beachwood, OH, Health Lecture Series 
"Female Hormones" 
1987 Sutter Hospital Symposium, Napa, CA, The Menopausal Patient 
"HRT - The Risk/Benefit Ratio in Perspective" 
1987 Timkin Mercy Medical Center, Canton, OH     
"Estrogen Therapy in Menopause" 
1987 26th Annual OB/GYN Spring Symposium, University of Oklahoma 
College of Medicine and ACOG District VII, Oklahoma City, OK 
"Controversies in the Management of Estrogen and Progesterone 
Therapy" 
1987 Mt. Sinai Medical Center New York, OB/GYN Grand Rounds, NYC, NY 
"Menopause and Hormone Additive Therapy" 
1987 Long Island Family Practice Association, Freeport, RI 
"Estrogen Therapy" 
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1987 North Carolina Academy of Family Physicians, "Mid Summer Family 
Practice Digest", Keynote Speaker, Myrtle Beach, SC 
"Estrogen Replacement Therapy" 
1987 Lake Tahoe, NV, Current Perspectives in the Management of the 
Postmenopausal Patient 
"Overview on Menopause" 
"Summation" 
1987 St. Joseph Hospital Symposium "Controversial Topics of Medicine", 
Elyria, OH 
"Osteoporosis and Estrogen Supplementation" 
1987 Universities of Modena and Pavia Schools of Medicine Pain and 
Reproduction Symposium, Modena, Italy 
"Postmenopausal Pain Syndromes" 
1987 Lega Per L'osteoporosi Piemonte, Convention on Osteoporosis, Turin, 
Italy 
“Experience with Transdermal Estradiol in Treatment of the Climacteric" 
1987 St. John's Mercy Medical Center, St. Louis, MO, Hospital Grand Rounds 
"The Menopause - Current Trends in Management" 
"New Horizons in Infertility" 
1987 GE Lighting Institute World Headquarters, Nela Park, OH 
"Menopause" 
1987 San Antonio OB/GYN Society Quarterly Meeting, San Antonio, TX 
"Hormone Therapy into the 21st Century" 
1987  Wilford Hall Air Force Medical Center, San Antonio, Grand Rounds 
"Menopause" 
1987  Brooke Army Medical Center, Fort Sam Houston, TX, Grand Rounds 
"HRT in Perspective" 
1987 University of Texas at San Antonio, Health Science Center, OB/GYN 
Grand Rounds 
"Climacteric as an Endocrinopathy" 
1987 Niagara, Ontario, Canada Medical Group (CIBA Foundation) 
"Recent Advances in Estrogen Therapy" 
1987 Toronto, Canada Medical Group (CIBA Foundation) 
"Recent Advances in Estrogen Therapy" 
1987 Jornada Brasileira de Climaterio Da SOBRAC (1st Brazilian Menopause 
Conference) Sao Paulo, Brazil 




"Recent Advances in Hormone Therapy" (Keynote Lecture) 
1988 Clinical Update in Obstetrics and Gynecology, Albany Medical College 
Postgraduate Course, Stratton Mountain, Vermont 
"Menopause" 
"Getting and Keeping Patients on HRT" 
1988 International Health Foundation, Lausanne, Switzerland 
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"Obstetrical Implications of Pregnancy After Age 30" 
1988 Western Reserve Care System Clinical Update in OB/GYN, Vienna, OH 
"Oral Contraceptives in the Perimenopausal Woman" 
"Transdermal and Oral Estrogen Therapy" 
1988 University of Louisville OB/GYN Grand Rounds, Kentucky 
"Surrogate IVF Pregnancy" 
1988 Current Perspective in Menopause, Banff Springs, Canada 
"Menopause in Perspective" 
1988  Johnson & Johnson Scientific Advisory Committee, New Brunswick, NJ 
"Menopause in Perspective" 
1988 NIH/AFS Menopause Meeting, NIH, Bethesda, MD 
"Menopause, Hormone Replacement Therapy and Quality of Life" 
1988 WHO, Geneva, Switzerland, Menopause Meeting 
"From Premenopause to Climacteric" 
1988 Menopause Postgraduate Course, Hilton Inn, Cleveland, OH 
"Climacteric in Perspective" 
6/88 OB/GYN Group, Milwaukee, WI 
"What is the Climacteric?" 
6/88 Southside OB/GYN Group, Chicago, IL   
"Recent Advances in HRT" 
6/88 University of Minnesota  
"Pathophysiology of Menopause" 
6/88 Minnesota Osteoporosis Society, Minneapolis, MN   
"Recent Perspectives of Climacteric and HRT" 
6/88 OB/GYN Group, Atlanta, GA   
"Menopause and HRT" 
7/88 Tampa Internal Medicine Group, Tampa, FL 
"Menopause and HRT" 
7/88 Miami OB/GYN Group, Miami, FL 
"Alternate Forms of HRT" 
7/88 Cuban Medical Society Bi-Annual Convention, Miami, FL 
"What's New in Gynecology - Menopause" 
9/88 Emory University, Atlanta, Georgia, Conference - Menopause:  A Health 
Care Challenge   
"Fate of the Untreated Menopause" 
11/88 Contemporary Management of Menopause, Cleveland Clinic   
"Estrogen Replacement Therapy" 
11/88 Community Dialogue in Biomedical Ethics, Center for Biomedical Ethics, 
Case Western Reserve University   
"Reproductive Technologies and Who is Using Them" 
11/88 Italian Menopause Society 3rd Congress, Bologna, Italy   
"The Climacteric Syndrome" 
"Tolerability of Transdermal Estradiol" 
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11/88 Netherlands Society for Study of Climacteric, Meeting on Climacteric in 
Perspective, Ede, Holland   
"The Untreated Menopause" 
11/88 International Conference on Reproductive Medicine in the Year 2000, 
University of Alcala de Henares, Madrid, Spain   
"Hormone Replacement Therapy in the Future" 
"The Fate of the Neglected Climacteric and the Societal Impact     
by the Year 2000" 
1/89 Cleveland Clinic Foundation, Department of Internal Medicine Grand 
Rounds, Cleveland, OH   
"Some Issues of Hormone Additive Therapy" 
1/89 University of Maryland, Davidge Hall, OB/GYN Grand Rounds   
"Recent Advances in Menopause Management" 
"IVF - Surrogacy - Medical and Ethical Issues" 
2/89 University of Cape Town, Cape Town, South Africa, Grand Rounds  
"Current Thoughts on Menopause" 
4/89 PACE Meeting, Palm Desert Marriott, Palm Springs, CA 
"Estrogen Replacement Therapy:  Long-Term Benefits and Risks" 
5/89 Regional Symposium on Menopause, Loyola University Stritch School 
of Medicine, Oakbrook, MI   
"The Fate of the Untreated Menopause" 
5/89 Current Perspectives on Management of Menopause, Hilton Head, SC 
"Overview on Menopause” 
5/89 Cleveland Metropolitan General Hospital OB/GYN Grand Rounds   
"HRT - Risk and Benefit" 
6/89 Third Annual Symposium on the Long-Term Effects of Estrogen   
Deprivation, Estoril, Portugal   
“Risk-Benefit Analysis:  Quality of Life Enhancement" 
7/89 Novo Advisory Group, Copenhagen, Denmark   
"The Peri and Post-menopause" 
9/89 First International Course on Climacteric, Buenos Aires, Argentina 
"The Climacteric" 
"Treatment of Osteoporosis" 
"Risk and Benefit of HRT" 
"Selection and Work-Up of Patients" 
"Establishing a Menopause Clinic" 
10/89 Board of Trustees, Lakewood Hosp. Ann. Retreat, Lakewood, OH 
"Trends in OB/GYN and Opportunities for the Future" 
10/89 Symposium on Vaginal Dryness:  Overview and Update, Stanhope 
Hotel, New York 
"Hormone Replacement Therapy" 
11/89 Symposium:  Perspective in Treatment of Menopause, University of 
Nevada, Las Vegas, NV 
"Hormone Replacement in the Menopausal Patient" 
1/90 Cleveland OB/GYN Society, Hilton Hotel South, Cleveland 
"Menopause, Hormones and Heart Disease" 
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1/90 Evansville Public Forum, Deaconess Hospital, Evansville, IN 
"Cold Facts on Hot Flashes" 
1/90 Hospital-wide Grand Rounds, Deaconess Hospital, Evansville, IN 
"Current Postmenopausal HRT" 
2/2/90 Eastern Regional Conference on Long-Term Effects of Estrogen   
Deprivation, Marco Island, FL,  Meeting Chairman 
"Introduction and Overview" 
"HRT Regimens and Risks" 
4/90 Hadassah Women's Organization Keynote Lecture, Nico Malan Opera 
Theatre, Cape Town, South Africa 
"Menopause" 
5/90 University Hospitals of Cleveland, Women's Auxiliary Annual Gen. Mtg. 
"Recent Advances in Gynecology" 
5/90 47th Annual Scientific Meeting American Geriatrics Society, Atlanta, GA 
"Risk/Benefit of HRT" 
5/90 University Hospitals of Cleveland, Endocrine Grand Rounds 
"Limits and Possibilities of HRT after Menopause" 
7/90 Atlanta Medical Internist Group, Ritz Carlton, Atlanta, GA 
"New HRT Cycling Alternatives" 
7/90 Los Angeles OB/GYN Group, Bistro Gardens, Beverly Hills, Los 
Angeles, CA 
"New Trends in HRT" 
8/90 Menopause Postgraduate Course, Univ. of Maryland, Baltimore, MD 
"Overview of Safety of Estrogen Replacement" 
9/90 University of Colorado, Postgraduate Lecture Series, Denver, CO 
"Menopause in Perspective" 
9/90 Spanish Society of Gynecology Symposium on Menopause, Hotel de la 
Gavino, S'Agara, Costa Brava, Spain 
"Risk-Benefit of Hormone Replacement Therapy" 
10/90 Cleveland Clinic Foundation Course on Treating Sexual Problems,  
Cleveland Clinic, Cleveland, OH 
"Menopause and Sexuality" 
10/90 Canyon Ranch, Tucson, AZ 
"Managing Menopause" 
11/90 St. Margaret's Hospital for Women/Tufts University, Boston, MA 
"The Long-Term Consequences of Estrogen Deprivation" 
11/90 Mercy General Hospital, Sacramento, CA, Women's Health Program 
"Managing Your Menopause" 
12/90 Fairmount Temple Sisterhood, Cleveland, OH 
"Rx for Sexual Longevity" 
12/90 Temple Emanu El Sisterhood, Cleveland, OH 
"Advances in Women's Health Care" 
12/90 Veterans Administration Hospital, Topics in Geriatric Medicine Program, 
VA Hospital, Cleveland 
"Current Issues in Menopause and HRT" 
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1/91  AMICI Medicine, Case Western Reserve Univ., Cleveland, OH 
           "Help for Infertility" 
1/91 University of California, Los Angeles (UCLA) Department of Family  
  Medicine Course on Office Gynecology for the Primary Care  
           Physician, Los Angeles, CA 
"Current Perspectives in the Management of the Postmenopausal 
Patient" 
2/91 Operation Hunger sponsored symposium on Menopause, Keynote 
lecture Transvaal Automobile Club, Johannesburg, South Africa 
  "Menopause" 
4/91 American Association of University Women, Euclid, OH 
  "Women's Health Issues" 
4/91 CIBA-GEIGY Australian Visiting Professor Professional Lecture Series 
  "Current Concepts on Hormone Replacement Therapy" 
4/91 Regent Hotel, Melbourne 
4/91 Sheraton Brisbane Hotel, Brisbane 
5/91 Regent Hotel, Sydney 
5/91 Jefferson Medical College, Department of OB/GYN CME Course, 
Atlantic City, NJ 
  "Hormone Replacement Therapy" 
6/91 Society of Gynecology and Obstetrics of Monterrey, and College of 
Medicine Cirujanos de Nuero Leon 15th Annual Meeting, Mexico 
  "Menopause and Osteoporosis" 
  "Estrogen Therapy and Cardiovascular Disease"  
10/91 Wayne State University Visiting Professor, Hutzel Hospital, Detroit, MI 
  Department of OB/GYN 
  "HRT - Cancer and Coronary Heart Disease" 
11/91 ACOG District V Annual District Meeting, Louisville, KY 
  "Hormone Replacement Therapy in Menopause" 
11/91 Women’s Health Seminar on Taking Control of Menopause, Stouffer’s 
Tower City Center, Cleveland, OH 
  "Taking the Mystery out of Menopause - Understanding Hormone  
  Replacement Therapy" 
11/91 We're Getting Older, We're Getting Better Symposium, Menorah Park, 
Cleveland, OH 
  "Risks and Benefits of HRT after Menopause" 
1/92 Westwood Country Club, Women's Health Program, Westlake, OH 
  "Taking The Mystery Out of Menopause" 
2/92 Food and Drug Administration Maternal Health Drugs Advisory   
  Committee, Rockville, MD 
"Rationale for Undertaking HRT Research in Women With Previous 
Breast Cancer" 
3/92 Royal Melbourne Hospital/University Hospitals 1992 Reunion 
Symposium, Royal Melbourne Hospital, Australia 




3/92 Royal Melbourne Women's Hospital, Melbourne, Australia 
  "Breast Cancer and HRT" 
4/92 Seoul National University Hospital, Special Lecture, Seoul, Korea 
  "Breast Cancer and HRT" 
4/92 Inaugural Lecture of 1st Meeting of Korean Menopause Society, Seoul, 
Korea 
  "HRT - Perceptions and Realities of Long-Term Use" 
4/92 Ewha Women's University Hospital, Special Lecture, Seoul, Korea 
  "Menopause and Clinical Practice" 
4/92 American College of Obstetricians and Gynecologists, Breakfast 
Seminar (Dowden/CIBA-GEIGY), Mirage Hotel, Las Vegas, NV 
  "Developing a Menopause Component in Your OB/GYN Practice" 
6/92 Seventh Annual Feld Memorial Lecture, Sinai of Detroit and Wayne 
State University, Detroit, MI 
  "Current Trends in Menopause Management" 
6/92 Sinai of Detroit, Grand Rounds, Detroit, MI 
  "HRT, The Breast Cancer Issue and Research Needs" 
10/92 Harvard Medical School/Massachusetts Gen. Hosp., Boston, MA 
  "Menopause, HRT and Breast Cancer" 
10/92 Menorah Park Center for the Aging, Beachwood, OH 
  “Is Estrogen for Me?" 
 11/92  Japan Menopause Society Annual Meeting, Tokyo, Japan 
Keynote Lecture - "Menopause, Quality of Life, HRT - The Present and 
Future" 
10/92 Yale University, New Haven, CT 
  "Evaluating Breast Cancer Risk in Postmenopausal HRT" 
11/92 Resident Report Program, AFS Annual Meeting, New Orleans, LA 
  "Hormone Replacement Therapy" 
11/92 University Hospitals Consumer Program - A Women's Heart, 
Landerhaven, Cleveland, OH 
  "Menopause, Estrogen and Heart Disease" 
11/92 Case Western Reserve Univ. Medicine Fall 1992, Independence, OH 
  "Postmenopausal Hormone Replacement Therapy" 
11/92 Dept. of Reproductive Biology, CWRU CME Course, Postmenopausal 
Osteoporosis, Cleveland, OH 
  "Estrogen Prevention of Osteoporosis - Risks, Benefits, Options" 
11/92 CIBA-GEIGY Japan Head Office, Takarazuka, Japan 
  "Issues in HRT" 
11/92 Japan Menopause Society Symposium, Tokyo, Japan 
  "Practitioners of HRT - Risk and Benefit in Perspective" 
 11/92 Academic Medical Group Round Table, Hotel Okura, Tokyo, Japan 
  "Menopause Clinics - The Cleveland Example" 
12/92 Bronx OB/GYN Society Annual Dinner Meeting, Bronx, NY 
  "Development of a Menopause Program" 
12/92 Albert Einstein College of Medicine, Bronx, NY 




1/93 Department of Anatomy Seminar, Case Western Reserve University, 
Cleveland, OH 
  "Trends in Menopause Research" 
1/93 Women Aware, Cape Sun Hotel, Cape Town, South Africa 
  "Managing Your Menopause" 
2/93 Temple University, Department of OB/GYN Grand Rounds, 
Philadelphia, PA 
  "Menopause in Perspective" 
  "HRT and Breast Cancer" 
2/93 Brotman Med Center 31st Annual Scientific Seminar, Beverly Hills, CA 
 "Hormone Replacement Therapy – Risk/Benefit and Quality of Life" 
3/93 Gyn Grand Rounds, Cleveland Clinic, Cleveland, OH 
  "Breast Cancer, Menopause and Hormone Replacement Therapy" 
3/93 Cleveland OB/GYN Society, Cleveland, OH 
  "Update on Current Issues in Hormone Replacement Therapy" 
3/93 American College of General Practitioners, 30th Annual Convention, 
Orlando, FL 
  "Physiology of Menopause" 
3/93 National Institute on Aging, Workshop on Directions for Menopause 
Research, Bethesda, MD 
  "Ovarian-Function, Therapy-Oriented Definition of Menopause" 
4/93 Chile Society for Study of Menopause, Santiago, Chile 
  "HRT and Breast Cancer" 
  "Alternate Routes of Administration and Indications" 
4/93 Argentine Association for Study of Climacteric, Buenos Aires, Argentina 
  "HRT and Cardiovascular Disease" 
  "Duration of HRT and Recommendations for Practice" 
  "Categorization of Menopause" 
4/93 Solon Women's Club, Solon, OH 
  "Understanding Menopause and ERT" 
5/93 University of Ferrara, International Meeting on Bone Density, Ferrara, 
Italy "Menopause Centers - Concept, and Role in Society" 
5/93 North American Menopause Society Postgraduate Course, The Copley 
Plaza Hotel, Boston, MA 
“Estrogens and Breast Cancer" 
6/93  United Kingdom Lecture Tour:  "Menopause and HRT in Perspective" 
  1.  Dewsbury District Hospital, West Yorkshire, England 
  2.  Victoria Hospital, Blackpool, Lancashire 
  3.  University of Keele, Stoke on Trent, Staffordshire 
  4.  Conquest Hospital, Hastings, East Sussex 
  5.  Ticehurst Hospital, East Sussex 
6/93 Royal College of Obstetricians & Gynaecologists, Regents Park, London 
Course:  Advances in Treatment of the Menopause 
 "Hormone Replacement Therapy and Breast Cancer - Is There a 
Relationship" 
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7/93 International College of Surgeons US Section 55th Annual Meeting, 
Seattle, WA, Invited Opening Keynote Address: 
"HRT in Women in the 21st Century - Maximum Health Benefit with  
Diminishment of Risks and Surgery" 
7/93 International College of Surgeons, US Section, Invited lecture 
"Taking Control of Menopause" 
10/93 District V Annual Meeting, ACOG, Cincinnati, OH 
"Management of the Perimenopausal Years" 
11/93 Junior League Sustainers of Cleveland, Cleveland, OH 
"HRT" 
1/94 University of Florida Grand Rounds, Gainesville, FL 
"Menopause, HRT and Breast Cancer" 
12/94 American College of OB/GYN, Plaza Hotel, New York, National Press 
Conference 
"The Long-Term Effects of Estrogen Deficiency" 
1/95 Canyon Ranch, Tucson, AZ 
Guest Lecture, “Menopause in Modern Perspective” 
Staff Lecture, “Current Trends in Menopause Management” 
1/95 Shoreby Club, Cleveland, OH, Speaker of the Month 
"Challenges and Promises in Delivering Women's Health Care in 1995 
and Beyond" 
2/95 International Society of Gynecologic Endocrinology, Madonna di 
Campiglio, Italy 
“HRT in Climacteric Women” 
“Menopause - The Global Perspective” 
4/95 Women Aware Charity Lecture, Cape Town, South Africa  
"Menopause, HRT and Sexuality" 
4/95 OB/GYN Group, Cape Town, South Africa 
"Current Trends in Menopause Management" 
4/95 Jewish Women’s Benevolent Society, Johannesburg, South Africa 
"Menopause and Sexuality" 
4/95 Pretoria Physicians Practice Group, Pretoria, South Africa 
"Current Trends in HRT" 
5/95 Formosan Medical Association, Keynote Opening Lecture, Tainan, 
Taiwan 
"Menopause In Current Perspective" 
5/95 Mt. Sinai Medical Center of Cleveland, Cleveland, OH 
"Current Trends in Menopause Management" 
6/95 Osteoporosis Update, Cleveland Clinic, Marriott Society Hotel, 
Cleveland, OH 
"Treatment of Osteoporosis, Menopausal and Postmenopausal Uses of 
Estrogen" 
6/95 Endocrine Society 77th Annual Meeting, Nurses Society, Washington, 
DC 
"Menopause and Hormone Replacement" (Abstract N2-3, P. 6) 
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6/95 Contemporary Forums:  Advances in Health Care for Women Over 40, 
New Orleans, LA 
"HRT and Breast Cancer - What We Have Learned" 
6/95 Pacific Northwest Obstetrical and Gynecological Association Annual 
Meeting, Kelowna, British Columbia, Canada, Keynote Speaker: 
"Hormone Replacement Therapy and Breast Cancer" 
"Menopause and the Modern Perspective" 
"Primary Preventive Health Care After Menopause" 
7/95 27th British Congress of Obstetrics and Gynecology, Dublin, Ireland, 
Invited Keynote Lecture: 
"Direction, Misdirection and Misconception in Menopause Research and 
Management" 
7/95 CIBA/GENEVA Ann. Staff Convention, Dolphin Hotel, Orlando, FL 
"Risk/Benefit of HRT" 
9/95 NAMS Colloquium on Balancing the Equation of Long-Term HRT, San 
Francisco, CA 
"Clarifying the Role of Long-Term HRT in the Context of Primary   
Preventive Health Care for Women" 
9/95 1995 Annual Scientific Meeting of Royal Australian College of 
Obstetricians and Gynaecologists, Perth, Western Australia, Invited 
Keynote Speaker: 
"Women's Health Through Menopause:  A Modern Perspective"  
"HRT and Cancer" 
9/95 Australian Society for Psychosomatic Obstetrics and Gynecology, 22nd 
Annual Congress, Margaret River Hotel, Western Australia 
"The Comprehensive Care of Peri and Postmenopausal Women" 
10/95 FLACSYN, First Meeting of Latin American Menopause Society, Buenos 
Aires, Argentina 
"Women's Health Through Menopause - A Modern Perspective" 
"Dealing with Practical Aspects of HRT" 
11/95 Rheumatology Grand Rounds, University Hospitals of Cleveland 
"Current Controversies in Postmenopausal HRT" 
12/95 Israel Menopause Society, Tel Aviv, Israel, Keynote Lecturer: 
"The Challenge of Increased Longevity by Primary Preventive Health 
Care After Menopause" 
2/96 Fairmount Temple Sisterhood, Beachwood, OH 
"Staying Well at All Ages" 
3/96 University of Florida College of Medicine, Orlando, FL 
21st Annual Update in OB/GYN 
“Cardiovascular Risks in the Menopause" 
"Hormone Replacement Therapy - An Update" 
"Breast Cancer and HRT" 
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3/96 Argentine Symposium on Climacteric, San Martin de Los Andes,   
  Patagonia, Keynote Speaker: 
  "New Trends for Medical Care of Women After Menopause" 
  "HRT and Gynecologic Cancer" 
  "Practicalities of Delivering Health Care After Menopause" 
4/96 Ohio Coalition of Nurses with Specialty Certification (OCNSC), Ritz  
  Carlton, Cleveland, OH 
  "Modern Menopause Including Management of Osteoporosis" 
5/96 Managing Women's Health in the Year 2000 - Department OB/GYN, 
University Hospitals of Cleveland/CWRU Symposium, Marriott Society 
Center, Cleveland, OH 
   “Managing Women's Health After Menopause in the Year 2000" 
  "Osteoporosis, Menopause and HRT:  Management Priorities" 
5/96 Polish Menopause Society, Warsaw, Poland 
  "Women's Health Through Menopause" 
  "HRT and Cancer" 
5/96 German (including Swiss and Australian) Menopause Society, Berlin, 
Germany 
  "Individualizing Risk:  Benefit of HRT" 
5/96 National Press Club, Washington, DC, Launch of National Menopause 
Awareness Month 
  "Menopause" 
6/96 Hungarian Menopause Society, Budapest, Hungary 
  "Development in the Contemporary Management of Menopause" 
7/96 Geauga Regional Hospital, Chardon, OH 
  "The Changing Perspectives of Menopause" 
9/96 University of Cape Town, South Africa, OB/GYN Grand Rounds 
  "Primary Preventive Health Care for Women Over 50" 
11/96 Pieter van Keep Memorial Lecture, 8th International Menopause Society 
Meeting, Sydney, Australia 
12/96 Chilean Menopause Society, 2nd International Symposium, Santiago, 
Chile 
  “Menopause in Modern Perspective” 
 “Practicalities of Delivering Health Care to Women After Menopause” 
3/97 1997 Annual Scientific Meeting of the Taiwanese Menopause Society, 
Tainan, Taiwan 
  “HRT in Older Women” 
  “Rationale and Operation of a Menopause Clinic” 
4/97 University of Louisville, Louisville, KY, Course - Primary Care 
  Issues in Women’s Health 
  “Approaches to HRT” 
  “Management of Osteoporosis” 





5/97 First Meeting of GEORM (del Gruppo Operativo Emiliano Romagnola 
per la Menopausa), Cervia, Italy, Keynote Lecture: 
  “Estrogens and Other Components of Contemporary Menopause 
  Management” 
6/97 Department of Health, Republic of San Marino and University of Ferrara, 
San Marino, Italy, Special Lecture: 
  “Current Issues in Hormone Replacement Therapy” 
8/97 Chautauqua Inst. Lectures Hall of Philosophy, Chautauqua, NY 
  “Menopause and Hormones – the Conflict Between Science and  
  Pseudoscience” 
9/97 Merck Satellite on Osteoporosis at the 8th Annual NAMS Meeting, 
  Boston, MA 
  “Osteoporosis and the Role of the Primary Care Provider” 
9/97 3rd Congress of The Polish Menopause and Andropause Society, 
Warsaw, Poland 
  “History of the International Menopause Society” 
  “Osteoporosis and the Primary Care Provider” 
10/97 St. Louis University School of Medicine, Menopause and Beyond, 
  Ritz Carlton Hotel, St. Louis, MS 
  “Menopause in the Context of Primary Preventive Health Care for 
  Women”  
11/97  10th US Turner’s Syndrome Society Conference, Minneapolis, MN 
  “Risks and Benefits of ERT” 
12/97 Topics in Geriatric Medicine, Case Western Reserve University Claude 
Pepper Geriatric Center, VA Hospital, Cleveland, OH 
  “Hormone Replacement Therapy in Elderly Women” 
2/98 Second Annual Disease Management Congress, Pasadena, CA 
  “HRT in Perspective – Historical Through Recent Advances” 
3/98 Interactive Forums Symposium on Women’s Wellness Programs in the 
Workplace, Ritz Carlton, Chicago, IL 
Keynote Lecture:  “Healthcare Issues and Disease Prevention 
Strategies for the Mature Woman” 
4/98 Canyon Ranch, Tucson, AZ 
   Lecture to Physicians “New Drugs in Menopause Management” 
   Lecture to Health Staff “HRT and the Older Woman” 
  Guest Lecture “Navigating the HRT Maze” 
5/98 Health Museum of Cleveland, Cleveland, OH 
  “You Look Marvelous” Program - The Scoop on Menopause  
5/98 University of Cape Town, Groote Schuur Hospital, South Africa,  
  Department of OB/GYN Grand Rounds 
  “Role of Ultrasound Densitometry in Osteoporosis Management” 
6/98 Czech Medical Association, Menopause and Quality of Life, Prague, 
Czech 
  Invited Opening Keynote Lecture:   
“Role of the International Menopause Society in Women’s Right to 
Health After Menopause” 
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6/98 3rd International Symposium on Women’s Health and Menopause, 
  Fondazione Giovanni, Lorenzini, Florence, Italy 
   “Long-Term Low-Dose Estrogen Versus SERMS” 
 “Dose, Duration and Starting Age for HRT - The American Viewpoint” 
9/98 Women’s Health Beyond Midlife Symposium, Case Western Reserve 
University, Cleveland, Ohio 
  “Health Across the Feminine Life Cycle” 
11/98  18th Brazilian Congress on Human Reproduction, Porto Alegre, Brazil 
  Keynote Lecture:  “Menopause – Where Are We Heading To? 
“Basic Premises in the Therapeutic Approach to a Menopausal  
Woman” 
11/98 Jamaican Menopause Society Public Lecture, Kingston, Jamaica, West 
Indies 
  “What Is So Important About Menopause?” 
11/98 Inaugural Symposium, Jamaican Menopause Society, Kingston, 
Jamaica, West Indies 
   “Menopause in the Context of Primary Preventive Health Care” 
 “Current Concepts in HRT” 
11/98 University of West Indies, Jamaica 
Department of Community Medicine:  “Midlife Women’s Health and 
Public Policy” 
 Department of OB/GYN:  “Menopause and Primary Care” 
2/99 University of Cape Town, Department of OB/GYN Grand Rounds, 
Groote Schuur Hospital, South Africa 
  “Prescribing HRT in Women at High Risk of Breast Cancer” 
2/99 South African Menopause Society, Western Province Inaugural Lecture, 
Rotanga Junction, South Africa 
  “Current Trends in Menopause Management” 
3/99 Johnson & Johnson, Fourth Annual Leadership Council on Women’s 
Health, Bermuda 
  “Osteoporosis” 
3/99 Perspectives in Women’s Health, 4th District ACOG and University of 
Puerto Rico, San Juan, Puerto Rico 
  “Management of the Perimenopause” 
4/99 Association of Indian Physicians of Northern Ohio, Cleveland Playhouse 
Club, Cleveland, OH 
  “Menopause and Preventive Care” 
4/99 Solvay Pharmaceuticals Investigators meeting, Atlanta, GA 
  “Estrogens, Vasomotor Symptoms and FDA Regulations” 
9/99 American Society for Reproductive Medicine Annual Scientific Meeting, 
Toronto, Canada 
“Alternates to HRT for Vasomotor Symptoms and Osteoporosis 
Management” 
11/99 2nd International Merck Symposium on Menopause and Osteoporosis, 
Banalmadena-Costa del Sol, Spain 
  “Practical Paradigm for HRT Usage in Osteoporosis Prevention” 
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11/99 American Association of Pharmaceutical Scientists Annual Convention, 
Symposium on Clinical Studies in Women’s Health, New Orleans, LA 
“Progress and Issues in Women’s Health Through and Beyond 
Menopause” 
12/99 Ladies Home Journal Roundtable Series, New York, NY, Featured 
Speaker: 
“Women’s Health Through and Beyond Menopause” 
2/00 University of Cape Town School of Medicine, OB/GYN Grand Rounds 
“Hormone Replacement Therapy and the Older Woman” 
2/00 South African Menopause Society Special Lecture, Victoria & Alfred 
Hotel, Cape Town, South Africa 
“Management of Postmenopausal Women’s Health – the Role of 
SERMS” 
4/00 University of Puerto Rico, 5th Symposium on Women’s Health, San 
Juan, Puerto Rico 
“Hormone Replacement Therapy and the Older Woman”. 
4/00 American College of Physicians/American Society of Internal Medicine 
Annual Scientific Program 2000, Distinguished Lecture, Philadelphia, PA 
“Women’s Health After Menopause” 
5/00 Case Western Reserve University/UH Department of OB/GYN Grand 
Rounds, Cleveland, OH 
“Recent Advances in HRT” 
5/00 1st International Congress on Menopause and 4th National Congress, 
Turkish Society of Menopause and Osteoporosis, Antalya, Turkey 
“Progress and Issues in Women’s Health Care Beyond Menopause” 
“Current Trends in Postmenopausal HRT” 
“Algorithms for Postmenopausal HRT Usage” 
6/00 University of Pisa, Pisa, Italy, Grand Rounds 
“Recent Developments in Postmenopausal HRT” 
6/00 2nd Practical Course in Climacteric Medicine, University of Ferrara,     
Ferrara, Italy 
“Progress and Issues in Women’s Health After Menopause” 
6/00 EMAS Congress Satellite, Chia, Sardinia, Italy, Keynote Lecture 
“Long-term HRT in the 21st Century” 
10/00 Mini Medical School – The Great Medicine Series, Case Western 
Reserve University School of Medicine, Cleveland, OH 
“Menopause, Gender Difference and Health” 
11/00 Fairmount Temple Sisterhood, Cleveland, OH 
“Health, HRT and the Older Woman” 
11/00 Joint Jamaica and Caribbean Menopause Societies, Kingston, Jamaica, 
West Indies 
“Practical Menopause Management” 
1/01 CWRU School of Medicine Reproductive Biology Committee, Phase II 
“Contemporary Menopause Management”. 
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1/01 Canyon Ranch, Tucson, AZ 
  Guests:  “Navigating the Hormone Maze” 
  Medical Staff:  “Breaking News in Menopause Management”  
Program Development Committee: “Changing Concepts Regarding 
HRT” 
2/01 University of Cape Town, Groote Schuur Grand Rounds, Cape Town, 
South Africa 
  “Breaking News in Menopause Management” 
3/01 Harvard University and Massachusetts General Hospital Grand Rounds 
Boston, MA 
  “Breaking News in Menopause Management”. 
3/01 Dayton OB/GYN Society Dinner Keynote Lecture, Dayton, OH 
  “Breaking News in Menopause Management” 
3/01 Wright State University and Miami Valley Hospital Grand Rounds, 
Dayton, OH 
  “Practical Menopause Management” 
4/01 The Cleveland Clinic, Grand Rounds, Cleveland, OH 
  “Contemporary Menopause Management” 
5/01 ACOG 2001 Annual Clinical Meeting, Chicago, IL 
  NAMS Special Interest Group:  
  “Breaking News in Menopause Management” 
5/01 The Church of God of Cleveland, Cleveland, OH 
  “Understanding the Meaning of Menopause “ 
5/01 Riverside Methodist Hospital 2001 Women’s Health Symposium, Hyatt, 
Columbus, OH 
  “HRT and Heart Disease in Women” 
  “Clinical Management of the Postmenopausal Woman” 
5/01 1st Scientific Meeting of the Asia-Pacific Menopause Federation, Seoul, 
Korea 
Lecture to Japan Group:  “Problems Impacting on HRT Prescribing in 
the USA” 
 Plenary Lecture:  “Rapidly Changing Trends in Postmenopausal HRT” 
Satellite, Chairman and Lecture:  “Women’s HOPE Study, Vasomotor 
and VMI Results 
5/01 Vak Yeong Yoo QOL Institute, Seoul, Korea 
  “Menopause Related QOL” 
6/01 Chang Gung Memorial Hospital at Kaohsiung, Taiwan 
 Hospital Grand Rounds: “Breaking News in Menopause Management” 
  OB/GYN Grand Rounds:  “Practical Menopause Management” 
  Special Lecture:  “HRT and Heart Disease” 
8/01 The American Medical Women’s Association 2nd International 
Conference 
   Moderator, Panel on Evidence-based Approach to Menopause 




9/01 2nd World Congress on Controversial Issues in Obstetrics and 
Gynecology, Paris, France 
  “Does HRT Enhance Quality of Life?” 
10/01 Focus on HRT Meeting, Windsor Hotel, New Orleans, LA 
“Challenges and Considerations for Menopause Management: The 
Emerging Benefits of HRT” 
10/01 12th Annual Meeting, North American Society, New Orleans, LA 
 “HRT, Dose and Body Weight” 
 “Evaluation of the Perimenopausal Women” 
   “Pharmacotherapy after Menopause” 
10/01 Johns Hopkins University School of Medicine, OB/GYN Grand Rounds, 
Baltimore, MD 
 “The HOPE Data in the Context of Modern Menopause Management” 
11/01 NIH and the Smithsonian Institution, NIH Mini-Med School: Women’s 
Health Issues, Washington DC 
  “Women’s Reproductive Health” 
  “Osteoporosis” 
01/02 Adele Searle Mount Nelson 100 Club, Mount Nelson Hotel, Cape Town, 
South Africa 
  “Developing Trends in Women’s Health Care” 
3/02 2nd North American Women’s Healthcare Forum, Anaheim, CA 
  “Hormone Replacement Therapy and Quality of Life” 
3/02 Women and Cancer, Memorial Sloan-Kettering Cancer Center, New 
York City, NY 
 “Breast Cancer in the Risk/Benefit Equation of Postmenopausal HRT” 
3/02 Parexel/Berlex Female Health Care Visiting Faculty Program, Four 
Seasons, Las Vegas, NV 
 Opening Keynote Address:  “New Directions in Women’s Health Care” 
5/02 Albert Einstein Medical Center, Grand Rounds, Bronx, NY 
  “HOPE Data in the Context of Modern Menopause Management”. 
5/02  Thomas Jefferson University, OB/GYN Grand Rounds, Philadelphia, PA 
  “HOPE Data in the Context of Modern Menopause Management” 
5/02  New York Univ. Advanced Tutorial in Women’s Health, NYC, NY 
  “Overview of Women’s Health” 
  “Does HRT Enhance QOL?” 
  “Menopausal Medicine is More Than HRT” 
6/02 10th World Congress of the International Menopause Society, Berlin, 
Germany 
   “Does HRT Enhance Quality of Life?” 
 “Why Low-Dose HRT is Good” 
 “CAMS Overview - The NAMS Approach” 
6/02 58th Annual Clinical Meeting, Society of Obstetricians and 
Gynaecologists of Canada, Winnipeg, Manitoba, Canada 





8/02  The Cleveland Clinic Health Talks  
   “Menopause and HRT:  Coping with Controversy” 
  “What are the Long and Short Term Effects of Menopause?” 
  “A Balanced Perspective of Current Menopause Treatments”  
9/02 The Fifth Athens Congress on Women’s Health and Disease, Athens, 
Greece 
  “Rapidly Changing Trends in Postmenopausal Hormone Therapy” 
10/02 Department of Health & Human Services, National Institutes of Health 
Scientific Workshop, Menopausal Hormone Therapy, Natcher 
Conference Center, Bethesda, MD  
  “Implications of WHI  Report for NAMS” 
10/02 CWRU & NAMS Co-Sponsored Menopause Update, Tri-C East 
Campus, Cleveland, OH 
  “Health Education, Identification of Risk Factors” 
  “Prescription Intervention” 
 “Complementary and Alternative Medicine, and Counseling Skills” 
10/02 Albany Medical College, 5th Annual Menopausal Management Update, 
Albany, NY, Keynote Lecture 
 “Breast Cancer in the Risk/Benefit Equation of Postmenopausal HRT” 
11/02 American Association of Health Plans Women’s Health Summit,       The 
Capital Hilton, Washington DC 
  “Current Guidance on the HT Controversy” 
11/02 First Founders Commemorative Lecture, Woman’s Hospital, Baton 
Rouge, LA 
 “Rapidly Changing Trends in Postmenopausal Hormone Therapies” 
1/03 National Institutes of Health, Fertility Regulation and Systemic 
Hormones in HIV-Infected and  At-Risk Women, Ritz  Carlton Tyson’s 
Corner, McLean, VA 
“What is the Role of Hormonal Menopausal Therapy in HIV-Infected and 
At-Risk Women?” 
2/03 Visiting Professor, University of Cape Town, South Africa 
Combined postgraduate course on menopause for UCT and University 
of Stellenbosch: 
  Menopause Basics Part I 
  Menopause Basics Part II 
  Menopause Basics Part III 
2/03 Kingsbury Medical Center, Claremont, Cape, Grand Rounds 
“Current and Future Status of HT in Contemporary Menopause 
Management”  
2/03 South African Heart Foundation, Public Town Hall Meeting, UCT 
Business School, Cape Town, South Africa (fundraising event) 
  “Hormone Replacement Therapy – Understanding the Facts” 
2/03  City Park Chris Barnaard Medical Center, Cape Town, Grand Rounds 
“Current and Future Status of HT in Contemporary Menopause 
Management” 
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2/03 University of Cape Town Department of Obstetrics and Gynecology 
Grand Rounds, Cape Town, South Africa 
“Current and Future Status of HT in Contemporary Menopause 
Management” 
3/03 Wyeth Women’s Health Symposium, The Forum, V & A Hotel, Cape 
Town, South Africa 
“HRT – The Future” 
3/03 ACOG Quebec Section and the Jewish General Hospital, Montreal, 
Quebec, Canada, Public Town Hall Meeting 
“Modern Menopause Management” 
3/03 ACOG Quebec Section, McGill University, and the Jewish General 
Hospital, Montreal, Canada, Management of Menopause 2003 
Symposium 
“Menopause - Past, Present and Future” 
“Current Hormone Usage in Clinical Practice” 
3/03 Memorial Sloan-Kettering Cancer Center, New York City, Women and 
Cancer:  Issues and Answers 
“Strategies for Dealing with the Pharmacotherapeutic Controversy in 
Menopause Management” 
4/03 FDLI 46th Annual Education Conference, Regulation, Science, Business 
and the Law:  Formulations for Success, Washington DC 
“Lessons from WHI” 
4/03 Focusing on the Transdermal, Novartis, Prague, Czech Republic 
“HT and the WHI – The American Perspective” 
5/03 Johns Hopkins University School of Medicine, 2003 CME 
Teleconference Series (Same lecture repeated on 6 dates) 
“Individualizing Hormone Therapy With Lower-Dose Regimens”  
5/03 64th Annual May Day Clinic, OSF Saint Anthony Medical Center, 
Rockford, IL, Plenary Lecture 
“Postmenopausal Hormone Therapy – Coping with the Controversy” 
6/03 14th Annual Research Day, Department of OB/GYN, Robert Wood 
Johnson Medical School, Keynote Lecture, and Judge 
“Current and Future Status of Postmenopausal Hormone Usage” 
7/03 Cleveland Clinic Department of OB/GYN Grand Rounds, 
Intercontinental Hotel, Cleveland, OH 
“Postmenopausal Hormone Therapy:  Understanding the HOPE Study 
and the Rationale for Low-Dose Therapy” 
7/03 Park Lane Hospital, Parktown, Johannesburg, South Africa, Special 
Grand Rounds 
“Postmenopausal Hormone Therapy – Where We Are” 
7/03 University of Stellenbosch, Stellenbosch, South Africa, National 
Teleconference TV Lecture 
“Postmenopausal Hormone Therapy – The Light at the End of the 
Tunnel is not a Train” 
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10/03 Baptist College of Health Sciences, Memphis, TN, Changing 
Perspectives for the Perimenopausal Female 
“Background and Historical Overview of Menopause” 
“Strategies for Dealing with the HT Controversy” 
“Female Sexual Dysfunction” 
11/03 Beth Levenstein Hospital, Tel Aviv, Israel, ISHA Women’s Health 
Inauguration Lecture 
“Placing the Postmenopausal Hormone Controversy in Perspective” 
11/03 Hadassah University School of Medicine, Department of Obstetrics and 
Gynecology Grand Rounds, Hadassah Hospital, Jerusalem, Israel 
“The Postmenopausal Hormone Controversy in Clinical Perspective” 
1/04 Albert Einstein College of Medicine, Department of Obstetrics and 
Gynecology Grand Rounds, New York City 
“Quality of Life and Hormone Therapy” 
1/04 The New York Obstetrical Society, Dinner Lecture, the Yale Club,  
New York City, NY 
“Hormone Therapy – Past, Present and Future” 
2/04 University of Stellenbosch, Department of OB/GYN Special Lecture, 
Stellenbosch, South Africa 
“Update 2004 on Current and Future Status of HT after Menopause” 
2/04 4th South African Menopause Society Congress, Advanced 
Postgraduate Menopausal Course, Port Elizabeth, South Africa 
“Menopause Past and Present – How We Got to Where We Are” 
“Understanding Recent Hormone Studies and Quality of Life” 
3/5/04 Combined Meeting of University of Cape Town and University of 
Stellenbosch, NAMS Visiting Professors, Contemporary Menopause 
Management, Groote Schuur Hospital, Cape Town, South Africa 
“Setting the Scene – the NAMS 2003 HT Position Statement” 
3/04 Scientific Symposium at the 2nd Scientific Meeting of the Asia Pacific 
Menopause Federation, Pattaya, Thailand:  The New Direction in 
Hormone Therapy – Customizing Low Dose Therapy 
“Appropriate Use of Low Dose Hormone Therapy for Menopausal 
Symptoms:  Women’s HOPE Study” 
4/04 5th International Symposium on Women’s Health and Menopause, 
Lorenzini Foundation, Palazzo dei Congressi, Florence, Italy 
“Quality of Life Through and Beyond Menopause – Definition and 
Evaluation” 
“NAMS and Other Position Statements on Postmenopausal HT Usage” 
5/04 The Cleveland Clinic, Public Seminar, Beachwood, OH 
“The Current Accepted Use of Hormones After Menopause” 
5/04 IOF World Congress on Osteoporosis, Rio de Janeiro, Brazil 
Satellite on Bone and Healthy Aging:  The Spectrum of Risk 
“Health Beyond Menopause” 
5/04 IFFS 18th World Congress on Fertility and Sterility, Montreal, Canada 
Trilogy Lecture:  “Menopause Related Definitions” 
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6/04 Residency Reunion Education Program, Case Western Reserve 
University, Cleveland, OH 
  “Understanding the Current Status of Hormone Therapy” 
8/04 University of Cincinnati College of Medicine, Covington, KY 
  Recent Advances in Obstetrics & Gynecology 
  “Quality of Life – the Real Issue in Menopause Management” 
“Finding Common Ground – an Analysis of International Position 
Statements on Postmenopausal HT” 
11/04  IV Latin American FLASCYM Congress on Climacteric, Santiago, Chile 
Keynote: “Developing Consensus – An Analysis of National and 
International HT Position Statements” 
2/05 University of Stellenbosch School of Medicine, Stellenbosch, Cape, 
South Africa 
  Menopause Basics Course, Part I 
2/05 South African Menopause Society, Symposium, Cullinan Hotel, Cape 
Town, South Africa 
“Hormone Therapy in Perspective – Analysis of International Position 
Statements” 
2/05 Christiaan Barnard Memorial Hospital General Grand Rounds, Cape 
Town, South Africa 
  “Postmenopausal Hormone Therapy – Where Are We?” 
2/05 University of Stellenbosch School of Medicine, Stellenbosch, Cape, 
South Africa 
  Menopause Basics Course, Part II 
3/05 University of Stellenbosch School of Medicine, Stellenbosch, Cape, 
South Africa 
  Menopause Basics Course, Part III 
3/05 Witwatersrand University School of Medicine and Park Lane Hospital, 
Johannesburg, South Africa, Symposium, Keynote Address:   
  “Breast Cancer in the Risk/Benefit Equation of Postmenopausal 
Hormone Therapy” 
4/05 1st Annual Women’s Health Summit, The Cleveland Clinic, Cleveland, 
OH 
  “Randomized Controlled Trials, the Media and Women’s Health” 
9/7/05 Town Hall Meeting on Menopause, U S Senate Hart Senate Building, 
Washington DC, Opening Keynote Address: 
  “Menopause - What it is and What to Do” 
10/05 International Menopause Society 11th World Congress on Menopause, 
Buenos Aires, Argentina 
  Keynote Plenary Lecture:  “Setting Goals for Quality of Life” 
Wyeth Satellite:  “Finding Common Ground – An Analysis of National 
and International Position Statements on Postmenopausal HT” 
NAMS Session:  “Practical Application of the NAMS Position Statement 
on HT” 
11/05  Blanchard Valley Regional Health Center Grand Rounds, Findlay, OH 
  “Current and Future Status of Postmenopausal Hormone Therapy” 
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1/06 Center for Business Development Meeting on Menopause and 
Pharmacotherapeutic Development, Philadelphia, PA 
Opening Keynote Lecture: “The Role of Pharmacotherapy for 
Menopause Related Conditions” 
3/06 South African Menopause Society, Sun City, South Africa, Keynote 
Lectures: 
“Determining and Achieving Quality of Life Goals for Women after 
Menopause” 
  “HT after Menopause – Now that the Dust has Settled on WHI” 
3/06 University of Cape Town Department of OB/GYN Grand Rounds, 
Groote Schuur Hospital, Cape Town, South Africa 
  “Postmenopausal Hormone Therapy in Current Perspective” 
4/06 St John’s Mercy Medical Center, 38th Annual Matt Weiss Symposium, St 
Louis, MO 
 ”Current and Future Roles for Hormone Therapy after Menopause” 
4/06 St. John’s Mercy Medical Center, 38th Annual Matt Weiss Lecture, St 
Louis, MO 
 “Women’s Health Care:  Setting Goals for Enhancing Quality of Life” 
9/16/06 Case School of Dentistry, Daniel Verne Symposium, Health Museum,  
  Cleveland. 
  “Update on Postmenopausal Hormone Therapy” 
10/12/06 Opening Keynote Lecture, 17th Annual NAMS Scientific Meeting,   
  Nashville, Tennessee. 






CONGRESS PRESENTATIONS AND ABSTRACTS 
 
 4/68   South African Society of Obstetricians and Gynaecologists, Hermanus 
 9/68  South African Paediatric Association, 8th Congress, Cape Town 
 7/69    South African Medical Congress, Pretoria 
 3/70     South African Society of Obstetricians and Gynaecologists, 
Bloemfontein 
 4/70     6th World Congress of Gynaecology and Obstetrics, New York (TV) 
 5/71     19th British Congress of Gynaecology and Obstetrics, Dublin 
 7/73    South African Medical Congress, Cape Town 
 8/73   7th World Congress of Gynaecology and Obstetrics, Moscow (Paper 
Presented in Absentia) 
 9/73   22nd Iranian Medical Congress and the 7th International Congress 
    Iranian Gynaecologists and Obstetricians, Ramseh, Iran 
 7/74   20th British Congress of Gynaecology and Obstetrics, London (Paper 
Presented in Absentia) 
 10/74  South African Society of Obstetricians and Gynaecologists, 17th 
Congress, Johannesburg 
 10/74  4th International Congress of Psychosomatic Obstetrics and 
Gynecology, Tel Aviv 
 6/76  International Symposium on Oestrogens, Bordeaux, France 
 6/76    International Congress on the Menopause, La Grande Motte, France 
 10/77  International Symposium on Menopause, Athens, Greece 
 3/78   The American Fertility Society 34th Annual Meeting, New Orleans 
 4/78    American College of Obstetricians and Gynecologists Annual Meeting, 
Anaheim, CA 
 6/78  2nd International Congress on Menopause, Jerusalem, Israel 
 6/78  International Symposium on Menopause, Rome 
 2/79   The American Fertility Society 35th Annual Meeting, San Francisco, CA 
 3/79  American Society of Abdominal Surgeons 20th Annual Mtg., Tampa, FL 
 4/79  International Symposium on Percutaneous Steroids, Paris 
 7/79  6th Congress of Australian Society of Psychosomatic Obstetrics and 
Gynaecology, Sydney, Australia 
 9/79  Seminar on Current Views on Estriol, Oss, Holland 
 9/79  International Health Foundation Workshop, "The Brain as an Endocrine 
Target Organ in Health and Disease", Bordeaux, France    
 9/79  6th International Congress of Psychosomatic Obstetrics and 
Gynecology, Berlin 
 Main Keynote Lecture:  "Health Implications in Women Aged 35-45" 
              Chairman - Workshop on Premenstrual Syndrome 
 10/80  International Symposium on Menopause and Obesity, Rome  
    Chairman of Plenary Session on Therapy 
              Lecture:  "Endocrinology of Menopause and Obesity" 
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11/80 The Menopause Workshop, Rutgers Medical School: 
"Endocrinology of Menopause" 
"Osteoporosis" 
3/81 9th Annual Conference on Psychosomatic Obstetrics and Gynecology, 
Philadelphia, PA, Invited Keynote Lecture: 
"Estrogens and Menopause 
6/81 Third International Congress on Menopause, Ostend, Belgium 
1/82 Eighth Venezuelan Congress of Obstetrics and Gynecology - Special 
invited guest including Postgraduate Course lecture, Round Table 
Chairman, and Keynote Lectures 
3/82 Italian Congress on Psychosomatic Obstetrics and Gynecology,  
University of Pavia, Italy 
"Somato-psychic and Psycho-somatic Contribution to Menopausal 
Symptoms" 
3/82 American Fertility Society 38th Annual Meeting, Las Vegas, NV 
"Efficacy of 32% Dextran 70 in the Prevention of Peritoneal Adhesions 
and Utility of Second-look Laparoscopy in Infertility Surgery" (with G. 
diZerega) 
10/82 Tenth World Congress of Gynecology and Obstetrics (FIGO), San 
Francisco, CA 
"Psychotropic Action and Indication for Sex-Steroid Therapy in the 
Climacteric" 
5/83 International Health Foundation Workshop on: 
"Recent Advances in Oral Contraception" 
“Oral Contraception Formulations - Influence on User Compliance and 
Reliability of the Method" 
6/83 11th World Congress on Fertility and Sterility, Dublin, Ireland 
"Prevention of Postoperative Adhesions" 
9/83 Jan Falfijn European Congress on Menopause, Antwerp, Belgium 
Chairman of Major Plenary Session 
9/83 International College of Surgeons XII Western Hemisphere Congress 
and 1983 Annual Meeting, Cleveland, OH 
"Development in Infertility Microsurgery" 
"Logistics of an In Vitro Fertilization Program" 
2/84 International Health Foundation, Geneva, Switzerland 
Workshop on Oral Contraception 
"The Influence of Oral Contraceptive Formulations on User Compliance 
and Reliability of the Method" 
4/84 40th Annual Meeting - AFS, New Orleans, LA 
"In Vitro Fertilization" 
"Intrauterine Insemination" 
4/84 25th Annual Meeting, American Society of Abdominal Surgeons 
"Use and Abuse of Estrogen Treatment after Menopause" 
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10/84  XI Latin American Congress of Obstetrics and Gynecology, FLASOG, 
Caracas, Venezuela, Special Invited Guest including Chairman at 
Plenary Sessions: 
"Menopause and Climacteric" 
"Advances in Infertility and Microsurgery" 
11/84  Fourth International Menopause Congress, Orlando, FL 
Chairman of Workshop on: 
"Technology and Techniques" 
5/85  ACOG 33rd Annual Clinical Meeting, Washington, DC 
"Infertility Microsurgery:  Part I - Learning the Techniques" - 
(videotape) 
5/85  International Symposium on Menopause, Cleveland, OH 
"Menopause in Modern Perspective" 
"Cost-effectiveness of HRT" 
5/85  Second Annual MacDonald Conference on Reproductive Endocrinology, 
Cleveland, OH 
"Infertility Microsurgery" 
9/85  XI World Congress of Gynecology and Obstetrics (FIGO), Berlin, 
West Germany.  Transdermal Estrogen Substitution Symposium: 
"Comparative Efficacy and Tolerability of Transdermal Estradiol and of 
Conjugated Estrogens, Double Blind Multi-Center Study" 
Modern Approach to Perimenopausal Years Symposium: 
"Non-Hormonal Medication" 
9/85  American Fertility Society 41st Annual Meeting, Chicago, IL 
"IVF vs. Traditional Therapy in Tubal Disease" 
11/85   XIV Congress Brasileiro De Ginecologica e Obstetricia, Racife, Brazil 
"Menopause in Perspective" 
"Non-Hormonal Therapy" 
3/86    1st International Congress on Gynecological Endocrinology, Madonna di 
Campiglio, Italy 
"The Climacteric Syndrome" 
3/86  International College of Surgeons, Las Vegas, NV 
"The Menopause" 
9/86  American Fertility Society 42nd Annual Meeting, Toronto, Canada 
Presentation with James M. Goldfarb and Leon A. Sheean 
"Improved Hamster Penetration Assay Results After Freeze-Thawing 
Sperm in Egg Yolk Citrate" 
4/87  5th International Congress on the Menopause, Sorrento, Italy 
Schering Lecture:  "Benefit/risk Ratio of Oral Contraceptives in the  
Woman Above 40" 
Chairman, CIBA International Symposium on "Benefits of Transdermal 
Estradiol Substitution" 
Ayerst Lecture "Historical Perspectives into the Climacteric – Where We 
Were" 
Workshop - Transdermal Estrogen Delivery Systems 
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 4/87  Satellite Menopause Meeting, Rome, Italy 
             "Osteoporosis" 
 4/87  Fifth World Congress on In Vitro Fertilization and Embryo Transfer, East 
Virginia, with Leon A. Sheean and James M. Goldfarb 
              “Surrogate Pregnancy and IVF” 
“Isolation of Motile Sperm Populations from Oligospermic and 
Astheospermic Semen Samples:  Simple Washing vs. Density Gradient 
Centrifugation 
 9/87   American Fertility Society 43rd Annual Meeting, Reno, NV 
“Density Gradient Sperm Preparation for Intrauterine Insemination (IVI)  
Using Percoll” with Leon A. Sheean and James M. Goldfarb 
              “Alternate Routes of Postmenopausal Therapy”  
 3/88  2nd International Congress on Gynecological Endocrinology, 
Crans-Montana, Switzerland 
              “Transdermal Estradiol in Perspective” 
 3/88  Society for Gynecologic Investigation  
“Gonadotropin Dependent Production and Release of Steroid Hormones 
in the Rat Ovary - Two Separate Entities (George I. Gorodeski, Leon A. 
Sheean, Wulf H. Utian) 
 5/88  ACOG 36th Annual Meeting, Boston, MA (Presented by George 
Gorodeski) 
“Effect of CA and MG on In Vitro Steroid Synthesis by Rat Ovarian 
Tissue Homogenates (George Gorodeski, Leon A. Sheean, Wulf H. 
Utian) 
 10/88  American Fertility Society 44th Annual Meeting, Atlanta, GA  
    Real Meaning of Menopause (Round Table) 
 10/88  XII World Congress of Gynecology and Obstetrics - FIG, Rio de Janerio, 
Brazil 
              Symposium on Menopause 
 4/89  VI World Congress IVF and Alternate Assisted Reproduction, 
Jerusalem, Israel 
              "In Vitro Fertilization - Surrogate Gestational Pregnancy" 
 9/89  1st Meeting - North American Menopause Society/New York Academy of 
Sciences 
              "The Menopause in Perspective - From Potions to Patches" 
 11/89   American Fertility Society 45th Annual Meeting, San Francisco, CA  
    "Modern Protocols for Postmenopausal HRT" 
 3/90  2nd Congress of the International Society of Gynecological  
              Endocrinology, Jerusalem, Israel 
 "Menopause - Overview of Recent Advances and Current Challenges" 
 4/90  25th Congress South African Society of Obstetricians and 
Gynaecologists, Cape Town, South Africa, Chairman, Symposium - 






 6/90  The Endocrine Society 72nd Annual Meeting - Atlanta, GA 
"Hormonal regulation of Ectocervical Epithelial Cell Differentiation"  
Gorodeski G, Eckert RL, Utian W, Rorke EA 
              Presented by E. Rorke.  (Abstracts p. 199) 
 6/90  Fourth Italian Congress on Obstetrical and Gynaecological Sciences 
SGO), Elba Island, Italy (6/4-6/9) 
              "Postmenopausal Transdermal Estradiol in Perspective" 
 10/90  6th International Congress on the Menopause, Bangkok, Thailand 
    Upjohn Lecture and Chairman of Symposium 
               "Impact of Menopause" 
Chairman, CIBA International Symposium on Menopause and Lecture:  
"Risk Versus Benefit of HRT" 
              Organon Lecture:  Menopause Clinics 
              Chairman Plenary Session on Patient Care, and Lecture: 
                     "Menopause and Quality of Life" 
 3/91  12th Annual Meeting, the Society of Behavioral Medicine, Washington, 
DC, Chairman and Discussant, Plenary Session on Menopause  
 4/91   The Australian Menopause Society Congress, Adelaide, Australia 
    “Cancer and Hormone Replacement Therapy” 
    “Transdermal Oestrogen” 
    “Management of the menopause in the USA” 
 6/91  73rd Annual Meeting, The Endocrine Society, Washington, DC 
“Sex Steroids and Growth Factors Differentially Regulate Growth and 
Differentiation of Cultured Human Endometrial Stromal Cells.  J. C. 
Irwin, WH Utian and RL Eckert 
“Histamine Increases Transiently Cytosolic Calcium Levels in Cultured 
Human Ectocervical Cells, GI Gorodeski, WH Utian  (Abstracts p.325) 
 9/91  2nd Annual Meeting, The North American Menopause Society, 
Montreal, Canada 
"Overview on Current Status of Menopause - Medical and Political" 
President's Address 
"Sexual Function in Menopausal Women", Walters MD, Kingsberg S, 
Boyle M, Utian W 
 9/91  31st Annual Meeting of the American Society Cell Biology, Boston, MA 
"Human Ectocervical Cell Cultures Grown on Porous Filters:  Electrical 
and Morphological Characteristics", GI Gorodeski, WH Utian (Abstract 
#2079, J Cell Biol 115, 358a, 1991) 
 9/92  3rd Annual Mtg., NAMS, Cleveland, OH 
    "President's Address - Future Challenges" 
    "Menopause Clinics - Concept and Role in Society" 
 11/92  American Society for Cell Biology, 32nd Annual Mtg., Denver, CO 
“Extracellular ATP Regulates Paracellular Transport in Human Uterine 
Ectocervical Cells”, G.I. Gorodeski, M.F. Romero, U. Hopfer and W.H. 





 6/93   7th International Congress on the Menopause, Stockholm, Sweden 
    Keynote Lecture:  "HRT - Anticipation, Actuality and Compliance" 
    Workshop Lecture:  "Non-Gynecologic Cancer and HRT" 
 9/93  4th Annual Mtg., North American Menopause Society, San Diego, CA 
Plenary:  "NAMS/Gallup Survey of Women's Attitudes About 
Menopause" 
Free Communication:  "Effects of a Combined Estrogen-Androgen 
Preparation on Sexual Behavior and Lipid Metabolism in Surgically 
Menopausal Women”, Sherwin B, Youngs D, Utian WH, Jurgens R and 
Daily R 
Poster:  "The Efficacy of Flexible Polypropylene (Pipelle) Endometrial 
Biopsy in Menopausal Women”, Ben-Ozer S, Peskin J, and Utian WH 
Poster:  "Evaluation of HRT and Serial Bone Mineral Density 
Measurements", Peskin J, Utian WH, Ganley J and Boyle M 
 10/93  American Fertility Society Annual Meeting, Montreal, Canada 
    "Estrogens and Breast Cancer" 
 9/94  5th Annual Mtg., North American Menopause Society, Washington, DC 
“What is Optimum Comprehensive Care and How Well Are We Meeting 
This Goal?” 
    “How to Establish a Menopause Clinic” 
 9/94   Scientific Free Communication - GI Gorodeski, WH Utian & MN Levy 
    "Estrogen Increases Coronary Flow By a Nitric Oxide Related 
Mechanism" 
 11/94  Italian Menopause Society 5th Annual Meeting, Rome, Italy  Invited 
Keynote Speaker 
    "Women's Health Through Menopause - A Modern Perspective" 
 12/94  34th Annual Mtg. American Society for Cell Biology, San Francisco, CA 
    “Basic Regulation of Paracellular Permeability in Human Cells by Two 
Distinct Nucleotide Receptors”, Gorodeski GI, Hopfer U, Utian WH, 
(Molec Biol Cell 5, 84a, 1994) 
 2/95  International Society of Gynecologic Endocrinol, Madonna di Campiglio, 
Italy, 4th World Congress 
     "Estrogens and Myocardial Vessels" 
 5/95  ACOG 43rd Annual Meeting, San Francisco, CA 
    "Comprehensive Evaluation After Menopause" 
 7/95   27th British Congress of Obstetrics and Gynaecology, Dublin, Ireland 
"Direction, Misdirection, and Misconception in Menopause Research 
and Management" 
 9/95   6th Annual Mtg. North American Menopause Society, San Francisco, CA 
"Progesterone Attenuates the Estrogen-induced Increase in Coronary 
Flow”, Gorodeski GI, Yang T, Utian WH, Levy M 
 11/95  The Gerontological Society of America 48th Annual Scientific Meeting, 
Los Angeles, CA 
"Menopausal Women's Preferences and Evaluations of Gynecological 
Care", Rose JH and Utian WH 
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5/96 9th World Congress on Human Reproduction, Philadelphia, PA 
Invited Lecture:  "HRT and Breast Cancer" 
6/96 11th Congress of the European Association of Gynecologists and 
Obstetricians (EAGO), Budapest, Hungary 
Invited Plenary Chairman 
"Role of Progestins in HRT" 
9/96 7th Annual Mtg. of The NAMS, Chicago, IL 
“Estrogen Increases Transendothelial Cation Selectivity:  A Novel  
Vasculoprotective Mechanism”, Cho MM, Utian WH, Gorodeski GI 
9/97 8th Annual Mtg. of The NAMS, Boston, MA 
“Effects of Estrogen on Cardiac Stunning in Female Rabbits”, Levy M, 
Utian WH, Gorodeski GI 
10/97 IV European Congress on Menopause, Hofburg Palace, Vienna, Austria 
“U.S. Dose Ranging Study with Oesclim in Highly Symptomatic  
Postmenopausal Women” 
5/98 ACOG 46th Annual Meeting, New Orleans, LA 
“The Role of Ultrasound in the Assessment of Osteoporosis” 
6/98 Czech Medical Association, Menopause and Quality of Life, Prague, 
Czech 
“Long-Term Low Dose Estrogen Versus SERMS” 
10/99 9th International Menopause Society World Congress on the 
Menopause, Yokohama, Japan. 
“Determinants and Quantification of Quality of Life After Menopause - 
The Utian Menopause Quality of Life Score (UMQOL)” 
10/99 Kyoto Satellite Symposium of the 9th International Menopause Society 
World Congress on the Menopause, Kyoto, Japan. 
“Hormone Replacement Therapy and the Older Woman” 
7/00 5th EMAS European Congress on Menopause, Copenhagen, Denmark 
“Quality of Life Aspects With Continuous Combined HRT” 
10/00 ASRM 2000, Annual Scientific Meeting, Moderator of Symposium on 
“Alternative Menopausal Therapies” 
12/00 8th World Congress of Gynecological Endocrinology, Florence, Italy 
“Measurement of Quality of Life – Utilization of the UQOL Instrument” 
“Improved Amenorrhea, Favorable Vasomotor and Lipid Effects, and 
Endometrial Safety with Lower Doses”, Archer DF, Lobo RA, Utian WH 
and Pickar JH 
2/01 South African Menopause Society, Stellenbosch, South Africa 
“Dealing with the Declining Rationale for Long-term Hormone Therapy” 
4/01 ACOG 2001 Annual Clinical Meeting, Chicago, IL 
“New HRT Dosing Options for Menopausal Symptom Relief” 
Poster Session:  “ Vasomotor Symptoms and Vaginal Atrophy“ 
5/01 2001 American Geriatrics Society Ann. Scientific Meeting, Chicago, IL 
Session Moderator and Presenter 
“The Theoretical Case for HRT in Older Women” 
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 5/01  4th International Symposium Women’s Health and Menopause, 
Washington, DC 
Utian WH, Janata JJ, Kingsburg S, “Measuring Menopause-Related 
QOL Across Communities and Cultures”  
 6/01      83rd Annual Meeting of the Endocrine Society, Denver, CO 
Poster:  “Lower HRT Doses and Effects on Vasomotor Symptoms and 
Vaginal Maturation Index“   
Clinical Symposium Chairman:  “Current Developments in Menopause 
Management” 
 10/01   12th Annual Mtg. of The North American Menopause Society, New 
Orleans, LA 
Utian WH, Janata JJ, Kingsberg S, “Components and Quality of Life 
After Menopause – The Utian Quality of Life Score (UQOL)”  
 5/02    ACOG 50th Annual Clinical Meeting, Los Angeles, CA 
Utian WH, Pickar JH, “ Lower Doses of Hormone Replacement Therapy:  
Effect on Body Weight and Role of Body Mass Index in Treatment 
Response” 
 6/02  11th  World Congress on Human Reproduction, Montreal, Canada 
    “Menopause and heart Disease” 
    “Advances in SERM Therapy” 
 6/02  10th World Congress of The International Menopause Society, Berlin, 
Germany 
“Components and Quantification of Quality of Life After Menopause – 
The UQOL” 
“Comparison of HRT Effects on Hot Flushes and the Greene Climacteric 
Scale” 
 10/02   13th Annual Mtg. of The NAMS, Chicago, IL 
    Lecture:  “2002 NAMS Gallup Survey on Quality of Life” 
”    Posters:  
Heuer MA, Utian WH, Schear M, Wright DC. “Trough serum levels of 
estradiol, estrone, and FSH following topical application of Estrasorb”  
Utian WH, Pickar JH. “Effects of lower doses of hormone replacement 
therapy on urinary symptoms”. 
Utian WH, Janata JJ, Barbier S, Ciaccia AV, Rosen A, Taylor MB. “Use 
of the Utian Quality of Life instrument in a postmenopausal treatment trial: 
Pilot study comparing Raloxifene to placebo”. 
Utian WH, Leonard TW, Davis AD, Vega RY. “The safety and efficacy of 
a new synthetic 10-component, modified release conjugated estrogens 
tablet”. 
10/13-15/2002  58th Annual Meeting, ASRM, Seattle 
Poster: Utian WH, Leonard TW, Davis, AD, Vega R. Efficacy and safety 
study of new synthetic 10-component, modified release conjugated 
estrogens tablet for treatment of vasomotor symptoms in 
postmenopausal  women. 




April 27-30, 2003  51st Annual Clinical Meeting, A.C.O.G., New Orleans. 
Poster:  Leonard TW, Utian WH, Bon C, Vega RY and Barth ST. “A 
cumulative vasomotor index for analysis of hot flush severity in a 12-week 
clinical trial”. 
September 17-20,2003  14th Annual NAMS Meeting, Miami, Florida. 
    Lecture: “The 2003 NAMS Hormone Therapy Advisory Report”. 
Poster:  “The impact of conjugated estrogens/trimegestone on health-
related quality of life in a double-blind, randomized, placebo-controlled 
study”. 
February 27, 2004  4th South African Menopause Society Congress, Port Elizabeth, South  
    Africa. 
Welcome Function Key Note Address: An analysis of current international 
guidelines of menopausal hormone usage. 
Lecture: Quality of life and clinical conundrums in menopause 
management. 
March 9-12, 2004  2nd Scientific Meeting of the Asia Pacific Menopause Federation,                         
    Pattaya, Thailand.  
    Lecture: HT beyond osteoporosis protection – quality of life. 
March 19 – 20, 2004  2nd World Congress on Women’s Mental Health, Washington DC. 
1. Quality of life through and beyond menopause – definition and   
evaluation. 
2. Comparing the NAMS and other organizational position statements on 
postmenopausal hormone therapy. 
May 1-5, 2004  ACOG 52nd Annual Clinical Meeting, Philadelphia, Penn. 
Poster: Simon JA, Nachtigall LE, Davis SR, Utian WH, Lucas JD and 
Braunstein GD : Transdermal testosterone patch improves sexual activity 
and desire in surgically menopausal women. 
October 7-10,2004 15th Annual Meeting, The North American Menopause Society 
Poster: Utian WH, Speroff L. and Ellman H. Comparison of a novel oral 
estrogen therapy (estradiol acetate) to micronized estradiol and 
conjugated equine estrogens for relief of menopausal symptoms. 
October 28-31, 2004 International Society for the Study of Women’s Sexual Health 
(ISSWSH), Atlanta, Georgia. 
1. Podium Presentation: Utian W, Braunstein G, Buster J, Lucas J, 
Simon J. Testosterone Transdermal Patch Improved Sexual Activity 
and Sexual Desire in Surgically Menopausal Women: Results from 
Two Phase II Studies. 
2. Podium Presentation:  Utian W,  Maclean DB, Symonds T,  Symons 
J, Somayaji V, Sisson M. A Methodology Study to Validate a 
Structured Diagnostic Method Used to Diagnose Female Sexual 
Dysfunction and its Subtypes in Postmenopausal Women. 
October 12 ,2006  17th Annual Meeting, NAMS, Nashville, Tennessee. Poster. 
    Simon JA, Zborowski J, Snabes M, and Utian WH.  
    Bio-E-Gel, an effective, low-dose, transdermal estradiol gel, is well- 




     
MEDICAL FILMS/VIDEOTAPES 
 
 1985  Infertility Microsurgery - Learning the Techniques 
 1986  Menopause - Changes for the Better - Lifetime TV Show Host 
 
CLOSED WORKSHOPS/SCIENTIFIC SYMPOSIA 
 
 1987  The National Forum on the Long-Term Effects of Estrogen Deprivation, 
Laguana Niguel, CA 
 1988    The Second Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation,  St. John, U.S. Virgin Islands 
 1988    The International Health Foundation, Lausanne, Switzerland 
          Oral Contraceptives After Age 30 
 1988     International Expert Meeting on Menopause Research, Paris, France 
 1988   Bio-Science Advisory Committee Meeting, Johnson & Johnson, Future 
of Climacteric, New Brunswick, NJ 
 1988     Consensus Development on Progestogens 
1989    The Third Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation,  Estoril, Portugal 
1990    The Fourth Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation, Taormina, Sicily, Italy  
1990    Forging a Women's Health Research Agenda, Symposium sponsored 
by the National Women's Health Resource Center and NIH, 
Washington, DC, Member of Menopause Panel 
1991  The Fifth Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation, Vancouver, Canada  
1991  American Board of Obstetrics and Gynecology, Impact of 
Subspecialization on Residency Training and Practice of Obstetrics and 
Gynecology, Chicago, IL 
1992  CUCOG Annual Meeting, Orlando, FL  
1992  The Sixth Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation, Rancho Bernardo, San Diego, CA 
1993  National Institute on Aging, Workshop on Directions for Menopause 
Research, Bethesda, MD  
1993  The Seventh Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation, Victoria Island, Vancouver, British Columbia 
1993  International Consensus Conference on Hormone Replacement 
Therapy and the Cardiovascular System, American Heart Association 
and AFS, Hyatt Regency, Bethesda, MD,  
   Chairman of Workshop on "Progestins, Androgens:  Compliance Issues" 
1994  World Health Organization, Geneva, Switzerland.  Scientific Group 
Meeting on Research in the Menopause in the 1990's  
1994  The Eighth Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation, Santa Barbara, CA 
1995  CUCOG Annual Meeting, Orlando, FL  
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1995 Healthy Women 2000 - Menopause, Osteoporosis and Health Issues, 
Hart Senate Building, Washington, DC (With First Lady Hilary Clinton 
1995 The Ninth Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation, Aspen, CO 
1996 The Tenth Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation, Sante Fe, NM  
1996 Biological and Clinical Effects of Soy, Santa Barbara, CA 
1997 The Eleventh Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation, Newport, RI 
1998 The Twelfth Annual Symposium on the Long-Term Effects of Estrogen 
Deprivation, Los Cabos, Mexico  
1998 1st Clinical Synthesis Meeting on HRT, European Oncology Institute, 
Lancet and MRC, Milan, Italy  
1999 Thirteenth Annual Symposium on the Long Term Effects of 
Estrogen Deprivation, Banff, Canada  
2000 The Fourteenth Annual Symposium on the Long Term Effects Of 
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The Menopause Manual - A Woman's Guide to the Menopause 
Wulf H. Utian 
ISBN:  0-85200-044-8 




Menopause in Modern Perspective 
Wulf H. Utian 
ISBN:  0-0385-6297-3 
RGI86.S87  618.l'75  79-18135 
Appleton-Century-Crofts, 1980 
 
Your Middle Years:  A Doctor's Guide for Today's Woman 
Wulf H. Utian 
ISBN:  0-8385-9937-9  Paperback 










Wulf H. Utian 
ISBN:  3-437-00347-X 
Gustan Fischer Verlag 
Stuttgart, New York, 1981 
The Premenstrual Syndrome 
Pieter van Keep, Wulf H. Utian 
ISBN:  0-85200-387-0 
MTP Press, Lancs. 1981 
The Controversial Climacteric 
Pieter van Keep, Wulf H. Utian, Alex Vermuelen 
ISBN:  0-85200-410-9 
MTP Press, Lancs. 1982 
Multidisciplinary Perspectives on Menopause 
Marcha Flint, Fredi Kronenberg, Wulf Utian 
ISBN: 0-89766-595-3 (cloth) 
0-89766-595-1 (paper) 
ISSN: 0077-8923 
Annals of the New York Academy of Sciences, Volume 592, June 13, 1990 
Managing Your Menopause 
Published July 23, 1990 
Wulf H. Utian and Ruth S. Jacobowitz 
ISBN:  0-13-582362-5 
Prentice Hall Press, New York, 1990  
South African Edition 
Published February 1991 
ISBN:  0-86978-520-6 
Struik-Timmins, Cape Town, 1991 
Paperback Edition 
Published July 4, 1991 
ISBN:  0-13-546268-1 
Prentice Hall Press, New York, 1991 
Italian Edition 
Vivere Bone La Menopausa 
Published March 1992 
ISBN:  88-200-1267-7 
Sperling and Kupfer Editori, Milan, 1992 
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First Fireside Edition, 1992 
ISBN: 0-671-76655-4 
Fireside - Simon & Schuster, New York, 1992 
 
Italian Edition - Paperback 
Vivere Bene La Menopausa 
Published December 1996 




The Menopause and Hormonal Replacement Therapy 
-  Facts and Controversies 
Published September 3, 1991 
Regine Sitruk-Ware and Wulf H. Utian 
ISBN 0-8247-8564-9 
Marcel Dekker, Inc., New York, 1991 
 
French Edition 
Menopause et Traitement Hormonal Substitutit 
Published December, 1994 
Regine Sitruk-Ware and Wulf H. Utian 
ISBN 2-87671-084-6 
Frison-Roche, Paris, 1994 
 
Spanish Edition 
Menopausia y Tratamiento hormonal sustitutivo 
Hechos y Controversias 
Published May, 1995 
Regine Sitruk Ware and Wulf H. Utian 
ISBN 84-7537-138-8 
Ancora SA, Barcelona, 1993 
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COURSES, WORKSHOPS AND CONFERENCES ORGANIZED/CHAIRED 
1979 Postgraduate Course in Gynecologic Endocrinology & Infertility  
Case Western Reserve University, Cleveland, OH 
1981 First Workshop in Fertility Surgery 
Mt. Sinai Medical Center of Cleveland, Case Western Reserve 
University 
1982 Gynecologic Microsurgery:  The Nursing Application 
Mt. Sinai Medical Center of Cleveland  
1982 Workshops in Fertility Surgery 
Mt. Sinai Medical Center of Cleveland, Case Western Reserve 
University (Basic/Advanced)  
1982 Organizing Committee - The Physical and Mental Health of Aged 
Women, Center on Health and Aging 
Case Western Reserve University, Cleveland, OH 
1983 Controversial Aspects of Obstetrics and Gynecology 
Harley Hotel of Cleveland  
1983 Women's Wellness Day 
Mt. Sinai Medical Center of Cleveland  
1983 Third Annual Workshop in Fertility Surgery (Advanced) 
Mt. Sinai Medical Center of Cleveland  
1983 Third Annual Workshop in Fertility Surgery (Basic) 
Mt. Sinai Medical Center of Cleveland  
1983 International College of Surgeons Western Hemisphere Meeting, 
Obstetrical and Gynecologic Program, Cleveland, OH 
1984 Women's Wellness Day 
Mt. Sinai Medical Center of Cleveland  
1984 Fourth Annual Workshops in Fertility Surgery 
Mt. Sinai Medical Center of Cleveland  
1984 XI Latin American Congress of Obstetrics and Gynecology, Organized 
Two Plenary Sessions:  Menopause; Infertility Microsurgery 
1984 Fourth International Congress on Obstetrics and Gynecology, 
Organizing Committee, Orlando, FL 
1985 Workshops for the In Vitro Fertilization of Human Oocytes 
Mt. Sinai Medical Center of Cleveland 
1985 Women's Wellness Day 
Mt. Sinai Medical Center of Cleveland 
1985 A Morning on Menopause - An International Informational Meeting 
Mt. Sinai Medical Center of Cleveland  
1985 Workshop for IVF 
Mt. Sinai Medical Center of Cleveland 
1985 International Symposium on Menopause - The Controversial 
Climacteric, Hilton Inn South, Cleveland, OH 
Mt. Sinai Medical Center and the International Menopause Society 
1985 5th Annual Workshops in Fertility Surgery 
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    Mt. Sinai Medical Center of Cleveland 
 1985  In Vitro Fertilization Workshop 
    Mt. Sinai Medical Center of Cleveland 
 1986  In Vitro Fertilization Workshop 
    Mt. Sinai Medical Center of Cleveland 
 1986  1st International Congress on Gyn Endocrinology Scientific Committee, 
Italy 
 1986  International College of Surgeons, U.S. Section, OB/GYN Program 
1986   New and Evolving Concepts in Menopause, Co-Chairman with Dr. 
Morris Notelovitz (Florida), Cancun, Mexico 
 1986  Current Perspectives in the Management of the Menopausal and 
Postmenopausal Patient, Co-Chairman with Dr. Howard Judd (UCLA), 
Banff Springs, Canada 
 1987  Current Perspectives in the Management of the Menopausal and 
Postmenopausal Patient, Co-Chairman with Dr. Robert Lindsay 
(Columbia University), Virgin Islands 
 1987  5th International Congress on the Menopause, Organizing Committee, 
Sorrento, Italy 
 1987   Current Perspectives in the Management of the Menopausal and 
Postmenopausal Patient, Co-Chairman with Dr. Robert Lindsay 
(Columbia University), Tahoe, NV 
 1987   An Evening on Menopause - For Women and Men, Too, Landerhaven, 
Lyndhurst, OH 
 1988  Current Perspectives in the Management of the Menopausal and 
Postmenopausal Patient, Co-Chairman with Dr. Robert Lindsay 
(Columbia University), Banff Springs, Canada 
 1988  Menopause - Midlife Preventive Medicine for Women 
    Hilton Inn South, Cleveland, OH 
 1988  Current Perspectives on Menopause, Co-Chairman with Dr. Robert 
Lindsay (Columbia University), Hyatt Regency, San Francisco, CA 
 1989   PACE (Patterns of Administering Cycle/Continuous Estrogens) 
Post-Study Meeting, Palm Desert Resort, Palm Springs, CA 
 1989  Current Perspectives in the Management of the Menopausal and 
Postmenopausal Patient, Hilton Head, SC 
 1989  Menopause - Staying in Control, A Health Seminar for Women,  
Keynote Speaker - Shirley Jones, Stouffer’s Tower City Plaza Center, 
Cleveland, OH 
 1989  Multidisciplinary Perspective on Menopause, Co-Sponsored by The 
New York Academy of Sciences and The North American Menopause 
Society (Inaugural Meeting) with F. Kronenberg, PhD and M. Flint, PhD 
 1989  Symposium on Vaginal Dryness:  Overview and Update,  Stanhope 
Hotel, New York, Co-Chair with Gloria Bachmann 
 1991  Chairperson, Roundtable Discussion "An Assessment of 17B Estradiol 
in Postmenopausal Women" for Healthcare Communication Network, 
The Boulders, Carefree, AZ 
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 1991  Chairperson, Roundtable Discussion "Controversies in the Management 
of the Menopause", Reid-Rowell, Palm Springs, CA 
 1991  Chair, U.S. Congress Office Technology Assessment Workshop,  
    Dirkson Senate Building, Washington, DC 
   "Hormone Replacement Therapy:  Policy and Practice" 
1991  Obstetrics and Gynecology Update 1991,  
Department of Reproductive Biology, CWRU, Ritz Carlton Hotel, 
Cleveland, OH 
 1991  2nd Annual Meeting of The North American Menopause Society, Queen 
Elizabeth Hotel, Montreal, Canada 
 1991  Organizer and Moderator, "Taking Control of Menopause:  A Health 
Seminar for Women", Stouffer’s Tower City Plaza Center, Cleveland, 
OH 
 1992  Organizer and Moderator, "Obstetrics and Gynecology Update 1992", 
Stouffer’s Tower City Plaza Center, Cleveland, OH  CWRU CME 
Course 
 1992  Organizer and Moderator, "Menopause - You’re Questions Answered", 
Stouffer’s Tower City Plaza Center, Cleveland, OH  Consumer 
Education 
 1992  3rd Annual Meeting of The North American Menopause Society, 
Stouffer's Tower City Plaza Center, Cleveland, OH 
 1992  Organizer and Moderator, "Postmenopausal Osteoporosis - Prevention, 
Diagnosis, Treatment" 
CWRU Department of Reproductive Biology CME Program, Forum 
Center, Cleveland, OH  
1993  National Institute on Aging, Workshop on Directions for Menopause 
Research, Bethesda, MD 
1993  The North American Menopause Society Postgraduate Course:  
Menopause - The Background and Skills for Effective Therapy,  The 
Copley Plaza Hotel, Boston, MA 
1993  4th Annual Meeting of The North American Menopause Society, San 
Diego Hyatt Regency, San Diego, CA 
1993  Organizer and Moderator, "Menopause - His and Hers", A Health 
Seminar for Men and Women, Stouffer’s Tower City Plaza Center, 
Cleveland, OH 
1994   5th Annual Meeting of The North American Menopause Society, The 
 Washington Hilton, Washington, DC 
1994  Organizer and Moderator, "Menopause - Confronting the 
Controversies", A Public Health Seminar, Stouffer’s Tower City Plaza 
Center, Cleveland, OH 
1995  NAMS Colloquium on Balancing the Risk:  Benefit Equation of Long-
Term Hormone Replacement Therapy, Co-Moderator with Fred Naftolin 
(Yale), San Francisco, CA 
1995  6th Annual Meeting of The North American Menopause Society, San 
Francisco Marriott, San Francisco, CA 
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1995  Organizer and Moderator, The Menopause Clinic - A Practical 
Workshop, Cleveland Menopause Clinic, Cleveland, OH 
1995  The Birthday Club/Plays for Living:  Menopause Education Program, 
Stouffer's Tower City Plaza Center, Cleveland, OH 
1996  7th Annual Meeting of The North American Menopause Society, 
Chicago, IL   
1996  Menopause:  Confronting the Controversies, University Hospitals  
   Consumer Education Program, Holiday Inn, Westlake, OH 
1996  Menopause:  Confronting the Controversies, University Hospitals 
Consumer Education Program, Executive Caterers at Landerhaven, 
Lyndhurst, OH 
1996  Scientific Committee, 8th International Menopause Congress, Sydney, 
Australia 
1997  Selective Estrogen Receptor Modulators, Moderator, Eli Lilly Satellite 
Symposium at NAMS Meeting, Boston, MA 
1997  8th Annual Mtg. of The North American Menopause Society, Boston, MA 
1997  Co-Organizer, Course on Women’s Health for Solvay Pharmaceuticals 
Senior Staff, Cleveland, OH 
 1998  9th Annual Meeting of The North American Menopause Society, Toronto, 
Canada 
1999  10th Annual Meeting of The North American Menopause Society, New 
York Hilton, NYC, NY 
1999  Co-Organizer and Moderator, “Hormones and Aging” and “Quiz the 
Experts”, Kyoto Satellite Symposium of the 9th International Menopause 
Society World Congress on the Menopause 
 2000  11th Annual Meeting of The North American Menopause Society, 
Orlando, FL 
2000  Organizer and Moderator, “Evaluating ERT/HRT for Postmenopausal 
Women” and “Quiz the Experts”, Council of Affiliated Menopause 
Societies, Ibero-American Regional Planning Meeting on Best Medical  
   Practice, Gainesville, FL 
2000 ASBMR 22nd Annual Meeting, Toronto, Canada 
  ASBMR/NAMS Joint Symposium:  Clinical Issues and HRT 
  Planner and Moderator 
2001 12th Annual Meeting of The North American Menopause Society, New 
Orleans, LA 
2002 Organizer and Moderator, “Justifying the Trend to Lower Doses of 
HRT”, “Tibalone” and “Quiz the Experts”, WPO/YPO Educational 
Program:  Menopause and Women’s Health, Shoreby Club, Cleveland, 
OH 
2002 13th Annual Meeting of The North American Menopause Society, 
Chicago, IL 
2002 NAMS and Case Western Reserve University, Co-Sponsored 
Postgraduate Course, “Menopause Basics”, Tri-C East Campus, 
Cleveland, OH 
2003 14th Annual Mtg. The North American Menopause Society, Miami, FL 
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2004 Advanced Postgraduate Menopausal Course, The South African 
Menopause Society, Port Elizabeth, South Africa 
2004 15th Annual Meeting of the North American Menopause Society, 
Washington, DC 
2004 Vulvodynia and Sexual Pain Disorders in Women, A State of the Art 
Conference, Atlanta, GA, Sponsored by NIH, NAMS and ISSWSH, W 
Utian and Vivian Pinn, Director of the NIH Office of Women’s Health 
Research, Co-Chairs 
2005 16th Annual Mtg., of The North American Menopause Society,  
San Diego, CA 
2006 17th Annual Mtg. of The North American Menopause Society,  
Nashville, Tennessee.  
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PAST AND PRESENT RESEARCH SUPPORT 
Funding Agency       PI     Duration Title       Direct Costs 
Herman Bequest W. Utian 1968-70 Metabolic Effects of 
Ovariectomy 
  $  30,000 
Atomic Energy 
Board 
W. Utian 1969-72 Radiodensometric 
Bone Evaluation 
      10,000 
Round Table 
Assn. 
W. Utian 1971 Risk/Benefit of 
Estrogen Therapy 














W. Utian 1973 Bromergocryptine & 
Galactorrhea 
      25,000 
University of 
Cape Town 




      50,000 




    125,000 
NIH W. Utian 1977 RR-D5410-16 
Adhesion Prevention 
      10,000 
NIH/Pharmacia W. Utian 1980-81 Hyskon Prevention 
Adhesion Study 
    100,000 
CIBA-GEIGY W. Utian 1983-85 Transdermal 
Estrogen Therapy 
    125,000 
Organon W. Utian 1986-88 OD-14, Hot Flashes 
& Bone Mass 
      56,000 
Wyeth-Ayerst W. Utian 1989- Estrogen-Progestin 
Study 
















     150,000 
Solvay W. Utian 1992 Randomized Trial 
Estratest HS and 
Estratab in Sexual 
Functioning 
       42,980 














Test the hypothesis 
that loss of estrogen 
in women unleashes 
the production 
and/or action of 
cytokines, such as 
IL-6, in the marrow 
microenvironment 
which are in turn 







     413,119 











      14,300 




Histology and Bone 








Fournier W. Utian 
(National 








Trial in Parallel  
Groups to Measure 
Efficacy and Safety 
of 12 Weeks 
Treatment with TS 
17 on Vasomotor 
Symptoms in  
Menopausal Patients  
      45,000 





of Lower Doses of 
Premarin and MPA  
in Postmenopausal 
Women 













1997 Multicenter Dose 










Placebo or the  





Parke-Davis W. Utian 1998- Quality of Life  
Validation Study 
     15,000 
 
MULTIPLE GRANTS BEYOND THIS TIME SUBJECT TO CONFIDENTIALITY 







  1981  AFS, In Vitro Fertilization 
 1982  Eastern Virginia Medical School, In Vitro Fertilization 
 1982    Serono Symposia, Carmel, CA, In Vitro Fertilization 
  1983    Bourn Hall, Cambridge, England, In Vitro Fertilization 
  1986    Residency Training Accreditation Course, New York 
 1986    Center for Biomedical Ethics, CWRU, Closed Workshop, "Ethical 
Aspects of Human Fetal Tissue Transplantation" 
 1987    Research Directions in Osteoporosis, NIH, Washington, DC 
  1987    Gynecology and Infertility Laser Surgery Workshop, Mt. Sinai Medical 
Center of Cleveland 
 1987  Food and Drug Administration Conf. on Osteoporosis, Bethesda, MD 
 1994  Law-Medicine Center, Case Western Reserve University, National 
Health Care Reform:  The Legal Issues 
 1996  Mandel Center for Non-Profit Organizations, Case Western Reserve 
University, Board and Administrative Responsibilities in Non-Profit 
Organizations 
 2001  International Society of Clinical Densitometry Course on Bone 
Densitometry, New Orleans, LA 
 2006  Harvard Business School Course on Excellence in Nonprofit 





 Date          Channel         Program              Title 
09/06/77 5 - WEWS Morning Exchange  Menopause 
09/21/77 3 - WKYC News  Menopause 
10/17/77      Greek Nat'l TV  News/Discussion  Estrogen Therapy 
11/08/77      43                   Coffee Shoppe           Menopause 
11/30/77 3 - WKYC           News                      Microsurgery 
06/10/78      Italian Nat'l TV    News                     Menopause 
07/27/78      3 - WKYC           News                     Microsurgery 
08/02/78      5 - WEWS          Morning Exchange     Infertility 
05/02/79      3 - WKYC           Zapp Show               Tubal Reversal 
          05/29/79     8                    News                     Pregnancy Tests 
07/07/80     5 -WEWS          Morning Exchange    Menopause - Book 
07/09/80      3 -WKYC                    Dave Patterson Show Your Middle Years 
07/15/80      43                   AM Show                 Menopause 
09/09/81      5 - WEWS         News                    Microsurgery 
09/20/81      3 - WKYC           News                Microsurgery 
10/15/81      3 - WKYC           Dave Patterson Show     Infertility/PMS 
04/27/82     5 - WEWS         Morning Exchange        PMS 
08/19/82      3 - WKYC           Dave Patterson Show     PMS/Menopause 
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10/03/82 3-5-8     All News Stations     In Vitro Fertilization 
10/16/82 3 - WKYC     Dave Patterson Show  IVF/ET 
12/16/82 5 - WEWS     Live on 5/Wilma Smith IVF/ET 
02/03/83 ABC Cincinnati Braun & Company     Labor/Delivery/IVF 
2/21-25/83 3 - WKYC  11:00 News     Infertility 
02/22/83 5 - WEWS Morning Exchange     Hope for Childless 
03/09/83 5 - WEWS Morning Exchange     IVF/ET 
05/28/83 5 - WEWS Live on 5     PMS 
09/20/83 5 - WEWS 6:00 & 11:00 News Microsurgery 
11/05/83 3 - WKYC  6:00 & 11:00 News First In Vitro Birth 
11/06/83 3 - WKYC  6:00 & 11:00 News First In Vitro Birth 
11/06/83  5 - WEWS 6:00 & 11:00 News First In Vitro Birth 
11/06/83 8     6:00 & 11:00 News First In Vitro Birth 
11/07/83 8     6:00 & 11:00 News First In Vitro Birth 
11/08/83 5 - WEWS Morning Exchange    First In Vitro Birth  
11/14/83 3 - WKYC  11:00 News     Medical Miracles  
12/07/83 8     PM Magazine     Infertility 
03/05/84 3 - WKYC  AM Cleveland     IVF First Baby 
04/11/84 5 - WEWS Live on 5     Women's Wellness 
04/28/84 3 - WKYC  Cleveland Challenge Medical Research 
05/02/84 5 - WEWS Dorothy Fuldheim     Interview - Infertility 
06/22/84 8     6:00 & 11:00 News    Embryo Cryo 
08/02/84 27 Youngstown 6:00 & 11:00 News    In Vitro Fertilization 
08/26/84 8     Evening News     Midwives 
09/12/84 8     Evening News 11:00 Microsurgery  
09/21/84 3 - WKYC  AM Cleveland     New Conceptions  
10/19/84 5 - WEWS Live on 5     In Vitro Fertilization 
11/05/84 3 - WKYC AM Cleveland IVF - First Birthday  
Baby Micchia 
11/22/84 8 Evening News In Vitro Fertilization 
11/23/84 8 Evening News Costs of Treating  
 Infertility 
05/10/85 3 - WKYC AM Cleveland Menopause 
05/22/85 5 - WEWS Live on 5 Fertility Drugs 
05/23/85 5 - WEWS  News Smoking & Infertility 
08/23/85 VIACOM Eastwatch Menopause 
08/27-29/85  All National Networks, Local Stations World's First Post- 
             and Newspapers Nationally     Hysterectomy 
Surrogate Preg. 
08/30/85 5 - WEWS Morning Exchange Surrogate-IVF 
Pregnancy 
11/18/85 25     MEDI-SCENE Infertility 
11/21/85 3 - WKYC News IVF - Surrogate 
04/16/86 International News Coverage IVF-Surrogate 
Pregnancy 
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07/17/86 NTL Phil Donahue IVF-Surrogate  
Pregnancy 
08/12/86 NTL Phil Donahue Show IVF-Surrogate  
Pregnancy 
08/29/86 5 - WEWS          Morning Exchange  Menopause 
09/12/86 5 - WEWS          Morning Exchange  Estrogens 
09/16/86 National Press Conference, Plaza Hotel, The Transdermal 
New York - All Media Estrogen 
10/05/86 LIFETIME  Health Network Menopause - 
10/12/86 Changes for  
the Better 
11/04/86 PBS     NOVA High-Tech Babies 
11/21/86 WTAE-ABC News  TTS Estrogen 
11/28/86 PA     Evening News TTS Estrogen 
02/08/87 PBS     MEDI-SCENE Menopause and  
Estrogen 
03/02/87 3 - WKYC AM Cleveland Cleveland  
Menopause Clinic 
03/03/87 5 - WEWS Morning Exchange Cleveland 
Menopause Clinic 
03/15/87 LIFETIME Physicians Journal Patients & Medicine 
Update 
04/05/87 LIFETIME Physicians Journal Management of 
Menopause Update 
04/28/87 Fox TV High-Tech Babies   Surrogate - IVF 
National Special 
04/30/87 5 -WEWS Morning Exchange Surrogate-IVF With  
All Parties 
Involved 
08/16/87 NBC National News IVF-Surrogate Legal 
Case 
08/24/87 PBS MEDI-SCENE Changing Medicine 
1-Hour Special for Women:  The 
Bitter Pills 
10/15/87 5 - WEWS Morning Exchange Menopause - For  
Men and Women 
01/24/88 LIFETIME OB/GYN Update Osteoporosis 
02/03/88 5 - WEWS Live on 5     Menopause 




04/02/88 CBS Phil Donahue   Women's Health 
06/13/88 3 - WKYC Evening News Menopause 
09/06/88 3 - WKYC AM Cleveland  Menopause 
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06/08/89      5 - WEWS          Morning Exchange       Menopause with 
                                                        Shirley Jones 
06/17/89      3 - WKYC          NBC Sunday Today    Menopause with 
                                                        Shirley Jones 
01/07/90     LIFETIME            Family Practice         HRT - Update 
01/21/90      5 - WEWS          Health Matters          Osteoporosis 
01/24/90      Public TV 25        McNeil-Lehrer News      Estrogen &  
    Menopause 
04/09/90      South African TV    Antenna                 Menopause 
07/23/90      CBS                  CBS This Morning        Menopause 
                                  Host:  Paula Zahn 
07/23/90      CNN                  Sonya Live              Menopause 
07/24/90      Continental         Fairfield Exchange      Menopause 
              Cablevision         Hosts:  Rebecca Surran     
              Norwalk, CT         and David Smith 
07/25/90      Atlanta              A Women's Place         Menopause 
              Interfaith           Host:  Angela Rice 
07/27/90      5 - WEWS              Morning Exchange        Menopause 
07/30/90      KFMB-CBS            Sun-Up San Diego        Menopause 
07/30/90      KGTV-ABC            Staying Healthy         Menopause 
08/07/90       National Satellite Television Tour News  Managing Your        
              Programs and Talk Shows, 23 Cities Menopause 
09/05/90      KKTV-CBS            News at Noon            Menopause 
              Colorado Springs 
09/05/90      KRSO-ABC            Health Report           Menopause 
              Colorado Springs 
09/05/90      KTVD                 About Town              Menopause 
              Denver 
09/06/90      KMGH-CBS            News                    Menopause 
              Denver 
09/06/90      KUSA-ABC            Good Afternoon          Menopause 
              Denver, Colorado       
06/28/91 TV-2  News Menopause 
 Monterrey, Mexico 
09/09/91 NBC  Cover to Cover Hormone Therapy 
 National  w/Robin Swoboda 
10/10/91 8 - CBS  News Menopause & HRT 
10/18/91 5 - WEWS  Morning Exchange One Hour on PMS 
03/31/92 3 - ABC  Evening News Menopause/HRT 
05/27/92 8 - CBS  CBS Evening News Eye on America - 
   Dan Rather Menopause  
06/03/92 8 - CBS  Noon News - Local Menopause 
09/10/92 5 - WEWS  News at 11:00 p.m. Pregnancy after  
    Menopause 
03/24/93 CNN  News NIH, Menopause 
   Meeting 
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04/01/93 5 - WEWS  Morning Exchange NIH, Menopause 
04/19-20/93 Argentina - Multiple National Networks -  Menopause 
05/06/93 8 - CBS  News Malpractice  
    Pressure &  
   Premature  
   Retirement 
05/14/93 5 - NBC  Live on 5 Menopause & HRT 
07/03/93 Lifetime TV  Special Facts with Menopause Myths 
   Debbie Reynolds 
09/03/93 CBS - San Diego News Menopause Edu. 
10/27/93 5 - WEWS  Morning Exchange Menopause – His 
    and Hers 
10/28/93 5 - NBC  Live on 5 Menopause – His 
     and Hers 
04/27/94 8 - CBS  Evening News South Africa 
05/20/94 American  Distribution Menopause 
 Medical TV   
05/27/94 5 - ABC  World Evening News Menopause 
   with Peter Jennings     
10/28/94 WSB TV-2  Atlanta Hot Flash 
11/01/94 PBS  Women's Health  Menopause - 
    Moderator of 
    Live Call-In 
    Panel 
12/06/94 MedEdNet  Obstetrics & Comprehensive 
 Satellite  Gynecology Health Care 
 Network  Estrogen Menopause 
08/08/95 5 - WEWS  Live on 5 Hormones & Mood 
10/11/95 5 - WEWS  Morning Exchange Menopause - Plays 
    for Living Program 
05/31/96 National -  Live from National Natl Menopause 
 Multiple  Press Club, Wash, DC Awareness Month 
10/17/96 5 - WEWS Morning Exchange Menopause - NAMS 
02/19/97 ABC - National Prime Time Live HRT 
06/20/97 5 - WEWS Morning Exchange HRT & Longevity 
08/14/97 5 - WEWS Morning Exchange Designer Estrogens 
09/04/97 CNN - National News NAMS 1997 Gallup 
   Survey 
09/09/97 FOX TV-8 News NAMS 1997 Gallup 
   Survey 
09/24/97 Polish National TV  News Menopause 
03/01/98 Channel 19 - CBS    News                                  Menopause 
03/23/98 FOX-TV News Health Program Male Menopause 
07/24/98 5 - WEWS Morning Exchange ERT/Patch 
09/03/98 5 - WEWS Morning News Estrogen Research 
09/17-18/98 Multiple Canadian TV  NAMS Gallup 
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Survey 
10/98 Public TV Menopause 
11/27/98 Jamaican Natl TV Sunrise Menopause 
04/05/00 3 - WKYC News/Health Women Heart 
Disease 
04/19/00 3 - WKYC Morning News Hot Flashes 
05/24/00 3 - WKYC Morning News Overactive Bladder 
07/06/00 3 - WKYC Morning News Birth Control Pills 
07/26/00 3 - WKYC Morning News Irritable Bowel   
    Syndrome 
08/09/00 3 - WKYC Morning News Sexual Arousal  
08/16/00 19/43 Evening News Long Cycle OC’s 
08/30/00 5 - WEWS Live on 5 NAMS and 
Menopause 
09/08/00 NBC Florida News Testosterone Patch 
09/20/00 3 - WKYC Morning News Heart Disease 
10/12/00 3 - WKYC News with Fred Griffith World Menopause  
12/13/00 3 - WKYC Morning News HRT & Heart 
Disease 
12/20/00 3 - WKYC Morning News HRT & Cancer 
08/06/01 NBC National news EVA Trial 
Evista/Alendronate 
08/14/01 Health Channel Menopause 
10/04/01 CBS New Orleans Evening News NAMS/Menopause 
12/09/01 15/17 Cleveland Mr. Robinson Women’s Health 
05/26/02 5 - WEWS News with Fred Griffith Osteoporosis 
05/26/02 KYC Golden Opportunities Osteoporosis 
06/06/02 NTV Turkey National News Menopause 
06/20/02 3  World News/Peter  HRT 
Jennings 
07/10/02 CBS Evening News/Dan Rather  WHI and HRT 
07/21/02 KYC Golden Opportunities Sexual Dysfunction 
08/09/02 8 FOX Morning News Alternates to HRT 
08/26/02  15/45 Cleveland Larry Robinson Menopause & WHI 
09/01/02 15/45 Larry Robinson Menopause & WHI 
11/20/02 CBS Evening News Dan Rather HRT and conflict 
01/28/03 15/45 Cleveland Larry Robinson Menopause   
Estrogen 
01/29/03 15/45 Cleveland Larry Robinson Male Menopause 
05/18/03 KYC Golden Opportunities Osteoporosis  
01/22/04 TV5 ABC Evening News PMDD and PMS 
01/29/04 TV5 ABC Evening News Menopause  
Research 
02/11/04 TV5 ABC Evening News NAMS/Menopause 
06/29/04 TV5 ABC Evening News New VMS Drug 
11/15/05 TV5 ABC Evening News PMS 
202 
12/05/05 National – Multiple News Bioidentical HT 
12/27/05 CBS National Evening News Bioidentical HT 
01/12/06 NBC Good Company Menopause 
01/24/06 TV5 ABC Morning News HPV Vaccine 
03/05/06 SABC(South Africa) House Calls (1 Hour Live) Menopause 
06/21/06 Bravo Health/Family Redefining 
 Menopause 
07/31/06 WB 11 NYC News Factfinders Bio-identical HT 
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